



SMW Consultants Ltd.
Writing & Consulting Medical Research
Kylliäisentie 9, FIN-21620 Kuusisto, FINLAND.

LIST OF SCIENTIFIC CONTRIBUTIONS

Prof. Kari Syrjänen, MD, PhD, FIAC

President and CEO,
SMW Consultants Ltd.,
Kaarina, FINLAND

ORIGINAL PAPERS, REVIEWS AND BOOK CHAPTERS

- 1.Syrjänen, K.J. Morphologic manifestations of tumor-host relationships in association with breast, gastric and colorectal carcinoma. M.D. (Ph.D.) Thesis, University of Helsinki, pp. 1-86, 1975. (**ISBN-951-99064-3-6**)
- 2.Syrjänen, K.J. Histologic changes in mouse lymph nodes after treatment with anti-theta globulin. *Exp. Pathol.* 14, 171-179, 1977. (I.F. 0.500)
- 3.Syrjänen, K.J. and Hjelt, L.H. Tumor-host relationships in colorectal carcinoma. *Dis. Colon & Rectum* 21, 29-36, 1978. (I.F. 3.739)
- 4.Syrjänen, K.J. and Hjelt, L.H. The influence of anti-theta globulin treatment on the growth of mastocytoma in mice. *Exp. Pathol.* 14, 208-214, 1977. (I.F. 0.500)
- 5.Syrjänen, K.J. and Hjelt, L.H. Morphology of the regional lymph nodes of gastric carcinoma and ulcer of the stomach in relation to immunological functions. *Scand. J. Gastroent.* 12, 903-909, 1977. (I.F. 2.199)
- 6.Syrjänen, K.J. and Hjelt, L.H. Paracortical activity of the regional lymph nodes as a prognostic determinant in gastric carcinoma. *Scand. J. Gastroent.* 12, 897-902, 1977. (I.F. 2.199)s
- 7.Syrjänen, K.J. and Hjelt, L.H. Grading of human renal adenocarcinoma. *Scand. J. Urol. Nephrol.* 12, 49-55, 1978. (I.F. 1.243)
- 8.Syrjänen, K.J. and Hjelt, L.H. Ultrastructural characteristics of human renal cell carcinoma in relation to the light microscopic grading. *Scand. J. Urol. Nephrol.* 12, 57-65, 1978. (I.F. 1.243)
- 9.Syrjänen, K.J. and Hjelt, L.H. Tumor-host interrelationships in carcinoma of the female breast. *Surg. Gynec. Obstet.* 147, 43-48, 1978. (I.F. 3.651)
- 10.Syrjänen, K.J. The effects of anti-theta-globulin treatment on the morphology of the mouse spleen. *Exp. Pathol.* 15, 38-45, 1977. (I.F. 0.500)
- 11.Syrjänen, S.M. and Syrjänen, K.J. Mast cells in the healing process of the extraction wound in man. *Proc. Finn. dent. Soc.* 73, 220-224, 1977.
- 12.Syrjänen, K.J. Thymic morphology in mice following treatment with anti-theta and anti-thymus globulins. *Exp. Pathol.* 15, 169-178, 1978. (I.F. 0.500)
- 13.Syrjänen, S.M. and Syrjänen, K.J. The influence of Alvogyl^R on the healing of extraction wound in man. *Int. J. Oral Surg.* 8, 22-30, 1979. (I.F. 1.563)
- 14.Syrjänen, K.J. and Hjelt, L.H. Prognostic factors in gastric carcinoma. *Neoplasma* 25, 365-373, 1978. (I.F. 1.865)
- 15.Syrjänen, K.J. Post-capillary venules in the lymphatic tissues of mice bearing experimental neoplasia. *Exp. Pathol.* 15, 348-354, 1978. (I.F. 0.500)
- 16.Syrjänen, K.J. IgG in the walls of the post-capillary venules of human lymph nodes. *Lymphology* 11, 71-74, 1978. (I.F. 1.489)
- 17.Syrjänen, K.J. Post-capillary venules of the lymphatic tissues in mice with special reference to the depletion of T-lymphocyte population. *Exp. Molec. Pathol.* 29, 291-302, 1978. (I.F. 2.706)

- 18.Syrjänen, K.J. Post-capillary venules in the human lymph nodes draining malignant tumors. *Arch. Geschwulstforsch.* 49, 155-161, 1979.
- 19.Syrjänen, K.J. Morphology of the lymph nodes draining renal adenocarcinoma in relation to immunological functions. *Scand. J. Urol. Nephrol.* 13, 177-183, 1979. (I.F. 1.243)
- 20.Syrjänen, K.J. Paracortical post-capillary venules of human lymph nodes with special reference to the distribution of their endothelial IgG. *Lymphology* 11, 117-122, 1978. (I.F. 1.489)
- 21.Syrjänen, K.J. Bronchial carcinoma and its regional lymph nodes in relation to immunological functions. *Z.Immun.- Forsch. Immunobiol.* 155, 212-222, 1979. (I.F. 3.044)
- 22.Syrjänen, K.J. A diffuse mixed histiocytic-lymphocytic lymphoma associated with immunological abnormalities. *Arch. Geschwulstforsch.* 49, 289-298, 1979.
- 23.Syrjänen, K.J. IgG in the walls of the post-capillary venules of mouse lymphatic tissue. *Exp. Pathol.* 17, 40-43, 1979. (I.F. 0.500)
- 24.Syrjänen, K.J. Renal adenomatosis. Report of an autopsy case. *Scand. J. Urol. Nephrol.* 13, 329-334, 1979. (I.F. 1.243)
- 25.Syrjänen, K.J. Paracortical activity in the lymph nodes draining female breast carcinoma. *Neoplasma* 26, 95-102, 1979. (I.F. 1.865)
- 26.Syrjänen, K.J. Post-capillary venules of the mouse lymphatic tissues with special reference to the distribution of their endothelial IgG. *Exp. Pathol.* 17, 134-142, 1979. (I.F. 0.500)
- 27.Syrjänen, K.J. Condylomatous lesions in dysplastic and neoplastic epithelium of the uterine cervix. *Surg. Gynec. Obstet.* 150, 372-376, 1980. (I.F. 3.651)
- 28.Syrjänen, K.J. Endothelium-associated IgG in the post-capillary venules of the lymphatic tissues in mice bearing experimental neoplasia. *Exp. Pathol.* 17, 264-270, 1979. (I.F. 0.500)
- 29.Syrjänen, K.J. Histological and cytological evidence of a condylomatous lesion in association with an invasive carcinoma of uterine cervix. *Arch. Geschwulstforsch.* 49, 436-443, 1979.
- 30.Syrjänen, K.J. Condylomatous epithelial changes in uterine cervix and their relationship to cervical carcinogenesis. *Int. J. Gynaecol. Obstet.* 17, 415-420, 1980. (I.F. 1.674)
- 31.Syrjänen, K.J. Morphologic survey of the condylomatous lesions in dysplastic and neoplastic epithelium of the uterine cervix. *Arch. Gynaecol.* 227, 153-161, 1979. (I.F. 1.680)s
- 32.Syrjänen, K.J. Condylomatous changes in neoplastic bronchial epithelium. Report of a case. *Respiration* 38, 299-304, 1979. (I.F. 2.924)
- 33.Syrjänen, S.M. and Syrjänen, K.J. Hyperplastic gingivitis in a child receiving sodium valproate treatment. *Proc. Finn. dent. Soc.* 75, 95-98, 1979.
- 34.Syrjänen, S.M. and Syrjänen, K.J. Plasma cells and their immunoglobulins in the normal and delayed healing of the extraction wound in man. *Brit. J. Oral Surg.* 18, 100-106, 1980. (I.F. 1.133)

- 35.Syrjänen, K.J. Current views on the condylomatous lesions in uterine cervix and their possible relationship to cervical squamous cell carcinoma. *Obstet. Gynecol. Surv.* 35, 685-694, 1980. (I.F. 2.361)
- 36.Partanen, S., Syrjänen, K. and Hjelt, L.H. Light microscopical and fluorescence histochemical observations on the endocrinological activity of human pulmonary neoplasia. *Arch. Geschwulstforsch.* 50, 97-104, 1980.
- 37.Syrjänen, K.J. The pattern of human lymph node involvement by the non-Hodgkin lymphomas of B-cell lineage. *Neoplasma* 26, 589-596, 1979. (I.F. 1.865)
- 38.Syrjänen, K.J. An osteogenic sarcoma of the thyroid gland. Report of a case and survey of the literature. *Neoplasma* 26, 623-628, 1979. (I.F. 1.865)
- 39.Syrjänen, K.J. Morphology of the spleen white pulp as an indicator of the immunological state in patients with widespread malignant melanoma of the skin. *Indian J. Dermatol. Venereol. Leprol.* 46, 6-14, 1980. (I.F. 1.387)
- 40.Syrjänen, K.J. Spleen white pulp morphology as an indicator of the immunological state of DBA/2 mice bearing mastocytoma. *Exp. Pathol.* 18, 223-231, 1980. (I.F. 0.500)
- 41.Syrjänen, K.J. Non-Hodgkin malignant lymphomas of B-cell lineage with special reference to their lymph node involvement pattern. *Arch. Geschwulstforsch.* 50, 66-71, 1980.
- 42.Syrjänen, K.J. Spleen white pulp morphology in the evaluation of the immunological reactivity of the patients with widespread colorectal carcinoma. *Dis. Colon & Rectum* 23, 228-235, 1980. (I.F. 3.749)
- 43.Syrjänen, K.J., Heinonen, U-M., and Kauraniemi, T. Cytological evidence of the association of condylomatous lesions with the dysplastic and neoplastic changes in uterine cervix. *Acta Cytol.* 25, 17-22, 1981. (I.F. 1.562)
- 44.Syrjänen, K.J. Fine needle aspiration cytology of thyroid osteosarcoma. Report of a case. *J. Cancer Res. Clin. Oncol.* 96, 319-323, 1980. (I.F. 3.141)
- 45.Syrjänen, K.J. Morphology of the spleen white pulp in relation to the immunological functions in patients with far advanced bronchial carcinoma. *Immunobiol.* 157, 67-77, 1980. (I.F. 3.044)
- 46.Syrjänen, K.J. Spleen white pulp architecture in the assessment of immunity in patients with far advanced pancreatic carcinoma. *Scand. J. Gastroent.* 15, 609-615, 1980. (I.F. 2.199)
- 47.Soimakallio, S. and Syrjänen, K.J. Experimental cancer immunotherapy in DBA/2 mouse-mastocytoma model utilizing autologous tumor tissue polymerized with ethylchlorformiate. *Exp. Pathol.* 18,346-352, 1980. (I.F. 0.500)
- 48.Syrjänen, K.J. Immunological reactivity in patients with widespread carcinoma of the liver and bile ducts as evaluated on the basis of spleen white pulp morphology. *Arch. Geschwulstforsch.* 50, 220-229, 1980.
- 50.Syrjänen, K.J. Epithelial lesions suggestive of a condylomatous origin found closely associated with invasive bronchial squamous cell carcinoma. *Respiration* 40, 150-160, 1980. (I.F. 2.924)
- 51.Syrjänen, S.M. and Syrjänen, K.J. The effects on extraction wound healing of a new drug combination introduced for use in the prevention of post-extraction complications. *Brit. J. Oral Surg.* 19, 57-66, 1981. (I.F. 1.133)

- 52.Syrjänen, S.M. and Syrjänen, K.J. A new combination of drugs intended to be used as a preventive measure for the post-extraction complications. *Int. J. Oral Surg.* 10, 17-22, 1981. (I.F. 1.563)
- 53.Syrjänen, K.J. and Soimakallio, S. Immunological reactivity in the lymph nodes of the host following experimental cancer immunotherapy utilizing polymerized autologous tumor tissue particles. *Neoplasma* 27, 387-398, 1980. (I.F. 1.865)
- 54.Syrjänen, S.M., Syrjänen, K.J., Lamberg, M.A. and Sainio, P. Focal osteoporotic bone marrow defects of the jaws. Report of a case and survey of the literature. *Proc. Finn. dent. Soc.* 76, 219-224, 1980.s
- 55.Syrjänen, K.J. Morphology of the spleen in women who died of metastatic genital tract cancer. *Arch. Gynecol.* 230, 33-40, 1980. (I.F. 1.680)
- 56.Syrjänen, K.J. and Soimakallio, S. The use of polymerized autologous tumor tissue particles for experimental cancer immunotherapy in rats bearing Shay chloroma. *Exp. Pathol.* 19, 122-129, 1981. (I.F. 0.500)
- 57.Syrjänen, K.J. Condylomatous lesions of the uterine cervix with special reference to squamous cell carcinogenesis. *Gynecol. Obstet. Invest.* 11, 350-364, 1980. (I.F. 1.672)
- 58.Syrjänen, K.J. Bronchial squamous cell carcinomas associated with epithelial changes identical to condylomatous lesions of the uterine cervix. *Lung* 158, 131-142, 1980. (I.F. 2.000)
- 59.Syrjänen, K.J. and Syrjänen, S.M. Histological evidence for the presence of condylomatous epithelial lesions in association with laryngeal squamous cell carcinoma. *ORL*, 43, 181-194, 1981. (I.F. 0.880)
- 60.Syrjänen, K.J. Spleen white pulp morphology in the evaluation of the immunological reactivity of patients died in widespread gastric carcinoma. *Arch. Geschwulstforsch.* 50, 647-656, 1980.
- 61.Partanen, S. and Syrjänen, K.J. Argyrophilic cells in carcinoma of the female breast. *Virchows Arch. A. path. anat.* 391, 45-51, 1981. (I.F. 2.651)
- 62.Syrjänen, K.J. and Soimakallio, S. Polymerized autologous tumor tissue particles in experimental cancer immunotherapy with special reference to the effects on the immune system of the host. *Arch. Geschwulstforsch.* 50, 724-734, 1980.
- 63.Syrjänen, K.J. and Syrjänen, S.M. Premalignant epithelial changes in the uterine cervix of women aged less than thirty with special emphasis on the coexistent condylomatous lesions. *Indian J. Dermatol. Venereol. Leprol.* 47, 88-97, 1981. (I.F. 1.387)
- 64.Syrjänen, K.J. Immunomorphology in the evaluation of tumor-host relationships in patients with colorectal carcinoma. *Colo-Proctology* 3, 8-14, 1981.
- 65.Syrjänen, K.J. Evaluation of immunological reactivity on the basis of spleen white pulp morphology in patients with far advanced urological malignancy. *Neoplasma* 28, 209-218, 1981. (I.F. 1.865)
- 66.Syrjänen, K.J. Epithelioid cell granulomas in the lymph nodes draining human cancer. Ultrastructural findings of a breast cancer case. *Diagn. Histopathol.* 4, 291-294, 1981. (I.F. 0.410)

67.Syrjänen, K.J. Condylomatous lesions associated with precancerous changes and carcinomas of the uterine cervix. *Neoplasma* 28, 497-509, 1981. (I.F. 1.865)

68.Syrjänen, K.J. The Lymph Nodes. Reactions to Experimental and Human Tumors. *Exp. Pathol. Suppl.* 8, 1-132, 1982 (**ISSN 0232-2862**). (I.F. 0.500)

69.Väyrynen, M., Romppanen, T., Koskela, E., Castren, O. and Syrjänen, K. Verrucous squamous cell carcinoma of the female genital tract. Report of three cases and survey of the literature. *Int. J. Gynaecol. Obstet.* 19, 351-356, 1981. (I.F. 1.473)

70.Syrjänen, K.J. and Soimakallio, S. Tumor-host cell interactions in rats bearing Shay chloroma. Ultrastructural observations in animals receiving specific and nonspecific cancer immunotherapy. *Exp. Pathol.* 20, 135-145, 1981. (I.F. 0.500)

71.Syrjänen, S.M. and Syrjänen, K.J. Exfoliative cytology of the parotid saliva. A new technique for collecting a specimen without aspiration. *Proc. Finn. dent. Soc.* 77, 283-287, 1981.

72.Syrjänen, S.M. and Syrjänen, K.J. Prevention and treatment of post-extraction complications. Comparison of the effects on wound healing of Alvogyl® and a new drug combination. *Proc. Finn. dent. Soc.* 77, 305-311, 1981.

73.Syrjänen, K.J. Prenatal development of the post-capillary venules in human lymphatic tissue. *Lymphology* 14, 155-160, 1981. (I.F. 1.489)

74.Syrjänen, S.M. and Syrjänen, K.J. A morphometric analysis of the labial salivary glands of healthy young adults. In: *Morphometry in Morphological Diagnosis*, (Eds.) Y. Collan and T. Romppanen, Kuopio University Press, Kuopio, pp. 169-173, 1982.

75.Syrjänen, K.J. and Naukkarinen, A.H.M. Post-capillary venules in the T-cell area of chicken cloacal bursa with reference to the state of local immune response. In: *Morphometry in Morphological Diagnosis*, (Eds.) Y. Collan and T. Romppanen, Kuopio University Press, Kuopio, pp. 211-216, 1982.

76.Syrjänen, K.J. and Naukkarinen, A. Effects of a per anum immunization with SRBC on the structure of the post-capillary venules in the T-cell area of chicken cloacal bursa. *Immunol.* 45, 721-726, 1982. (I.F. 4.078)

77.Syrjänen, K.J. and Kosma, V-M. Hormone receptor levels related to histological parameters of tumor-host relationships in female breast carcinoma. *J. Surg. Oncol.* 21, 49-53, 1982. (I.F. 3.244)

78.Syrjänen, K.J. and Pyrhönen, S. Demonstration of human papilloma virus (HPV) antigen in the condylomatous lesions of the uterine cervix by immunoperoxidase technique. *Gynecol. Obstet. Invest.* 14, 90-96, 1982. (I.F. 1.672)

79.Syrjänen, S.M. and Syrjänen, K.J. Morphological and enzyme histochemical characterization of normal human labial salivary glands. *Proc. Finn. dent. Soc.* 78, 59-63, 1982.

80.Partanen, S. and Syrjänen, K. Histochemically demonstrable enzyme activities and their independence of the hormone receptor content in female breast carcinoma. *Histopathol.* 6, 771-777, 1982. (I.F. 3.425)

81.Syrjänen, K.J. Syrjänen, S.M. and Pyrhönen, S. Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas. *ORL* 44, 323-334, 1982. (I.F. 0.880)

- 82.Syrjänen, S., Tammisalo, E., Lilja, R. and Syrjänen, K. Radiological interpretation of the periapical cysts and granulomas. *Dentomaxillofac. Radiol.* 11, 89-92, 1982. (I.F. 1.919)
- 83.Syrjänen, K.J. Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. *Arch. Geschwulstforsch.* 52, 283-292, 1982.
- 84.Syrjänen, K.J., Pyrhönen, S., Syrjänen, S.M. and Lamberg, M.A. Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. *Brit. J. Oral Surg.* 21, 147-153, 1983. (I.F. 1.133)
- 85.Syrjänen, K.J., Pyrhönen, S., Aukee, S. and Koskela, E. Squamous cell papilloma of the oesophagus: a tumour probably caused by Human papilloma virus (HPV). *Diagn. Histopathol.* 5, 291-296, 1982. (I.F. 0.410)
- 86.Syrjänen, S., Syrjänen, K. and Horsmanheimo, M. Structure and function of salivary glands in psoriatics. *Arch. Dermatol. Res.* 274, 295-301, 1982. (I.F. 1.902)
- 87.Nuutinen, J. and Syrjänen, K. Angioleiomyoma of the larynx. Report of a case and review of the literature. *Laryngoscope* 93, 941-944, 1983. (I.F. 2.272)
- 88.Syrjänen, K.J., Pyrhönen, S. and Syrjänen, S.M. Evidence suggesting Human papillomavirus (HPV) etiology for the squamous cell papilloma of the paranasal sinus. *Arch. Geschwulstforsch.* 53, 77-82, 1983.
- 89.Mähönen, M., Uusitupa, M. and Syrjänen, K. Granulomatous hepatitis associated with carbamazepine treatment. *Duodecim* 98, 1341-1344, 1982.
- 90.Syrjänen, K., Väyrynen, M., Castren, O., Mäntyjärvi, R., Pyrhönen, S. and Yliskoski, M. Morphological and immunohistochemical evidence of Human papilloma virus (HPV) involvement in the dysplastic lesions of the uterine cervix. *Int. J. Gynaecol. Obstet.* 21, 261-269, 1983. (I.F. 1.473)
- 91.Syrjänen K.J. and Pyrhönen, S. Immunoperoxidase demonstration of Human papilloma virus (HPV) in dysplastic lesions of the uterine cervix. *Arch. Gynecol.* 233, 53-61, 1982. (I.F. 1.680)
- 92.Syrjänen, K.J. Syrjänen, S.M., Lamberg, M.A. and Pyrhönen, S. Human papillomavirus (HPV) involvement in the squamous cell lesions of the oral cavity. *Proc. Finn. dent. Soc.* 79, 1-8, 1983.
- 93.Syrjänen, K.J. and Pyrhönen, S. Demonstration of Human papilloma virus antigens in a case of urethral condyloma. *Scand. J. Urol. Nephrol.* 17, 267-270, 1983. (I.F. 1.243)
- 94.Syrjänen, K.J., Syrjänen, S.M., Lamberg, M.A. and Happonen, R.P. Local immunological reactivity in oral squamous cell lesions of possible HPV (Human papillomavirus) origin. *Arch. Geschwulstforsch.* 53, 537-546, 1983.
- 95.Syrjänen, K.J. Genital papillomavirus infections in the human. In: L.G.Keith, G.S. Berger and D.A. Edelman (Eds). *Infections in Reproductive Health. Vol. II. Uncommon Infections and Special Topics.* MTP Press Ltd., Lancaster, England. pp. 155-173, 1985.
- 96.Syrjänen, K.J. Human papillomavirus (HPV) lesions in association with cervical dysplasias and neoplasias. *Obstet. Gynecol.* 62, 617-624, 1983. (I.F. 5.656)
- 97.Syrjänen, K.J. Immunocompetent cells in uterine cervical lesions of Human papillomavirus (HPV) origin. *Gynecol. Obstet. Invest.* 16, 327-340, 1983. (I.F. 1.672)
- 98.Syrjänen, K., Syrjänen, S., Lamberg, M., Pyrhönen, S. and Nuutinen, J. Morphological and

immunohistochemical evidence suggesting Human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. *Int. J. Oral Surg.* 12, 418-424, 1983. (I.F. 1.563)

99.Kasurinen, J. and Syrjänen, K.J. Stainability of the peptide hormones in gastrointestinal apudomas as demonstrated by immunoperoxidase kits. *Scand. J. Gastroent.* 19, 167-172, 1984. (I.F. 2.199)

100.Syrjänen, S.M. and Syrjänen, K.J. Lysozyme in the labial salivary glands of patients with rheumatoid arthritis. *Z. Rheumatol.* 42, 332-336, 1983. (I.F. 0.569)

101.Partanen, K., Soimakallio, S., Kivimäki, T., Syrjänen, K., and Kormanen, M. Dynamic topography of the contrast enhancement of the spleen. *Eur. J. Radiol.* 4, 101-106, 1984. (I.F. 2.369)

102.Syrjänen, S., Markkanen, H. and Syrjänen, K. Morphological and immunohistochemical assessment of juvenile periodontitis. *J. Pedodont.* 8, 257-267, 1984.

103.Syrjänen, S., Markkanen, H. and Syrjänen, K. Inflammatory cells and their subsets in lesions of juvenile periodontitis.. A family study. *Acta Odontol. Scand.* 42, 285-292, 1984. (I.F. 1.309)

104.Syrjänen, K., Väyrynen, M., Castren, O., Mäntyjärvi, R. and Yliskoski, M. The relation between the type of immunoreactive cells found in Human papillomavirus (HPV) lesions of the uterine cervix and the subsequent behaviour of these lesions. *Arch. Gynecol.* 234, 189-196, 1984. (I.F. 1.680)

105.Syrjänen, S., Syrjänen, K. and Yli-Urpo, A. Transferrin reactivity in oral mucosa adjacent to different dental restorations. *Acta Odontol. Scand.* 42, 321-325, 1984. (I.F. 1.309)

106.Naukkarinen, A. and Syrjänen, K.J. Effects of anti-T lymphocyte serum on immunological reactivity and on the T-cell area of the cloacal bursa in the chicken. *Acta Path. Microbiol. Immunol. Scand. Sect. C.* 92, 145- 151, 1984. (I.F. 1.922)

107.Syrjänen, S.M. and Syrjänen, K.J. Enumeration of T cell subsets with antibodies in minor salivary glands of patients with rheumatoid arthritis. *Scand. J. Dent. Res.* 92, 275-281, 1984. (I.F. 1.956)

108.Syrjänen, K., Väyrynen, M., Castren, O., Yliskoski, M., Mäntyjärvi, R., Pyrhönen, S. and Saarikoski, S. Sexual behaviour of the females with Human papillomavirus (HPV) lesions in the uterine cervix. *Brit. J. Vener. Dis.* 60, 243-248, 1984. (I.F. 3.401)

109.Lamberg, M., Calonijs, B., Mäkinen, J., Paavolainen, M. and Syrjänen, K. Malignant myxoma (myxosarcoma) of the maxilla. *Scand. J. Dent. Res.* 92, 352-357, 1984. (I.F. 1.956)

110.Syrjänen, K., Happonen, R.P., Syrjänen, S. and Calonijs, B. Human papillomavirus (HPV) antigens and local immunological reactivity in oral squamous cell tumors and hyperplasias. *Scand. J. Dent. Res.* 92, 358-370, 1984. (I.F. 1.956)

111.Syrjänen, K., Mäntyjärvi, R., Väyrynen, M., Castren, O., Yliskoski, M., Saarikoski, S. and Pyrhönen, S. Herpes simplex virus infection of females with Human papillomavirus (HPV) lesions in the uterine cervix. *Cervix & l.f.g.t.* 2, 25-32, 1984. (I.F. 1.936)

112.Syrjänen, S., Syrjänen, K., Ikenberg, H., Gissmann, L. and Lamberg, M.A. Human papillomavirus closely related to HPV 13 found in a focal epithelial hyperplasia lesion (Heck Disease). *Arch. Dermatol. Res.* 276, 199-200, 1984. (I.F. 1.902)

- 113.Syrjänen, K.J. Current concepts on Human papillomavirus (HPV) infections in the genital tract and their relationship to intraepithelial neoplasia and squamous cell carcinoma. *Obstet. Gynecol. Surv.* 39, 252-265, 1984. (I.F. 2.361)
- 114.Kasurinen, J. and Syrjänen, K.J. The new endocrine tumors of the pancreas. *Duodecim* 100, 525-532, 1984.
- 115.Syrjänen, S., Markkanen, H. and Syrjänen, K. Cytokeratins in gingival epithelium of periodontally healthy and diseased subjects. *Proc. Finn. Dent. Soc.* 80, 115-120, 1984.
- 116.Syrjänen, K.J. Ihmisen papilloomavirus (HPV) ja levyepiteelisyöpä. *Solubiologi* 1, 3-7, 1984.
- 117.Naukkarinen, A. and Syrjänen, K.J. Effects of anti macrophage serum on immunological reactivity and on T cell area of the cloacal bursa in the chicken. *Acta path. microbiol. immunol. scand. Sect. C.* 92, 201-205, 1984. (I.F. 1.922)
- 118.Syrjänen, K., Mäntyjärvi, R., Väyrynen, M., Castren, O., Yliskoski, M. and Saarikoski, S. Chlamydial cervicitis in women followed-up for Human papillomavirus (HPV) lesions of the uterine cervix. *Acta Obstet. Gynecol. Scand.* 64, 467-471, 1985. (I.F. 1.985)
- 119.Syrjänen, K.J. Female genital tract infections by Human papillomavirus (HPV) and their association with intraepithelial neoplasia and squamous cell carcinoma. *Cervix & l.f.g.t.* 2, 103-126, 1984. (I.F. 1.936)
- 120.Syrjänen, S. and Syrjänen, K. Localization of transferrin in the labial salivary glands of patients with rheumatoid arthritis. *Clin. Rheumatol.* 3, 345-350, 1984. (I.F. 2.042)
- 121.Syrjänen, S.M. and Syrjänen, K.J. Inflammatory cell infiltrate in the labial salivary glands of patients with rheumatoid arthritis with special emphasis on tissue mast cells. *Scand. J. Dent. Res.* 92, 557-563, 1984. (I.F. 1.956)
- 122.Syrjänen, S., Linkosalo, E. and Syrjänen, K. Nasal cytology of patients with hypertrophic inferior conchae in panoramic radiographs. *Dentomaxillofac. Radiol.* 13, 129-133, 1984. (I.F. 1.919)
- 123.Pääkkönen, M., Alhava, E.A., Karjalainen, P., Korhonen, R., Savolainen K. and Syrjänen, K. Long term follow-up after partial gastrectomy by Billroth I and II partial gastrectomy. Gastrointestinal tract function and changes in bone metabolism. *Acta Chirurg. Scand.* 150, 485-488, 1984. (I.F. 0.716)
- 124.Kosma, V-M., Selkäinaho, K., Collan, Y., Syrjänen, K., Aalto, M-L. and Seppä, A. Grading of postcapillary venules in lymph nodes: Observer variation and reproducibility in subjective estimation and morphometric measurement. *Acta Stereol.* 3, 39-42, 1984.
- 125.Väyrynen, M., Syrjänen, K., Castren, O., Saarikoski, S. and Mäntyjärvi, R. Colposcopy in women with Papillomavirus lesions of the uterine cervix. *Obstet. Gynecol.* 65, 409-415, 1985. (I.F. 5.656)
- 126.Syrjänen, K., Kosma, V-M. and Collan, Y. Item classification and grading: An approach to non-mathematical morphometry. *Acta Stereol.* 2, 262-268, 1983.
- 127.Kosma, V-M., Collan, Y., Syrjänen, K., Aalto, M-L. and Selkäinaho, K. Observer variation and reproducibility of grading: Analysis of the postcapillary venules in human axillary lymph nodes using subjective and morphometric methods. *Acta Stereol.* 2, 342-348, 1983.

- 128.Naukkarinen, A.H.M. and Syrjänen, K.J. Effects of local and systemic administration of anti-macrophage serum on post capillary venules in the bursal T cell area of SRBC-immunized chickens. *Acta Stereol.* 2, 431-437, 1983.
- 129.Naukkarinen, A.H.M. and Syrjänen, K.J. Post-capillary venules in the bursal T cell area of SRBC-immunized chickens following local and systemic treatment with anti T lymphocyte serum. *Acta Stereol.* 2, 438-444, 1983.
- 130.Syrjänen, K., Väyrynen, M., Mäntyjärvi, R., Castren, O. and Saarikoski, S. Natural killer (NK) cells with HNK-1 phenotype in the cervical biopsies of women followed-up for Human papillomavirus (HPV) lesions. *Acta Obstet. Gynecol. Scand.* 65, 139-145, 1986. (I.F. 1.985)
- 131.Väyrynen, M., Syrjänen, K., Mäntyjärvi, R., Castren, O. and Saarikoski, S. Immunophenotypes of lymphocytes in prospectively followed up human papillomavirus lesions of the cervix. *Genitourin. Med.* 61, 190-196, 1985. (I.F. 3.401)
- 132.Väyrynen, M., Syrjänen, K., Mäntyjärvi, R., Castren, O. and Saarikoski, S. Langerhans cells in Human papillomavirus (HPV) lesions of the uterine cervix identified by the monoclonal antibody OKT-6. *Int. J. Gynaecol. Obstet.* 22, 375-383, 1984. (I.F. 1.674)
- 133.Kosma, V-M. and Syrjänen, K.J. Regional lymph node reactions related to hormone receptor status in female breast carcinoma. *Arch. Geschwulstforsch.* 55, 123-130, 1985.
- 134.Kasurinen, J. and Syrjänen, K.J. Peptide hormone immunoreactivity and prognosis in small cell carcinoma of the lung. *Respiration* 49, 61-67, 1986. (I.F. 2.651)
- 135.Syrjänen, K., Väyrynen, M., Hippeläinen, M., Castren, O., Saarikoski, S. and Mäntyjärvi, R. The in situ immunological reactivity and its significance in the clinical behaviour of the cervical Human papillomavirus lesions. *Neoplasma* 32, 181-190, 1985. (I.F. 1.865)
- 136.Syrjänen, K., Väyrynen, M., Saarikoski, S., Mäntyjärvi, R., Parkkinen, S., Hippeläinen, M. and Castren, O. Natural history of cervical Human papillomavirus (HPV) infections based on prospective follow-up. *Brit. J. Obstet. Gynaecol.* 92, 1086-1092, 1985. (I.F. 4.039)
- 137.Syrjänen, S., Markkanen, H. and Syrjänen, K. Gingival B -microglobulin in juvenile and chronic periodontitis. *Acta Odontol. Scand.* 43, 133-138, 1985. (I.F. 1.309)
- 138.Pääkkönen, M., Aukee, S., Syrjänen, K. and Mäntyjärvi, R. Gastritis, duodenogastric reflux and bacteriology of the gastric remnant in patients operated for peptic ulcer by Billroth I operation. *Ann. Clin. Res.* 17, 32-36, 1985.
- 139.Syrjänen, K., Väyrynen, M., Mäntyjärvi, R., Saarikoski, S. ja Castren, O. Ihmisen papillomavirus (HPV) ja kohdunkaulan syöpä. *Duodecim*, 101, 959-968, 1985.
- 140.Syrjänen, K.J. Human papillomavirus (HPV) infections of the female genital tract and their associations with intraepithelial neoplasia and squamous cell carcinoma. *Pathol. Annu.* 21, 53-89, 1986. (I.F. 1.818)
- 141.Syrjänen, K., de Villiers, E-M., Väyrynen, M., Mäntyjärvi, R., Parkkinen, S., and Castren, O. Cervical papillomavirus infection progressing to invasive cancer in less than three years. *Lancet* 325, 510-511, 1985. (I.F. 39.207)
- 142.Syrjänen, K., Väyrynen, M., Hippeläinen, M., Castren, O., Saarikoski, S. and Mäntyjärvi, R. Electron microscopic assessment of cervical punch biopsies in women followed-up for Human papillomavirus (HPV) lesions. *Arch. Geschwulstforsch.* 55, 131-138, 1985.
- 143.Vaara, J., Tukiainen, H., Syrjänen, K. and Terho, E.O. Solitary amyloid tumour of the lung: a rare manifestation of primary amyloidosis. *Eur. J. Respir. Dis.* 67, 385-387, 1985.

144.Syrjänen, K.J. and Syrjänen, S.M. Human Papillomavirus (HPV) infections related to cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma of the uterine cervix. *Ann. Clin. Res.* 17, 45-56, 1985.

145.Naukkarinen, A., Väätäinen, N., Syrjänen, K.J. and Horsmanheimo, M. Immunophenotyping of the dermal cell infiltrate in lichen planus treated with PUVA. *Acta Dermato-Venereol.* 65, 398-402,1985. (I.F. 3.025)

146.Naukkarinen, A. and Syrjänen, K.J. Immunoresponse in the gastrointestinal tract. In: *Gastrointestinal Toxicology.* (Eds.) K. Rozman and O. Hänninen. Elsevier Science Publishers B.V., Amsterdam. pp. 213-245, 1986.

147.Syrjänen, K., Väyrynen, M., Mäntyjärvi, R., Parkkinen, S., Saarikoski, S., Syrjänen, S. and Castren, O. Natural history of HPV infections in uterine cervix as determined by prospective follow-up. In: *Papilloma Viruses: Molecular and Clinical Aspects.* (Eds.) P.M. Howley and T.R. Broker. UCLA Symposia on Molecular and Cellular Biology, Alan R. Liss, Inc., New York. New Series, Vol. 32, 31-45, 1985.

148.Syrjänen, K., Mäntyjärvi, R., Parkkinen, S., Väyrynen, M., Saarikoski, S., Syrjänen, S. and Castren, O. Prospective follow-up in assessment of the biological behaviour of cervical HPV-associated dysplastic lesions. *Banbury Rep.* 21, 167-177, 1986.

149.Syrjänen, S., Syrjänen, K. and Yli-Urpo, A. Assessment of oral mucosal changes in patients treated with different metallic restorations and prosthesis. *J. Dent.* 13, 244-254, 1985. (I.F. 3.109)

150.Syrjänen, K., Nuutinen, J. and Kärjä, J. Tumor differentiation and tumor-host interactions as prognostic determinants in squamous carcinoma of the lip. *Acta Otolaryngol.* (Stockh). 101, 152-160, 1986. (I.F. 0.990)

151.Syrjänen, K., Mäntyjärvi, R., Väyrynen, M., Holopainen, H., Saarikoski, S. and Castren, O. Factors influencing the biological behaviour of cervical Human papillomavirus (HPV) infections in prospectively followed-up women. *Arch. Geschwulstforsch.* 55, 457-466, 1985.

152.Fräki, J., Väätäinen, N. and Syrjänen, K. Epidermodysplasia verruciformis esimerkkitautila virusten karsinogeneesistä. *Duodecim.* 102, 36-41, 1986.

153.Syrjänen, K., Mäntyjärvi, R., Väyrynen, M., Holopainen, H., Saarikoski, S., Syrjänen, S., Parkkinen, S. and Castren, O. Structural protein expression in biological behavior of Human papillomavirus infections in uterine cervix. *Cervix & I.f.g.t.* 3, 249-266, 1985. (I.F. 1.936)

154.Syrjänen, K., Parkkinen, S., Mäntyjärvi, R., Väyrynen, M., Syrjänen, S., Holopainen, H., Saarikoski, S. and Castren, O. Human papillomavirus (HPV) type as an important determinant of the natural history of HPV infections in uterine cervix. *Eur. J. Epidemiol.* 1, 180-187, 1985. (I.F. 7.105)

155.Syrjänen, K., Mäntyjärvi, R., Väyrynen, M., Parkkinen, S., Holopainen, H., Syrjänen, S., Saarikoski, S. and Castren, O. Coexistent Chlamydial infections related to natural history of Human papillomavirus (HPV) lesions in uterine cervix. *Genitourin. Med.* 62, 345-351, 1986. (I.F. 3.401)

156.Syrjänen, S., Syrjänen, K., Mäntyjärvi, R., Parkkinen, S., Väyrynen, M., Saarikoski, S. and Castren, O. Human papillomavirus (HPV) DNA sequences demonstrated by *in situ* DNA hybridization in serial paraffin-embedded cervical biopsies. *Arch. Gynecol.* 239, 39-48, 1986. (I.F. 1.680)

157. Tosi, P., Syrjänen, K., Cintonino, M., Mäntyjärvi, R., Luzi, P., Leoncini, L. and Laatikainen, A. Immune response against P815x2 mastocytoma growing in syngeneic DBA/2 mice. I. Morphometric assessment of lymph node immunoreactivity and analysis of circulating antibodies. *Exp. Pathol.* 30, 65-74, 1986. (I.F. 0.500)
158. Syrjänen, K., Tosi, P., Cintonino, M., Mäntyjärvi, R., Luzi, P., Leoncini, L. and Laatikainen, A. Immune response against P815x2 mastocytoma growing in syngeneic DBA/2 mice. II. Morphometric assessment of immunoreactivity in the thymus and spleen related to lymphocyte subsets in peripheral blood. *Exp. Pathol.* 30, 75-82, 1986. (I.F. 0.500)
159. Kentala, J., Luoma, H., Syrjänen, S., Syrjänen, K. and Spets-Happonen, S. Immunoreactivity of salivary glands and Peyer's patches to oral application of streptococcus mutans serotype g in gnotobiotic rats. In: *The Borderland Between Caries & Periodontal Disease III*. (Eds.) T. Lehner and G. Cimasoni. Editions Medicine et Hygiene, Geneva, Switzerland. pp. 269-273, 1986.
160. Lind, P., Syrjänen, S., Syrjänen, K., Koppang, H.S. and Aas, E. Local immunoreactivity and Human papillomavirus (HPV) in oral precancer and cancer lesions. *Scand. J. Dent. Res.* 94, 419-426, 1986. (I.F. 1.956)
161. Syrjänen, S.M., von Krogh, G. and Syrjänen, K. Detection of human papillomavirus DNA in anogenital condylomata in men using in situ DNA hybridization applied to paraffin sections. *Genitourin. Med.* 63, 32-39, 1987. (I.F. 3.401)
162. Syrjänen, K., Väyrynen, M., Mäntyjärvi, R., Holopainen, H., Saarikoski, S., Syrjänen, S., Parkkinen, S. and Castren, O. Electron microscopy in assessment of the biological behavior of Human papillomavirus (HPV) infections in the uterine cervix. *Neoplasma* 33, 493-506, 1986. (I.F. 1.865)
163. Parkkinen, S., Mäntyjärvi, R., Syrjänen, K. and Ranki, M. Detection of Human papillomavirus DNA by the nucleic acid sandwich hybridization method from cervical scraping. *J. Med. Virol.* 20, 279-288, 1986. (I.F. 2.347)
164. Santala, M., Suonio, S., Syrjänen, K., Uronen, M.T. and Saarikoski, S. Malignant fibrous histiocytoma of the vulva. *Gynec. Oncol.* 27, 121-126, 1987. (I.F. 3.774)
165. Syrjänen, S.M., Syrjänen, K.J. and Lamberg, M.A. Detection of Human papillomavirus (HPV) DNA in oral squamous cell lesions using in situ DNA-hybridization applied on paraffin-sections. *Oral Surg.* 62, 660-667, 1986. (I.F. 1.457)
166. Turakka, L., Syrjänen, S., Lammi, J. and Syrjänen, K. Hydrogel dosage form of the drug combination recently introduced for dental post-extraction complications. *Acta Pharm. Fenn.* 95, 77-81, 1986.
167. Syrjänen, S. and Syrjänen, K. An improved in situ DNA hybridization protocol for detection of Human papillomavirus (HPV) DNA sequences in paraffin-embedded sections. *J. Virol. Meth.* 14, 293-304, 1986. (I.F. 1.781)
168. Tukiainen, H., Terho, O., Syrjänen, K. and Sutinen, S. Keuhkojen benigni lymfosyyttinen angiitti ja granulomatoosi. *Duodecim*, 103, 47-51, 1987.
169. Syrjänen, K., Mäntyjärvi, R., Väyrynen, M., Syrjänen, S., Parkkinen, S., Yliskoski, M., Saarikoski, S. and Castren, O. Human papillomavirus (HPV) infections involved in the neoplastic process of the uterine cervix as established by prospective follow-up of 513 women for two years. *Eur. J. Gynaecol. Oncol.* 8, 5-16, 1987. (I.F. 0.640)
170. Tosi, P., Syrjänen, K., Cintonino, M., Mäntyjärvi, R., Luzi, P., Miracco, C., Laatikainen, A., Leoncini, L. and Santopietro, R. Immune response against P815X2 mastocytoma growing

in syngeneic DBA/2 mice. III. Morphometric assessment of the dynamic changes in post-capillary venules as regulatory elements of lymphocyte recirculation in tumor-draining lymph nodes. Arch. Geschwulstforsch. 57, 7-15, 1987.

171.Syrjänen, K.J., Mäntyjärvi, R., Väyrynen, M., Syrjänen, S., Parkkinen, S., Yliskoski, M., Saarikoski, S., Sarkkinen, H., Nurmi, T. and Castren, O. Assessing the biological potential of Human papillomavirus infections in cervical carcinogenesis. Cancer Cells 5, 281-289, 1987.

172.Syrjänen, S., Partanen, P. and Syrjänen, K. Comparison of the in situ DNA hybridization protocols using S-labeled probes and biotin-labeled probes in detection of HPV DNA sequences. Cancer Cells 5, 329-336, 1987.

173.Syrjänen, K.J. Papillomaviruses and Cancer. In: Papillomaviruses and Human Disease. (Eds.). K. Syrjänen, L. Gissmann, L. Koss. Springer Verlag, Berlin, Heidelberg, pp. 468-503, 1987.

174.Kärjä, J., Syrjänen, K. and Nuutinen, J. Immunocompetent cell reaction in prognostic evaluation of squamous cell carcinoma of the lip. Acta Otolaryngol. (Stockh). 103, 640-643, 1987. (I.F. 1.099)

175.Syrjänen, K.J. and Syrjänen, S.M. Immunology of Human Papillomavirus (HPV) infections in the reproductive tract. In: Perspectives in Immunoreproduction: Conception and Contraception. (Eds.) S. Mathur and C.M. Fredericks. Hemisphere Publishing Corporation, Washington, D.C., pp. 319-336, 1988.

176.Syrjänen, K.J. Histopathology, cytology, immunohistochemistry and HPV typing techniques. In: Genital Papilloma Virus Infection: A Survey for the Clinician. (Eds.) G. von Krogh and E. Rylander. Conpharm AB, Karlstad, Sweden. pp. 33-67, 1989.

177.Syrjänen, K., Mäntyjärvi, R., Väyrynen, M., Syrjänen, S., Parkkinen, S., Yliskoski, M., Saarikoski, S. and Castren, O. Evolution of Human papillomavirus (HPV) infections in the uterine cervix during a long-term prospective follow-up. Appl. Pathol. 5, 121-135, 1987.

178.Syrjänen, S., Syrjänen, K., Mäntyjärvi, R., Collan, Y. and Kärjä, J. Human papillomavirus DNA in squamous cell carcinomas of the larynx demonstrated by in situ DNA hybridization. ORL 49, 175-186, 1987. (I.F. 0.667)

179.Syrjänen, K. and Syrjänen, S. Human papillomavirus DNA in bronchial squamous cell carcinomas. Lancet 329, 168-169, 1987. (I.F. 39.207)

180.Syrjänen, K.J. Biology of Human papillomavirus (HPV) infections and their role in squamous cell carcinogenesis. Med. Biol. 65, 21-39, 1987.

181.Laatikainen, A., Syrjänen, K., Mäntyjärvi, R. and Tosi, P. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. V. Spleen immunoreactivity and cell mediated cytotoxicity. Arch. Geschwulstforsch. 57, 265-274, 1987.

182.Laatikainen, A., Syrjänen, K., Mäntyjärvi, R. and Tosi, P. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. IV. Lymph node immunoreactivity and cell mediated cytotoxicity. Neoplasma 34,431-440, 1987. (I.F. 1.865)

183.Syrjänen, S., Happonen, R-P., Virolainen, E., Siivonen, L. and Syrjänen, K. Detection of Human Papillomavirus (HPV) structural antigens and DNA types in nasal inverted papillomas and squamous cell carcinomas of the nasal cavities and paranasal sinuses. Acta Otolaryngol (Stockh) 104, 334-341, 1987. (I.F. 1.099)

184.Syrjänen, K.J., Mäntyjärvi, R., Väyrynen, M., Yliskoski, M., Syrjänen, S.M., Seppo Saarikoski, S., Nurmi, T., Parkkinen, S., Castren, O. Cervical smears in assessment of the

natural history of cervical Human papillomavirus (HPV) infections in prospectively followed women. *Acta Cytol.* 31, 855-865, 1987. (I.F. 1.562)

185.Syrjänen, K.J. Les infections a papillomavirus humain (HPV) facteur carcinogene possible by carcinoma epidermoide du col uterin. *Contracept. Fertil. Sexual.* 15, 963-973, 1987. (I.F. 0.256)

186.Syrjänen, K. and Syrjänen, S. Morphological relationship of papillomavirus infections to cervical, vulvar and penile cancer. In: *Herpes and Papilloma Viruses*, vol II. (eds). G. de Palo, F. Rilke and H. zur Hausen. Serono Symposia Publications, Raven Press, Vol 46, 179-198, 1988.

187.Syrjänen, S., Cintonino, M., Armellini, D., Del Vecchio, M.T., Leoncini, P., Bugnoli, M., Pallini, V., Silvestri, S., Tosi, P., Mäntyjärvi, R. and Syrjänen, K. Expression of cytokeratin polypeptides in Human papillomavirus (HPV) lesions of the uterine cervix. I. Relationship to Grade of CIN and HPV Type. *Int. J. Gynec. Pathol.* 9, 23-38, 1988. (I.F. 1.665)

188.Syrjänen, S.M., Syrjänen, K.J., Happonen, R-P. and Lamberg, M.A. In situ DNA hybridization analysis of Human papillomavirus (HPV) sequences in benign oral mucosal lesions. *Arch. Dermatol. Res.* 279, 543-549, 1987. (I.F. 1.902)

189.Syrjänen, K.J. Virology and pathogenesis. In: *Genital Papilloma Virus Infections and Their Sequelae*. Proceedings of an international symposium held during the 17th World Congress of Dermatology, Berlin, May 1987. pp. 5-15, 1987.

190.von Krogh, G., Syrjänen, S. and Syrjänen, K. Advantage of human papillomavirus typing in the clinical evaluation of genitoanal warts; Experience with the in situ deoxyribonucleic acid hybridization technique applied on paraffin sections. *J. Amer. Acad. Dermatol.* 18, 495-503, 1988. (I.F. 4.449)

191.Tosi, P., Luzi, P., Santopietro, R., Miracco, C., Lio, R., Syrjänen, S., Mäntyjärvi, R. and Syrjänen, K. Morphometric assessment of the biological potential of Human papillomavirus (HPV) infections in the uterine cervix. *Appl. Pathol* 6, 247-257, 1988.

192.Syrjänen, K.J. Human papillomavirus (HPV) infections and their associations with squamous cell neoplasia. *Arch. Geschwulstforsch.* 57, 417-443, 1987.

193.Tukiainen, H., Vaara, J., Syrjänen, K. and Terho, E.O. Granulomatous gastritis as a diagnostic problem between sarcoidosis and other granulomatous disorders. *Sarcoidosis*, 5, 66-67, 1988. (I.F. 1.744)

194.Tukiainen, H., Terho, E.O., Syrjänen, K. and Sutinen, S. Benign lymphocytic angiitis and granulomatosis. A case report. *Thorax* 43, 649-650, 1988. (I.F. 8.121)

195.Parkkinen, S., Syrjänen, S., Syrjänen, K., Yliskoski, M., Tenhunen, J., Mäntyjärvi, R. and Ranki, M. Screening of premalignant cervical lesions for HPV 16 DNA by sandwich and in situ hybridization techniques. *Gynec. Oncol.* 30, 251-264, 1988. (I.F. 3.774)

196.Cintonino, M., Syrjänen, S., Leoncini, P., Bellizzi De Marco, E., Petracca, R., Pallini, V., Tosi, P., Mäntyjärvi, R., and Syrjänen, K. Altered expression of filaggrin in Human papillomavirus (HPV) lesions of the uterine cervix. *Arch. Gynecol. Obstet.* 241, 235-248, 1988. (I.F. 1.680)

197.Syrjänen, S., Partanen, P., Mäntyjärvi, R. and Syrjänen, K. Sensitivity of in situ hybridization techniques using biotin- and S-labeled Human papillomavirus (HPV) DNA probes. *J. Virol. Meth.* 19, 225-238, 1988. (I.F. 1.781)

198.Syrjänen, K., Mäntyjärvi, R., Saarikoski, S., Väyrynen, M., Syrjänen, S., Parkkinen, S., Yliskoski, M., Saastamoinen, J. and Castren, O. Factors associated with progression of cervical Human papillomavirus (HPV) infections into carcinoma in situ during a long-term prospective follow-up. *Brit. J. Obstet. Gynaecol.* 95, 1096-1102, 1988. (I.F. 3.862)

199.Sorvari, T., Sarnesto, A. and Syrjänen, K. Type IV collagen in the basal membrane of Human papillomavirus (HPV) associated premalignant and malignant squamous cell lesions of the uterine cervix. *Gynec. Obstet. Invest.* 26, 324-331, 1988. (I.F. 1.696)

200.Syrjänen, K.J. Infecciones de transmisión sexual por papillomavirus humano (HPV): Evaluación de su historia natural y significación clínica. Revista Ibero-Latinoamericana de E.T.S. 1, 7-18, 1987.

201.Syrjänen, K.J. Genital papillomavirus (HPV) infections: Clinical significance and associations with genital cancer. *Anglo-Scandinavian Conference on Sexually Transmitted Diseases.* (Eds.) J.D. Oriel and M. Waugh. *Roy. Soc. Med. Serv. Int. Cong. Symp. Ser.* 135, 45-53, 1988.

202.Mäntyjärvi, R., Sarkkinen, H., Parkkinen, S., Ryhänen, A., Karjalainen, H., Syrjänen, K. and Syrjänen, S. Phenotypic transformation of primary mouse fibroblasts by BPV 1 DNA. *Arch. Virol.* 100, 17-25, 1988. (I.F. 2.390)

203.Mäntyjärvi, R., Sarkkinen, H., Karjalainen, H., Parkkinen, S., Ryhänen, A., Syrjänen, K., Jägerroos, H. and Nurmi, T. Tumour-associated antigens in primary mouse fibroblasts induced by transformation with bovine papillomavirus type 1. *Exp. Pathol.* 35, 25-33, 1988. (I.F. 0.500)

204.Lindeberg, H., Syrjänen, S., Kärjä, J. and Syrjänen, K. Human papillomavirus (HPV) type 11 DNA in squamous cell carcinomas and pre-existing multiple laryngeal papillomas. *Acta Otolaryngol. (Stockh).* 107, 141-149, 1989. (I.F. 1.099)

205.Syrjänen, S.M., Syrjänen, K.J., Happonen, R-P. Human papillomavirus (HPV) DNA sequences in oral precancerous lesions and squamous cell carcinoma demonstrated by in situ hybridization. *J. Oral Pathol.* 17, 273-278, 1988. (I.F. 1.870)

206.Syrjänen, K., Syrjänen, S., Kellokoski, J., Kärjä, J. and Mäntyjärvi, R. Human papillomavirus (HPV) type 6 and 16 DNA sequences in bronchial squamous cell carcinomas demonstrated by in situ DNA hybridization. *Lung* 167, 33-42, 1989. (I.F. 2.000)

207.Yliskoski, M., Saarikoski, S., Syrjänen, K., Syrjänen, S. and Castren, O. Cryotherapy and CO₂-laser vaporization in the treatment of Human papillomavirus (HPV) infections in the uterine cervix and vagina. *Acta Obstet. Gynecol. Scand.* 68, 619-625, 1989. (I.F. 1.985)

208.Mäntyjärvi, R., Sarkkinen, H., Parkkinen, S., Laatikainen, A., Ryhänen, A., and Syrjänen, K. Tumorigenicity of primary mouse fibroblasts transformed by bovine papillomavirus type 1. *Intervirology* 29, 311-319, 1988. (I.F. 1.822)

209.Parkkinen, S., Mäntyjärvi, R., Syrjänen, K. and Ranki, M. Sandwich hybridization in solution: A rapid method to screen HPV 16 DNA in cervical scrapes. *Molec. Cell. Probes.* 3, 1-11, 1989. (I.F. 1.852)

210.Syrjänen, K. ja Syrjänen, S. Gynekologisten papillomavirus (HPV)-infektioiden biologinen merkitys ja niiden DNA-diagnostiikka. *Duodecim* 104, 1864-1873, 1988.

211.Syrjänen, K. Human papillomavirus (HPV) lesions of the vulva: Histopathology. In: *Patologia Benigna e Maligna della Vulva.* (eds). A. Cardone and R. Piccoli, CIC Edizioni Internazionali, Roma, pp. 39-47, 1989.

- 212.Klemi, P.J., Joensuu, H., Syrjänen, S., Syrjänen, K., Siivonen, L. and Virolainen, E. Association of DNA aneuploidy with Human papillomavirus induced malignant transformation of sino-nasal transitional papillomas. *Otolaryngol. Head Neck Surg.* 100, 563-567, 1989. (I.F. 2.021)
- 213.Syrjänen, K., Sarikoski, S., Väyrynen, M., Syrjänen, S., Saastamoinen, J. and Castren, O. Factors associated with the clinical behavior of cervical human papillomavirus infections during a long-term prospective follow-up. The experience of the Kuopio Institute. *Cervix & I.f.g.t.* 7, 131-143, 1989. (I.F. 1.963)
- 214.Kataja, V., Syrjänen, K., Mäntyjärvi, R., Väyrynen, M., Syrjänen, S., Saarikoski, S., Parkkinen, S., Yliskoski, M., Salonen, J.T., and Castren O. Prospective follow-up of cervical HPV infections: Life-table analysis of histopathological, cytological and colposcopic data. *Eur. J Epidemiol.* 5, 1-7, 1989. (I.F. 7.105)
- 215.Costa, S., Poggi, M.G., Palmisano, L., Syrjänen, S., Yliskoski, M. Syrjänen, K. Intramuscular β -interferon treatment of human papillomavirus lesions in the lower female genital tract. *Cervix & I.f.g.t.* 6, 203-212, 1988. (I.F. 1.963) (I.F. 1.963)
- 216.Syrjänen, S., von Krogh, G. and Syrjänen, K. Anal condylomas in men. I. Histopathological and virological assessment. *Genitourin. Med.* 65, 216-224, 1989. (I.F. 3.401)
- 217.Syrjänen, K. HPV in genital squamous cell tumors: Epidemiology and clinical synopsis. In: *Genital Papillomavirus Infections: Modern Diagnosis and Treatment*. Eds. G. Gross, S. Jablonska, H. Pfister, H.E. Stegner. Springer Verlag, pp. 3-12, 1990.
- 218.Santala, M., Syrjänen, K. and Saarikoski, S. Squamous cell carcinoma of the vulva with cutaneous metastases. *Acta Obstet. Gynecol. Scand.* 68. 271-273, 1989. (I.F. 1.985)
- 219.Syrjänen, K. and Syrjänen, S. Concept on the existence of Human papillomavirus (HPV) DNA in histologically normal squamous epithelium of the genital tract should be re-evaluated. *Acta Obstet. Gynec. Scand.* 68, 613-617, 1989. (I.F. 1.985)
- 220.Leoncini, P., Petracca, R., Ruggiero, P., Cintorino, M., Syrjänen, S., Mäntyjärvi, R. and Syrjänen, K. Expression of cytokeratin no. 19 polypeptide in genital papillomavirus lesions. *Gynec. Obstet. Invest.* 29, 59-66, 1990. (I.F. 1.672)
- 221.Yliskoski, M., Cantell, K., Syrjänen, K. and Syrjänen, S. Topical treatment with human leukocyte interferon of HPV 16 infections associated with cervical and vaginal intraepithelial neoplasia. *Gynecol. Oncol.* 36, 353-357, 1990. (I.F. 3.774)
- 222.Syrjänen, K., Hakama, M., Saarikoski, S., Väyrynen, M., Yliskoski, M., Syrjänen, S., Kataja, V. and Castren, O. Prevalence, incidence and estimated life-time risk of cervical human papillomavirus (HPV) infections in nonselected Finnish female population. *Sex. Transm. Dis.* 17, 15-19, 1990. (I.F. 2.842)
- 223.Mäntyjärvi, M., Syrjänen, S., Kaipainen, S., Mäntyjärvi, R., Kahlos, T. and Syrjänen, K. Detection of human papillomavirus type 11 DNA in a conjunctival squamous cell papilloma by in situ hybridization with biotinylated probes. *Acta Ophthalmol.* 67, 425-429, 1989. (I.F. 3.032)
- 224.Ji, H., Syrjänen, S., Syrjänen, K., Wu, A. and Chang, F. In situ hybridization analysis of HPV DNA in cervical precancer and cervical cancers from China. *Arch. Gynecol. Obstet.* 247, 21-29, 1990. (I.F. 1.680)

- 225.Chang ,F., Syrjänen, S., Qiong S., Hongxiu, J., and Syrjänen, K. Human papillomavirus (HPV) DNA in esophageal precancer lesions and squamous cell carcinomas from China. *Int. J. Cancer.* 45, 21-25, 1990. (I.F. 5.531)
- 226.Laatikainen, A., Karjalainen, H., Sarkkinen, H., Syrjänen, K. and Mäntyjärvi, R. Generation of cell-mediated cytotoxicity against bovine papilloma virus-transformed primary mouse cell lines. *Cancer Immunol. Immun.* 30, 351-356, 1990. (I.F. 4.846)
- 227.Kataja, V., Syrjänen, K., Syrjänen, S., Mäntyjärvi, R., Yliskoski, M., Saarikoski, S., Mäntyjärvi, R. and Salonen, J.T. Prospective follow-up of genital HPV infections: Survival analysis of the HPV typing data. *Eur. J. Epidemiol.* 6, 9-14, 1990. (I.F. 7.105)
- 228.Ji, H., Syrjänen, S., Matinlompola, T., Huovinen, K., Fuju, C.and Syrjänen, K. Subclinical HPV infections in the lower female genital tract: Histological evaluation and detection of HPV DNA by in situ hybridization with biotinylated probes. *Cervix & I.f.g.t.* 7, 255-266, 1989. (I.F. 1.963)
- 229.Syrjänen, K.J. Epidemiology of Human papillomavirus (HPV)infections and their associations with genital squamous cell cancer. *APMIS.* 97, 957-970, 1989. (I.F. 1.933)
- 230.Syrjänen, K.J. Papillomavirus infections, precancers and epidermoid cancers. In: *Papillomaviruses in Human Pathology. Recent Progress in Epidermoid Precancers.* Ed. J. Monsonego. Serono Symposia Publications 78, 13-29, 1990.
- 231.Syrjänen, K.J. and Syrjänen, S.M. Papillomavirus infections, precancers and epidermoid cancers of sinuses, oropharynx, oesophagus and lung. In: *Papillomaviruses in Human Pathology. Recent Progress in Epidermoid Precancers.* Ed. J. Monsonego. Serono Symposia Publications 78,315-329, 1990.
- 232.Chang, F., Syrjänen, S., Shen, Q., Ji, H. and Syrjänen, K. Detection of Human papillomavirus (HPV) in genital warts and carcinomas by DNA in situ hybridization in Chinese patients. *Cytopathol.* 1, 97-103, 1990. (I.F. 1.761)
- 233.Naukkarinen, A. and Syrjänen, K. Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas. Correlation to tumour differentiation. *J. Pathol.* 160, 217-222, 1990. (I.F. 7.381)
- 234.Naukkarinen, A. and Syrjänen, K. Expression of transferrin, lactoferrin and breast carcinoma antigen in infiltrating breast carcinomas as related to tumor differentiation and hormone receptor status. *Arch. Geschwulstforsch.* 61, 82-88, 1991.
- 235.Syrjänen, S., von Krogh, G., Kellokoski, J. and Syrjänen, K. Two different papillomavirus (HPV) types associated with oral mucosal lesions in an HIV-seropositive male. *J. Oral. Pathol. Med.* 18, 366-370, 1989. (I.F. 1.859)
- 236.Hellberg, D., Nilsson, S., Gad, A., Hongxiu, J., Fuju, C., Syrjänen, S. and Syrjänen, K. Behavior of cervical intraepithelial neoplasia (CIN) associated with various human papillomavirus (HPV) types. *Arch. Gynecol. Obstet.* 252, 119-128, 1993. (I.F. 1.680)
- 237.Syrjänen, K. and Syrjänen, S. Epidemiology of Human papilloma virus infections and genital neoplasia. *Scand. J. Infect. Dis. Suppl.* 69, 7-17, 1990. (I.F. 1.640)
- 238.Syrjänen, S., Kärjä, V., Chang, F., Johansson, B., and Syrjänen K. Epstein-Barr Virus involvement in salivary gland lesions associated with Sjögrens syndrome. *ORL.* 52, 254-259, 1990. (I.F. 0.640)
- 239.Syrjänen, K.J. and Syrjänen, S.M. DNA hybridization techniques in diagnostic cytopathology. *Finska Läkaresällskapets Handlingar.* 133, 263-271, 1989.

- 240.Chang, F., Qiong, S., Jian, Z., Chao, W., Dongyu, W., Syrjänen, S. and Syrjänen, K. Detection of human papillomavirus (HPV) DNA in cytological specimens derived from esophageal precancer lesions and cancer. *Scand. J. Gastroenterol.* 25,383-388, 1990. (I.F. 2.199)
- 241.Kellokoski, J., Syrjänen, S., Syrjänen, K. and Yliskoski, M. Oral mucosal changes in women with genital HPV infection. *J. Oral Pathol. Med.* 19, 142-148, 1990. (I.F. 1.859)
- 242.Kellokoski, J., Syrjänen, S., Kataja, V., Yliskoski, M. and Syrjänen, K. Acetowhite staining and its significance in diagnosis of oral HPV infection in women with genital HPV infection. *J. Oral Pathol. Med.* 19, 278-283, 1990. (I.F. 1.859)
- 243.Syrjänen, K.J. Papillomavirus infections- Histology and cytology of genital infections. In: *Dermatology in Europe*. E. Panconesi (Ed.). Blackwell Scientific Publications, Oxford, pp. 74-79, 1991.
- 244.Syrjänen, S., Saastamoinen, J., Chang, F., Ji, Hx. and Syrjänen, K. Colposcopy, punch biopsy, in situ DNA hybridization and polymerase chain reaction in searching for genital Human papillomavirus (HPV) infections in women with normal PAP smears. *J. Med. Virol.* 31, 259-266, 1990. (I.F. 1.998)
- 245.Chang, F., Kosunen, O., Kosma-V-M., Syrjänen, S., Lahtinen, J. and Syrjänen, K. Verrucous carcinoma of the anus containing Human papillomavirus type 16 DNA detected by in situ hybridization. A case report. *Genitourin. Med.* 66, 342-345, 1990. (I.F. 3.401)
- 246.Costa, S., Terzano, P., Poggi, M.G., Fiorentini, D., Latorre, P., Palmisano, L., Syrjänen, K. and Orlandi, C. Interferon (IFN) treatment of human genital papillomavirus lesions with emphasis on HPV type. In: *Papillomaviruses in Human Pathology. Recent Progress in Epidermoid Precancers*. J. Monsonigo (Ed.). Serono Symposia Publications 78, 207-215, 1990.
- 247.Syrjänen, K.J. Genital Human papillomavirus (HPV) infections and their associations with squamous cell cancer: Reappraisal of the morphologic, epidemiologic and DNA data. In: *Progress in Surgical Pathology*. (Eds.) C.M. Fenoglio-Preiser, M. Wolff and F. Rilke. Field & Wood. Vol XII, pp. 217-240, 1992.
- 248.Chang, F., Syrjänen, S., Nuutinen, J., Kärjä, J. and Syrjänen, K. Detection of Human papillomavirus (HPV) DNA in oral squamous cell carcinomas by in situ hybridization and polymerase chain reaction. *Arch. Dermatol. Res.* 282, 493-497, 1990. (I.F. 1.902)
- 249.Syrjänen, S., Andersson, B., Juntunen, L. and Syrjänen, K. Use of polymerase chain reaction in generation of biotinylated human papillomavirus DNA probes for in situ hybridization. *J. Virol. Meth.* 31, 147-160, 1991. (I.F. 1.781)
- 250.Syrjänen, K.J. Natural history of genital HPV infections. *Papillomavirus Rep.* 1 (4), 1-5, 1990. (I.F. 0.440)
- 251.Syrjänen, K., Yliskoski, M., Kataja, V., Hippeläinen, M., Syrjänen, S., Saarikoski, S. and Ryhänen, A. Prevalence of genital human papillomavirus (HPV) infections in a mass-screened Finnish female population aged 20-65 years. *Int. J. STD & AIDS.* 1, 410-415, 1990. (I.F. 1.300)
- 252.Laatikainen, A., Sarkkinen, H., Syrjänen, K. and Mäntyjärvi, R. Local immune reaction in syngeneic mice against tumorigenic and nontumorigenic BPV-transformed mouse cell lines. *APMIS* 98, 909-915, 1990. (I.F. 1.933)

253.Eskelinen, M., Lipponen, P., Majapuro, R. and Syrjänen, K. Prognostic factors in prostatic adenocarcinoma assessed by means of quantitative histology. *Eur. Urol.* 19, 274-278, 1991. (I.F. 14.976)

254.Chang, F., Janatuinen, E., Pikkarainen, P., Syrjänen, S. and Syrjänen, K. Esophageal squamous cell papillomas. Failure to detect human papillomavirus (HPV) DNA by in situ hybridization and polymerase chain reaction (PCR). *Scand. J. Gastroenterol.* 26, 535-543, 1991. (I.F. 2.199)

255.Ji, HX., Syrjänen, S., Klemi, P., Chang, F., Tosi, P., Syrjänen, K. Prognostic significance of nuclear DNA content and human papillomavirus (HPV) type in invasive cervical cancer. Polymerase chain reaction (PCR) and flow cytometric analysis. *Int. J. Gynecol. Cancer.* 1, 59-67, 1991. (I.F. 2.116)

256.Chang, F., Syrjänen, S., Kellokoski, J. and Syrjänen, K. Human papillomavirus (HPV) infections and their associations with oral disease. *J. Oral Pathol. Med.* 20, 305-317, 1991. (I.F. 1.859)

257.Saastamoinen, J., Syrjänen, K., Syrjänen, S., and Mäntyjärvi, R. Interferon ointment in genital warts. In: *Genital Papillomavirus Infections: Modern Diagnosis and Treatment.* (Eds.) G. Gross, S. Jablonska, H. Pfister, H.E. Stegner. Springer Verlag, pp. 431-432, 1990.

258.Kellokoski, J., Syrjänen, S., Tosi, P., Cintorino, M., Leoncini, P. and Syrjänen, K. Cytokeratin pattern in normal and HPV infected oral mucosa in women with genital HPV infections. *J. Oral Pathol. Med.* 20, 26-31, 1991. (I.F. 1.859)

259.Belli, L., Frazer, I., Hogan, P., Kennedy, L., O'Connor, D., Hersey, P., Law, C., Arseneau, J., Dascal, A., Eiley, S., Ferenczy, A., Mendelson, J., Bouchard, C., Fortier, M., Champoux, F., Roy, M., van de Berg, G.M., Stolz, E., Freeman, K., **Syrjänen, K.**, Barclay, C., Boland, K., Fauchere, S., Kroon, M., Walker, M., Ryff, J.Ch., Smith, P., Wahl, M., Scott, K. Recurrent condylomata acuminata treated with recombinant interferon alfa-2a: A multicenter double-blind placebo-controlled clinical trial. *JAMA.* 265, 2684-2687, 1991 (I.F. 37.700)

260.Maw, R.D., Dinsmore, W., Horner, T., Lawther, H., Rinne, E., Lassus, A., Paavonen, J., Aho, M., Nieminen, P., Vesterinen, E., Tuimala, R.J., Juuakka, T., Saastamoinen, J., Syrjänen, S.M., **Syrjänen, K.J.**, Walker, M., Ryff, J.C., Smith, C., Budde, M., Blackburn, N., Ellmen, J. and Wahl, M. Comparison of interferon alpha-2a and podophyllin in the treatment of primary condylomata acuminata. *Genitourin. Med.* 67, 394-399, 1991. (I.F. 3.401)

261.Syrjänen, S., Kallio, P., Sainio, P., Chang, F. and Syrjänen, K. Epstein-Barr virus (EBV) genomes and c-myc oncogene in oral Burkitt's lymphomas. *Scand. J. Dental. Res.* 100, 176-180, 1992. (I.F. 1.956)

262.Yliskoski, M., Saarikoski, S. and Syrjänen, K. Conization for CIN associated with Human papilloma-virus infection. *Arch. Gynecol. Obstet.* 249, 59-65, 1991. (I.F. 1.680)

263.Yliskoski, M., Tervahauta, A., Saarikoski, S., Mäntyjärvi, R. and Syrjänen, K. Clinical course of cervical Human papillomavirus lesions in relation to coexistent cervical infections. *Sex. Transm. Dis.* 19, 137-139, 1992. (I.F. 2.842)

264.Kataja, V., Syrjänen, K., Syrjänen, S., Mäntyjärvi, R., Yliskoski, M., Saarikoski, S. and Salonen, J.T. Prognostic factors in cervical human papillomavirus (HPV) infections. *Sex. Transm. Dis.* 19, 154-160, 1992. (I.F. 2.842)

265.Ji, HX., Yliskoski, M., Väyrynen, M., Hippeläinen, M., Syrjänen, S., and Syrjänen, K. Colposcopic analysis of genital human papillomavirus (HPV) infections during an 8-year prospective follow-up. *Int. J. Gynec. Obstet.* 36, 291-300, 1991. (I.F. 1.674)

- 266.Syrjänen, S., Andersson, B., Juntunen, L., Syrjänen, K.J. Polymerase chain reaction for producing biotinylated Human papillomavirus DNA probes for in situ hybridization. *Sex. Transm. Dis.* 19, 140-145, 1992. (I.F. 2.842)
- 267.Nuutinen, J., Kansanen, M. and Syrjänen, K. Bilateral acinic cell tumours of the parotid gland. *J. Laryngol. Otol.* 105, 796-798, 1991. (I.F. 0.700)
- 268.Kellokoski, J., Syrjänen, S., Yliskoski, M. and Syrjänen, K. Dot blot hybridization in detection of human papillomavirus (HPV) infections in the oral cavity of women with genital HPV infections. *Oral Microbiol. Immunol.* 7, 19-23, 1992. (I.F. 2.807)
- 269.Hippeläinen, M., Yliskoski, M., Saarikoski, S., Syrjänen, S. and Syrjänen, K. Genital human papillomavirus lesions of the male sexual partners: the diagnostic accuracy of peniscopy. *Genitourin. Med.* 67, 291-296, 1991. (I.F. 3.401)
- 270.Eskelinen, M., Lipponen, P., Collan, Y. and Syrjänen, K. The role of nucleolar organizer regions (Ag-NORs) as prognostic factors in breast cancer. *Eur. J. Cancer.* 27, 989-992, 1991. (I.F. 5.417)
- 271.Syrjänen, S., Heinonen, O., Miettinen, R., Paljärvi, L., Syrjänen, K. and Riekkinen, P. Short biotinylated oligonucleotides bind nonspecifically to senile plaques of Alzheimer's disease. *Neurosci. Lett.* 130, 89-91, 1991. (I.F. 2.055)
- 272.Halmekytö, M., Hyttinen, J-M., Sinervirta, R., Utriainen, M., Myöhönen, S., Voipio, H-M., Wahlfors, J., Alhonen, L., Syrjänen, S., Syrjänen, K. and Jänne, J. Transgenic mice aberrantly expressing human ornithine decarboxylase gene. *J. Biol. Chem.* 266, 19746-19751, 1991. (I.F. 4.573)
- 273.Syrjänen, K. Human papillomavirus infection of the female genital tract. Editorial. *Cytopathol.* 2, 225-227, 1991. (I.F. 1.761)
- 274.Aaltomaa, S., Lipponen, P., Eskelinen, M., Alhava, E. and Syrjänen, K. Nuclear morphometry and mitotic indexes as prognostic factors in breast cancer. *Eur. J. Surg.* 157, 319-324, 1991. (I.F. 1.360).
- 275.Yliskoski, M., Syrjänen, K., Syrjänen, S., Saarikoski, S. and Nethersell A. Systemic alpha-interferon (Wellferon®) treatment of genital Human papillomavirus (HPV) type 6,11,16 and 18 infections. Double-blind, placebo-controlled trial. *Gynecol. Oncol.* 43, 55-60, 1991. (I.F. 3.774)
- 276.Syrjänen, K. Gynekologiset Papilloomavirusinfektioit, kondyloomat ja kohdunkaulan syövän esiasteet, histologiaa ja sytologiaa. Oppikirjassa: Kliininen Sytologia. Toim. A. Koivuniemi. Kandidaattikustannus Oy, Helsinki, ss. 61-72, 1994.
- 277.Eskelinen, M., Lipponen, P., Majapuro, R., Syrjänen, K. and Nordling, S. DNA ploidy, S-phase fraction and G₂ fraction as prognostic determinants in prostatic adenocarcinoma. *Eur. Urol.* 20, 62-66, 1991. (I.F. 14.976)
- 278.Tervahauta, A., Eskelinen, M., Syrjänen, S., Lipponen, P., Pajarinen, P. and Syrjänen, K. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance. *Anticancer. Res.* 11, 1677-1682, 1991. (I.F. 2.480)
- 279.Syrjänen, K.J. Genital human papilloma virus infections in HIV-infected males and females. In: *AIDS and Human Reproduction.* (Ed.). F. Melica. Karger, Basel. pp. 74-83, 1992.
- 280.Kataja, V., Syrjänen, S., Yliskoski, M., Hippeläinen M., Väyrynen, M., Saarikoski, S., Mäntyjärvi, R., Jokela, V., Salonen, JT, and Syrjänen, K. Risk factors associated with cervical

human papillomavirus (HPV) infections: A case-control study. *Am. J. Epidemiol.* 138, 735-745, 1993. (I.F. 5.036)

281. Niskanen, R.O., Kuokkanen, H.O., Syrjänen, K.J. and Korkala, O.L. Vapaa vaskularisoitu fibulasiirre reisiluun pään kuolion hoidossa. *Ensikokemuksia PHKS:ssa. SOT* 22,(3), 247-248, 1999.

282. Eskelinen, M., Lipponen, P. and Syrjänen, K. TAG 12 expression as a prognostic factor in female breast cancer. *Anticancer Res.* 11, 1683-1686, 1991. (I.F. 2.480)

283. Lipponen, P., Eskelinen, M., Syrjänen, S., Tervahauta, A. and Syrjänen, K. The use of immunohisto-chemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. *Eur. Urol.* 20, 238-242, 1992. (I.F. 14.976)

284. Kallio, P., Syrjänen, S., Tervahauta, A. and Syrjänen, K. A simple isolation of DNA from formalin-fixed, paraffin-embedded samples for PCR. *J. Virol. Meth.* 35, 39-47, 1991. (I.F. 1.781)

285. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E. and Syrjänen, K. Prognostic factors in axillary lymph node negative (pN-) breast carcinomas. *Eur. J. Cancer.* 27, 1555-1559, 1991. (I.F.5.417)

286. Syrjänen, K.J. Histology of genital papillomavirus infection. In: *Recent Advances in Cervical Pathology and Colposcopy.* (Eds.). L. Carenza, G. Alante, V. Pozzi and S. Luciani. Parthenon Publishing Group, Lancs., pp. 225-233, 1993.

287. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., Syrjänen, K. Prognostic value of nuclear morphometry and tumour proliferative activity in axillary lymph node-positive breast cancer. *Eur. Surg. Res.* 24, 160-168, 1992. (I.F. 1.431)

288. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., and Syrjänen, K. Histological assessment of the prognostic factors in female breast cancer. *Oncology* 49, 1-8, 1992. (I.F. 2.152)

289. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., Syrjänen, K. Hormone receptors as prognostic factors in female breast cancer. *Ann. Med.* 23, 643-648, 1991. (I.F. 2,566)

290. Tuppurainen, K., Raninen, A., Kosunen, O., Kankkunen, J-P., Kellokoski, J., Syrjänen, S., Mäntyjärvi, M. and Syrjänen, K. Squamous cell carcinoma of the conjunctiva. Failure to demonstrate HPV DNA by *in situ* hybridization and polymerase chain reaction. *Acta Ophthalmol.* 70, 248-254, 1992. (I.F. 3.032)

291. Heinonen, O., Syrjänen, S., Mäntyjärvi, R., Syrjänen, K. and Riekkinen, P. JC virus (JCV) infection and Alzheimer's disease. Reappraisal of the *in situ* hybridization data. *Ann. Neurol.* 31, 439-441, 1992. (I.F. 9.638)

292. Lipponen, P., Vesalainen, S., Kasurinen, J., Ala-Opas, M. and Syrjänen, K. A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour. *Anticancer Res.* 16, 2095-2100, 1996 (I.F. 2.480)

293. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E. and Syrjänen, K. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma. *Anticancer Res.* 11, 1701-1706, 1991. (I.F. 2.480)

294. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E. and Syrjänen, K. Prognostic score combining clinical, histological and morphometric variables in

assessment of the disease outcome in female breast cancer. *Int. J. Cancer.* 49, 885-892, 1991. (I.F. 5.531)

295.Tervahauta, A., Syrjänen, SM., Kallio, PJ. and Syrjänen, KJ. Immunohistochemistry, in situ hybridization and polymerase chain reaction (PCR) in detecting c-myc expression in human malignancies. *Anticancer Res.* 12, 1005-1011, 1992. (I.F. 2.480)

296.Tosi, P., Cintorino, M., Santopietro, R., Lio, R., Barbini, P., Ji, H., Chang, F., Kataja, V., Syrjänen, S. and Syrjänen, K. Prognostic factors in invasive cervical carcinomas associated with human papillomavirus (HPV): Quantitative data and cytokeratin expression. *Pathol. Res. Pract.* 188, 866-873, 1992. (I.F. 1.397)

297.Tosi, P., Pallini, V., Cintorino, M., Bugnoli, M., Covacci, A., Petracca, R., Syrjänen, S., Del Vecchio, M.T., Mäntyjärvi, R., Ruggiero, P., Armellini, D., Chang, F. and Syrjänen, K. Use of antibodies against a synthetic peptide of the E6 protein of human papillomavirus (HPV) type 16 for the diagnosis of genital HPV lesions. *Cytopathol.* 4, 3-15, 1993. (I.F. 1.761)

298.Chang, F., Wang, L., Zhao, Q., Zhu, Q., Wu, Y., Chen, C., Syrjänen, S. and Syrjänen, K. Investigation on the carcinogenic effects of coal tar pitch in rat respiratory tract by intratracheal instillations. *Carcinogenesis* 13, 233-239, 1992. (I.F. 5.334)

299.Eskelinen, M., Lipponen, P., Syrjänen, K. Expression of tumour markers CA 50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival. *Anticancer Res.* 12, 91-96, 1992. (I.F. 2.480)

300.Heinonen, O., Soininen, H., Syrjänen, S., Neittaanmäki, H., Paljärvi, L., Kosunen, O., Talasniemi, S., Syrjänen, K. and Riekkinen, P. Amyloid -protein immunoreactivity in skin is not a reliable marker of Alzheimer's disease: an autopsy-controlled study. In: Alzheimer's and Parkinson's Disease. Hanin, I. (eds). Plenum Press, New York, pp. 157-163, 1995.

301.Syrjänen, S. and Syrjänen, K. Human papillomavirus (HPV) infections of the genital tract. Clinical Significance and diagnosis by PCR. In: *Frontiers in Virology: Diagnosis of Human Viruses by Polymerase Chain Reaction Technology.* (Eds). Y. Becker, G. Darai, Springer-Verlag, Heidelberg. pp 185-207, 1992.

302.Chang, F., Syrjänen, S., Shen, Q., Wang, L., Wang D. and Syrjänen, K. Human papillomavirus (HPV) involvement in esophageal precancer lesions and squamous cell carcinomas as evidenced by microscopy and different DNA-techniques. *Scand. J. Gastroenterol.* 27, 553-563, 1992. (I.F. 2.199)

303.Syrjänen, K.J. Papilloma virus and cervical cancer. *Vox* 14, 3-12, 1992.

304.Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., and Syrjänen, K. Mitotix indexes as prognostic predictors in female breast cancer. *J. Cancer Res. Clin. Oncol.* 118, 75-81, 1992. (I.F. 3.141)

305.Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., and Syrjänen, K. Comparison of classic and quantitative prognostic factors in hormone receptor-positive and hormone receptor-negative female breast cancer. *Am. J. Surg.* 165, 307-311, 1993. (I.F. 2.850)

306.Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., and Syrjänen, K. J. Prediction of outcome after first recurrence of breast cancer. *Eur. J. Surg.* 158, 13-18, 1991. (I.F. 1.360)

307. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., and Syrjänen, K. J. The significance of nuclear morphometric variables as prognostic predictors in breast cancer. *Anticancer Res.* 11, 1663-1670, 1991. (I.F. 2.480)
308. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., and Syrjänen, K. J. Prognostic factors after 5 years follow-up in female breast cancer. *Oncology.* 49, 93-98, 1992. (I.F. 2.152)
309. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., and Syrjänen, K. J. Lymphocyte infiltrates as a prognostic variable in female breast cancer. *Eur. J. Cancer.* 28, 859-864, 1992. (I.F. 5.417)
310. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., and Syrjänen, K.J. Prognostic factors in invasive lobular carcinoma of the breast. *Diagn. Oncol.* 2, 74-80, 1992. (I.F. 0.417)
311. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V-M., Marin, S., Alhava, E., and Syrjänen, K. J. The predictive value of morphometric prognostic index in female breast cancer. *Oncology,* 50, 57-62, 1993. (I.F. 2.152)
312. Syrjänen, K., Kataja, V., Yliskoski, M., Chang, F., Syrjänen, S., and Saarikoski, S. Natural history of cervical Human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. *Obstet. Gynecol.* 79, 675-682, 1992. (I.F. 5.656)
313. Costa, S., Syrjänen, S., Vendra, C., Chang, F., Guida, G., Tervahauta, A., Hippeläinen, M. and Syrjänen, K. Detection of Human papillomavirus infections in the male sexual partners of women attending an STD clinic in Bologna. *Int. J. STD & AIDS.* 3, 338-346, 1992. (IF 1.300)
314. Syrjänen, K.J. Does Human papillomavirus (HPV) cause cervical cancer? *Int. J. Clin. Virol.* 1, 2-6, 1992.
315. Lipponen, P., Papinaho, S., Eskelinen, M., Klemi, P.J., Aaltomaa, S., Kosma, V-M., Marin, S. and Syrjänen, K. DNA ploidy, S-phase fraction and mitotic indices as prognostic predictors of female breast cancer. *Anticancer Res.* 12, 1533-1538, 1992. (I.F. 2.480)
316. Lipponen, P., Eskelinen, M., Papinaho, S., Klemi, P.J., Aaltomaa, S., Kosma, V-M., Marin, S. and Syrjänen, K. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer. *Anticancer Res.* 12, 677-681, 1992. (I.F. 2.480)
317. Aaltomaa, S., Lipponen, P., Papinaho, S., Klemi, P., Kosma, V-M., Marin, S., Eskelinen, M., Alhava, E. and Syrjänen, K. Nuclear morphometry and DNA flow cytometry as prognostic factors in female breast cancer. *Eur. J. Surg.* 158, 135-141, 1992. (IF 1.360)
318. Eskelinen, M., Lipponen, P., Papinaho, S., Aaltomaa, S., Kosma, V-M., Klemi, P., Syrjänen, K. DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. *Int. J. Cancer.* 51, 555-561, 1992. (I.F. 5.531)
319. Christophersen, J., From, E., Kristiansen, F., Möller, B., Blaakaer, J., Gross, G., Goos, M., Ikenberg, H., Mensing, H., Neumann, C., Bauer, R., Petzoldt, D., Meigel, W., Weissenbacher, E., Albrecht, G., Hoffmann, H., Petersen, E., Hagedorn, M., Orfanos, C.E., Bröker, E.M., Wassilew, S.W., Bonnerandi, J.J., Morrison, G.D., **Syrjänen, K.**, Syrjänen, S., Walker, M., Ryff, J.Ch., Smith, P., Wahl, M., Hammer, R., Drees, N., Blackburn, N. and Berger, F. Recurrent condylomata acuminata treated with recombinant interferon alpha-2a. *Acta Derm. Venereol.* 73, 223-226, 1993. (I.F. 3.025)

- 320.Soininen H., Syrjänen, S., Heinonen, O., Neittaanmäki, H., Miettinen, R., Paljärvi, L., Syrjänen, K., Beyreuther, K. and Riekkinen, P. Amyloid β -protein deposition in skin of patients with dementia. *Lancet* 339, 245, 1992. (I.F. 39.207)
- 321.Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V-M., Marin, S. and Syrjänen, K. The changing importance of prognostic factors in breast cancer during a long-term follow-up. *Int. J. Cancer.* 51, 698-702, 1992. (I.F. 5.531)
- 322.Eskelinen, M., Lipponen, P., Aaltomaa, S., Kosma, V-M., Syrjänen, K and Alhava, E. Breast cancer in young women: Clinical, histological and morphometric prognostic factors. *Anticancer Res.* 12, 1237-1242, 1992. (I.F. 2.480)
- 323.Chang, F., Wang, L., Syrjänen, S. and Syrjänen, K. Human papillomavirus (HPV) infections in the respiratory tract. *Am. J. Otolaryngol.* 13, 210-225, 1992. (I.F. 1.170)
- 324.Mälkki, Y., Pelkonen, K., Myllymäki, O., Törrönen, R., Hänninen, O. and Syrjänen, K. Effects of oat bran concentrate on rat serum lipids and liver fat infiltration. *Eur. J. Clin. Nutr.* 49 Suppl 3, S321-324, 1995. (I.F. 3.239)
- 325.Heinonen, O., Soininen, H., Syrjänen, S., Neittaanmäki, H., Paljärvi, L., Kosunen, O., Syrjänen, K. and Riekkinen, P. Amyloid β -protein immunoreactivity in skin is not a reliable marker of Alzheimer's disease: an autopsy-controlled study. *Arch. Neurol.* 51, 799-804, 1994 (I.F. 7.419)
- 326.Syrjänen, K.J. The normal cervix. Concept of the transformation zone. Proceeding of the 1st Europaen Course on genital HPV-associated pathology. *Cervix & l.f.g.t.* 10, 83-88, 1992. (I.F. 1.963)
- 327.Syrjänen, K.J. Cytology and histology of cervical lesions. Proceeding of the 1st Europaen Course on genital HPV-associated pathology. *Cervix & l.f.g.t.* 10, 89-94, 1992. (I.F. 1.963)
- 328.Aaltomaa, S., Lipponen, P., Papinaho, S. and Syrjänen, K. Proliferating cell nuclear antigen (PCNA) immunolabeling and other proliferation indices as prognostic factors in breast cancer. *J. Cancer Res. Clin. Oncol.* 119, 288-294, 1993. (I.F. 3.141)
- 329.Aaltomaa, S., Lipponen, P. and Syrjänen, K. Proliferating cell nuclear antigen (PCNA) immunolabelling as a prognostic factor in axillary lymph node negative breast cancer. *Anticancer Res.* 13, 533-538, 1993. (I.F. 2.480)
- 330.Syrjänen, K., Nurmi, T., Mäntyjärvi, R., Ilonen, J., Syrjänen, S., Surcel, H-M., Yliskoski, M., Väyrynen, M., Chang, F. and Saarikoski, S. HLA types in women with cervical human papillomavirus (HPV) lesions prospectively followed-up for 10 years. *Cytopathol.* 7, 99-107, 1996. (IF 1.761)
- 331.Syrjänen, K. The long-term consequences of genital HPV infections in Women. Editorial. *Ann. Med.* 24, 233-235, 1992. (I.F. 2.566)
- 332.Syrjänen, K.J. Indications du typage HPV. [Indications of HPV typing]. *Gynecol. Internat.* 5, 211-217, 1996.
- 333.Mendelson, J., Ferenczy, A., Arseneau, J., Dascal, A., Eiley, S., Frazer, I., Kennedy, L., Oconnor, D., Bouchard, C., Fortier, M., Champoux, F., Tio, T.T., Huisman, W.M., Vandeberg, G.M., Stolz, E., **Syrjänen, K.**, Syrjänen, S., Paavonen, J., Aho, M., Nieminen, P., Vesterinen, E., Leminen, A., Rinne, E., Boland, K., Fauchere, S., Holmstrom, S., Hammerjensen, R., Walker, M., Ryff, J.C., Becker, J. and Schlenker, R. Randomized placebo-controlled double-blind combined therapy with laser surgery and systemic interferon-alpha-2a in the treatment of anogenital condylomata acuminatum -the condylomata international collaborative study group. *J. Infect. Dis.* 167, 824-829, 1993. (I.F. 6.344)

334.Hippeläinen, M., Eskelinen, M., Lipponen, P., Chang, F. and Syrjänen, K. Mitotic activity index (MAI), volume corrected mitotic index and Human papilloma-virus suggestive morphology are not prognostic factors in carcinoma of the oesophagus. *Anticancer Res.* 13, 677-682, 1993. (I.F. 2.480)

335.Halmekytö, M., Syrjänen, K., Jänne, J. and Alhonen, L. Enhanced papilloma formation in response to skin tumor promotion in transgenic mice overexpressing the human ornithine decarboxylase gene. *Biochem. Biophys. Res. Commun.* 187, 493-497, 1992. (I.F. 2.297)

336.Syrjänen, K.J. HPV and squamous cell carcinogenesis. In: *Frontiers in Gynecologic and Obstetric Investigation.* (Eds.). A.R. Genazanni, F. Petraglia and A.D. Genazanni. Parthenon Publishing Group, Lancs., pp. 195-203, 1993.

337.Tervahauta, A., Syrjänen, S.M., Väyrynen, M., Saastamoinen, J. and Syrjänen, K. Expression of p53 protein related to the presence of Human papillomavirus (HPV) DNA in genital carcinomas and precancer lesions. *Anticancer Res.* 13, 1107-1112, 1993. (I.F. 2.480)

338.Syrjänen, K., Gissmann, L. and Koss, L.G. (eds). Papillomaviruses and Human Disease. Springer Verlag, Berlin, Heidelberg, pp. 1-518, 1987 (ISBN 0-387-16341-7; 3-540-16341-7).

339.Chang, F., Syrjänen, S., Kurvinen, K. and Syrjänen, K. The p53 tumor-suppressor gene as a common cellular target in human carcinogenesis. *Am. J. Gastroenterol.* 88, 174-186, 1993. (I.F. 10.755)

340.Chang, F., Syrjänen, S.M., Wang, L. and Syrjänen, K. Infectious agents in the etiology of esophageal cancer. *Gastroenterology* 103, 1336-1348, 1992. (I.F. 18.187)

341.Aaltomaa, S., Lipponen, P. and Syrjänen, K. Nucleolar organizer regions related to morphometry, flow cytometry, sex steroid receptor content, tumour histology and prognosis in female breast cancer. *Pathol. Res. Pract.* 189, 416-421, 1993. (I.F. 1.397)

342.Kärjä, V., Syrjänen, S., Kataja, V. and Syrjänen, K. C-erbB-2 oncogene expression in salivary gland tumours. *ORL.* 56, 206-212, 1994 (I.F. 0.640)

343.Syrjänen, K.J. The molecular biology of human papillomavirus. *Int. J. Clin. Virol.* 3, 13-16, 1992.

344.Hippeläinen, M., Yliskoski, M., Syrjänen, S., Saastamoinen, J., Saarikoski, S., Hippeläinen, M. and Syrjänen, K. Low concordance of genital Human papillomavirus (HPV) lesions and viral types in HPV-infected women and their male sexual partner. *Sex. Transm. Dis.* 21, 76-82, 1994. (I.F. 2.842)

345.Heinonen, O., Syrjänen, S., Soinen, H., Talasniemi, S., Kaski, M., Mäntyjärvi, R., Syrjänen, K. and Riekkinen, P. Circulating immune complexes in sera from patients with Alzheimer's disease, multi-infarct dementia and Down's syndrome. *Neurosci. Lett.* 149, 67-70, 1993. (I.F. 2.500)

346.Eskelinen, M., Lipponen, P. and Syrjänen, K. Nucleolar organizer regions (AgNORs) related to histopathological characteristics and survival in prostatic adenocarcinoma. *Anticancer Res.* 12, 1635-1640, 1992. (I.F. 2.480)

347.Syrjänen, K.J. Association of human papillomavirus with penile cancer. In: *Genital Warts. Human papillomavirus Infection.* A. Mindel. (Ed.). Edward Arnold, London, pp. 163-197, 1995.

348.Kellokoski, J., Syrjänen, S.M., Chang, F., Yliskoski, M. and Syrjänen, K. Southern blot hybridisation and PCR in detection of oral human papillomavirus (HPV) infections in women with genital HPV infections. *J Oral. Pathol. Med.* 21, 459-464, 1992. (I.F. 1.859)

349.Ho, L., Chan, S-Y., Burk, R.D., Das, B.C., Fujinaga, K., Icenogle, J.P., Kahn, T., Kiviat, N., Lancaster, W., Mavromara, P., Mitrani-Rosenbaum, S., Norrild, B., Pillai, M.R., Stoerker, J., **Syrjänen, K.**, Syrjänen, S., Tay, S-K., Villa, L.L., Wheeler, C.M., Williamson, A-L. and Bernard, H-U. The genetic drift of Human papillomavirus type 16 is a means reconstructing prehistoric viral spread and the movement of ancient human populations. *J. Virol.* 67, 6413-6423, 1993. (I.F. 4.439).

350.Hippeläinen, M.I., Syrjänen, S., Hippeläinen, M.J., Koskela, R., Pulkkinen, J., Saarikoski, S., Syrjänen, K. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males. A study on Finnish conscripts. *Sex. Transm. Dis.* 20, 321-328, 1993. **(I.F. 2.842)**

351.Leimola-Virtanen, R., Pennanen, R., Syrjänen, K. and Syrjänen, S. Estrogen response in buccal mucosa- A cytological and immunohistochemical assay. *Maturitas* 27, 41-45, 1997. (I.F. 2.942)

352.Syrjänen, K.J. Condyloma acuminatum and other HPV-related squamous cell tumours of the genito-anal area. In: *Human Papillomavirus Infections in Dermatovenereology*. Gross, G and von Krogh, G. (Eds.). CRC Press, Boca Raton, FL. pp. 151-180, 1997.

353.Aaltomaa, S., Lipponen, P. and Syrjänen, K. Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining. *Anticancer Res.* 12, 1281-1286, 1992. (I.F. 2.480)

354.Mälkki, Y., Törrönen, R., Pelkonen, K., Myllymäki, O., Hänninen, O. and Syrjänen, K. Effects of oat bran concentrate on rat serum lipids and liver fat infiltration. *Brit. J. Nutr.* 70, 767-776, 1993. (I.F. 3.453)

355.Lipponen, P.J., Ji, Hx, J., Aaltomaa, S., Syrjänen, S. and Syrjänen, K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. *Int. J. Cancer.* 55, 51-56, 1993. (I.F. 5.531)

356.Ji, HX., Lipponen, P., Aaltomaa, S., Syrjänen, S. and Syrjänen, K. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. *Anticancer Res.* 13, 1147-1152, 1993. (I.F. 2.480)

357.Chang, F., Syrjänen, S., Shen, Q., Wang, L. and Syrjänen, K. Screening for Human papillomavirus infections in esophageal squamous cell carcinomas by in situ hybridization. *Cancer.* 72, 2525-2530, 1993. (I.F. 5.068)

358.Chang, F., Syrjänen, S. and Syrjänen, K. Demonstration of Human papillomavirus (HPV) type 30 in esophageal squamous cell carcinomas by in situ hybridization. *Int. J. Cancer.* 55, 171-173, 1993. (I.F. 5.531)

359.Lappalainen, K., Urtti, A., Jääskeläinen, I., Syrjänen, K. and Syrjänen, S. Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells. *Antivir. Res.* 23, 119-130, 1994. (I.F. 3.938)

360.Hippeläinen, M.I., Syrjänen, S., Hippeläinen, M.J., Saarikoski, S. and Syrjänen, K. Diagnosis of genital Human papillomavirus (HPV) lesions in the male. Correlation of peniscopy, histology and in situ hybridization. *Genitourin. Med.* 69, 346-351, 1993. (I.F. 3.401)

361. Kurvinen, K., Syrjänen, S., Chang, F. and Syrjänen, K. The state of p53 gene in Human papillomavirus (HPV)-positive and HPV-negative genital precancer lesions and cancer as determined by single-strand conformation polymorphism analysis and sequencing. *Anticancer Res.* 14, 177-182, 1994. (I.F. 2.480)
362. Costa, S., Syrjänen, S., Vendra, C., Chang, F., Guida, G., Hippeläinen, M., Terzano, P., Tervahauta, A., Yliskoski, M. and Syrjänen, K. Human papillomavirus (HPV) infections in vulvar precancer lesions and cancer. *J. Reprod. Med.* 40, 291-298, 1995 (I.F. 0.800)
363. Tervahauta, A., Syrjänen, S.M., Mäntyjärvi, R. and Syrjänen, K.J. Detection of p53 protein and Ki-67 proliferation antigen in Human papillomavirus (HPV)-positive and HPV-negative cervical lesions by immunohistochemical double-staining. *Cytopathol.* 5, 282-293, 1994. (I.F. 1.761)
364. Chang, F., Syrjänen, S., Tervahauta, A. and Syrjänen, K. Tumorigenesis associated with the p53 tumor suppressor gene. *Brit. J. Cancer.* 68, 653-661, 1993. (I.F. 4.836)
365. Puranen, M., Yliskoski, M., Saarikoski, S., Syrjänen, K. and Syrjänen, S. Exposure of an infant to cervical human papillomavirus infection of the mother is common. *Am. J. Obstet. Gynecol.* 176, 1039-1045, 1997. (I.F. 3.278)
366. Lipponen, P., Aaltomaa, S., Papinaho, S. and Syrjänen, K. Nucleolar organizer regions in myofibroblasts in breast cancer. Relation to cancer cell morphometry, flow cytometry, sex steroid receptor content, tumour histology and prognosis. *Pathol. Res. Pract.* 189, 1030-1035, 1993. (I.F. 1.397)
367. Eskelinen, M., Lipponen, P., Hippeläinen, M., Seveus, L. and Syrjänen, K. Expression of tumour associated antigens 12H12, 2E11, 7A9, CEA, and DF3 in human breast cancer. *Anticancer Res.* 13, 2399-2406, 1993. (I.F. 2.480).
368. Lappalainen, K., Jääskeläinen, I., Syrjänen, K. and Syrjänen, S. Comparison of cell proliferation and toxicity assays by two cationic liposomes. *Pharmaceut. Res.* 11, 1127-1131, 1994. (I.F. 3.260)
369. Syrjänen, K.J. Histologie du col normal et des dysplasies cervicales. *Gynecol. Internat.* 5, 193-200, 1996.
370. Syrjänen, K.J. Human papillomavirus (HPV) in genital carcinogenesis. *Sex. Transm. Dis.* 21, s86-s89, 1994. (I.F. 2.842)
371. Tervahauta, A., Syrjänen, S., and Syrjänen, K. Epidermal growth factor receptor (EGF-R), c-erbB-2 proto-oncogene and estrogen receptor (ER) expression in Human papillomavirus (HPV) lesions of the uterine cervix. *Int. J. Gynecol. Pathol.* 13, 234-240, 1994. (I.F. 1.665)
372. Vesalainen, S., Nordling, S., Lipponen, P., Talja, M. and Syrjänen, K. Progression and survival in prostatic adenocarcinoma. A comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy. *Brit. J. Cancer.* 70, 309-314, 1994 (I.F. 4.836)
373. Lipponen, P., Ji, H., Aaltomaa, S. and Syrjänen, K. Tumour vascularity and basement membrane structure in breast cancer as related to tumour histology and prognosis. *J. Cancer Res. Clin. Oncol.* 120, 645-650, 1994 (I.F. 3.141)
374. Eskelinen, M., Lipponen, P., Aitto-Oja, L., Hall, O. and Syrjänen, K. The value of histoquantitative measurements in prognostic assessment of renal adenocarcinoma. *Int. J. Cancer.* 55, 547-554, 1993. (I.F. 5.531)
375. Syrjänen, K. Papilloomavirusinfektio. Kirjassa: Sukupuolitaudit, toim. Timo Reunala,

Jorma Paavonen, Timo Rostila. Kustannus Oy Duodecim, Helsinki. ss. 69-93, 1994.

376.Syrjänen, K. Sukupuolitaudit ja Syöpä. Kirjassa: Sukupuolitaudit, toim. Timo Reunala, Jorma Paavonen, Timo Rostila. Kustannus Oy Duodecim, Helsinki. ss. 274-301, 1994.

377.Vesalainen, S., Lipponen, P., Talja, M., Alhava, E. and Syrjänen, K. Tumour vascularity and basement membrane structure as prognostic factors in T1-2M0 prostatic adenocarcinoma. *Anticancer Res.* 14, 709-714, 1994. (I.F. 2.480)

378.Vesalainen, S., Lipponen, P., Talja, M., Alhava, E. and Syrjänen, K. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma. *Int. J. Cancer* 58, 303-308, 1994. (I.F. 5.531)

379.Tervahauta, A., Syrjänen, S., Yliskoski, M., Gold, L.I. and Syrjänen, K. Expression of transforming growth factor- 1 and - 2 in human papillomavirus (HPV)-associated lesions of the uterine cervix. *Gynecol. Oncol.* 54, 349-356, 1994. (I.F. 3.774)

380.Lipponen, P., Eskelinen, M., Hietala, K. and Syrjänen, K. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma. *Int. J. Cancer.* 57, 275-280, 1994. (I.F. 5.531)

381.Syrjänen, K.J. Condyloma acuminatum and other human papillomavirus (HPV)-induced squamous cell tumours of the anogenital tract. *Arch. STD/HIV Res.* 8, 53-69, 1994.

382.Hippeläinen, M.I., Hippeläinen, M., Saarikoski, S., Syrjänen, K. Clinical course and prognostic factors of Human papillomavirus infections in men. *Sex. Transm. Dis.* 21, 272-279, 1994. (I.F. 2.842)

383.Syrjänen, K. The Bethesda terminology and HPV: Biological connections. In: *Challenges of Modern Medicine. Papillomavirus in Human Pathology.* (ed. J. Monsonego). pp. 255-264, 1995.

384.Syrjänen, K. Exposure time and other risk factors of HPV: Biologic and epidemiologic aspects. In: *Challenges of Modern Medicine. Papillomavirus in Human Pathology.* (ed. J. Monsonego). pp. 75-86, 1995.

385.Lipponen, P., Aaltomaa, S. and Syrjänen, K. Morphometric quantitation of nucleolar organizer region proteins in breast cancer. *Anal. Quant. Cytol. Histol.* 15, 311-316, 1993 (I.F. 0.630)

386.Vesalainen, S., Lipponen, P., Talja, M. and Syrjänen, K. Mitotic activity and prognosis in prostatic adenocarcinoma. *Prostate.* 26, 80-86, 1995 (I.F. 3.565)

387.Syrjänen, K. Historia natural de las lesiones intraepiteliales escamosas. In: *Cancer Cervicouterino y Lesiones Premalignas. Genetica Molecular e Immunologia del VPH.* C.S.Pineda (Ed.), Mexico City. pp. 13-14, 1998.

388.Syrjänen, K. Control de calidad citologico para evitar frotis de Papanicolaou falsos negativos. In: *Cancer Cervicouterino y Lesiones Premalignas. Genetica Molecular e Immunologia del VPH.* C.S.Pineda (Ed.), Mexico City. pp. 42, 1998.

389.Syrjänen, K. Morfologia de las lesiones genitales asociadas al VPH. Revision de la terminologia citologica e histologica. In: *Cancer Cervicouterino y Lesiones Premalignas. Genetica Molecular e Immunologia del VPH.* C.S.Pineda (Ed.), Mexico City. pp. 55-56, 1998.

390.Syrjänen, K. Natural history of low grade SIL lesions. In: *Challenges of Modern Medicine. Papillomavirus in Human Pathology.* J. Monsonego. (Ed.). EUROGIN, Paris, pp 97-110, 1995.

391.Vesalainen, S., Lipponen, P., Talja, M. and Syrjänen, K. Histological grade, perineural infiltration, tumour infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. *Eur. J. Cancer.* 30, 1797-1803, 1994. (I.F. 5.417)

392.Kurvinen, K., Hietanen, S., Syrjänen, K. and Syrjänen, S. Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem™. *J. Virol. Meth.* 51, 43-54, 1995 (I.F. 1.781)

393.Vesalainen, S., Lipponen, P., Talja, M. and Syrjänen, K. Biochemical parameters as prognostic factors in prostatic adenocarcinoma. *Acta Oncol.* 34, 53-59, 1995 (I.F. 3.730)

394.Chang, F., Syrjänen, S., Lipponen, P., Tervahauta, A., Syrjänen, K. Transitional cell carcinomas of the bladder: Failure to demonstrate HPV DNA by in situ hybridization and polymerase chain reaction. *J. Urol.* 152, 1429-1433, 1994 (I.F. 4.700)

395.Lipponen, P., Saarelainen, E., Ji, H., Aaltomaa, S. and Syrjänen, K. Expression of E-cadherin as related to other prognostic factors in breast cancer. *J. Pathol.* 174, 101-109, 1994 (I.F. 7.381)

396.Vesalainen, S., Lipponen, P., Nordling, S., Talja, M. and Syrjänen, K. Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology. *Anticancer Res.* 15, 569-574, 1995. (I.F. 2.480)

397.Syrjänen, K. Deteccion de cancer cervical en Finlandia. In: *Cancer Cervicouterino y Lesiones Premalignas. Genetica Molecular e Immunologia del VPH.* C.S.Pineda (Ed.), Mexico City. pp. 72-73, 1998.

398.Lu, S., Syrjänen, K., Havu, V.K. and Syrjänen, S. Failure to demonstrate Human papillomavirus (HPV) involvement in Bowen's disease of the skin. *Arch. Dermatol. Res.* 289, 40-45, 1996. (I.F. 1.902)

399.Lappalainen, K., Urtti, A., Söderling, E., Jääskeläinen, I., Syrjänen, K. and Syrjänen, S. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. *Biochim. Biophys. Acta - Biomembranes* 1196, 201-208, 1994. (I.F. 4.381)

400.Lipponen, P., Aaltomaa, S., Kosma, V-M., and Syrjänen, K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. *Eur. J. Cancer.* 30A, (14), 2068-2073, 1994. (I.F. 5.417)

401.Vesalainen, S., Lipponen, P., Talja, M., Kasurinen, J. and Syrjänen, K. Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas. *Prostate.* 27, 110-117, 1995. (I.F. 3.565).

402.Kärjä, V., Syrjänen, K. and Syrjänen, S. Collagen IV and tenascin immunoreactivity as prognostic determinant in benign and malignant salivary gland tumours. *Acta Oto-Laryngologica.* 115, 569-575, 1995. (I.F. 1.099)

403.Lu, S., Syrjänen, K., Havu, V.K. and Syrjänen, S. No evidence of Human papillomavirus DNA in actinic keratosis. *Arch. Dermatol. Res.* 287, 649-651, 1995. (I.F. 1.902)

404.Chang, F., Syrjänen, S., Shen, Q., Cintonino, M., Santopietro, R., Tosi, P. and Syrjänen, K. Presence of HPV, CMV, HSV and EBV in esophageal squamous cell carcinomas from a high-incidence area of China. *Anticancer Res.* 20, 3935-3940, 2000 (I.F. 2.480)

405.Zhu, ZR., Ågren, J., Pietinen, P., Eskelinen, M., Syrjänen, K. and Uusitupa, M. Fatty acid composition of breast adipose tissue in breast cancer patients and in patients with benign breast disease. *Nutr. Cancer.* 24, 151-160, 1995. (I.F. 2.322)

- 406.Hietanen, S., Grenman, S., Syrjänen, K., Kauppinen, J., Carey, T. and Syrjänen, S. Human papillomavirus in vulvar and vaginal carcinoma cell lines. *Brit. J. Cancer.* 72, 134-139, 1995. (I.F. 4.836)
- 407.Chang, F., Syrjänen, S. Tervahauta, A., Kurvinen, K., Wang, L. and Syrjänen, K. Frequent mutations of p53 gene in esophageal squamous cell carcinomas with and without Human papillomavirus (HPV) involvement suggest the dominant role of environmental carcinogens in esophageal carcinogenesis. *Brit. J. Cancer.* 70, 346-351, 1994. (I.F. 4.836)
- 408.Pietiläinen, T., Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V-M., and Syrjänen, K. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. *Anticancer Res.* 15, 959-964, 1995. (I.F. 2.480)
- 409.Lipponen, P., Eskelinen, M., Hietala, K. and Syrjänen, K. Expression of proliferating cell nuclear antigen, p53 protein and c-erbB-2 in renal adenocarcinoma. *Int. J. Cancer* 57, 275-280, 1994. (I.F. 5.531)
- 410.Costa, S., Vendra, C., Chang, F., Guida, G., Hippeläinen, M., Terzano, P., Tervahauta, A., Saarikoski, S. and Syrjänen, K. Genital Human papillomavirus infections in adolescent women with cytological abnormalities detected during the cervical cancer screening programme. *Cervix & I.f.g.t.* 13, 63-71, 1995. (I.F. 1.963)
- 411.Hietanen, S.H., Kurvinen, K., Syrjänen, K., Grenman, S., Carey, T., McClathey, K. and Syrjänen, S. Mutation of tumour suppressor gene p53 is frequently found in vulvar carcinoma cells. *Am. J. Obstet. Gynecol.* 173, 1477-1482, 1995 (I.F. 3.973).
- 412.Toropainen, E., Lipponen, P. and Syrjänen, K. Expression of insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis. *Eur. J. Cancer.* 31A, 1443-1448, 1995. (I.F. 5.417)
- 413.Chang, F., Syrjänen, S. and Syrjänen, K. Implications of the p53 tumor suppressor gene in clinical oncology. *J. Clin. Oncol.* 13, 1009-1022, 1995. (I.F. 20.982)
- 414.Lipponen, P., Pietiläinen, T., Kosma, V-M., Aaltomaa, S., Eskelinen, M. and Syrjänen, K. Apoptosis suppressing protein bcl-2 is expressed in well differentiated breast carcinomas with favourable prognosis. *J. Pathol.* 177, 49-55, 1995. (I.F. 7.381)
- 415.Syrjänen, K.J. Quality assurance in the cytopathology laboratories of the Finnish Cancer Society. In: *Compendium on Quality Assurance, Proficiency Testing and Workload Limitations in Clinical Cytology.* George L. Wied, Catherine M. Keebler, Dorothy L. Rosenthal, Ulrich Schenck, Theresa M. Somrak, G. Peeter Vooijs. (Eds.). *Tutorials of Cytology*, Chicago, Illinois, USA. pp. 134-142, 1995.
- 416.Toropainen, E., Lipponen, P. and Syrjänen, K. Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis. *Anticancer Res.* 15 (6B), 2669-2674, 1995. (I.F. 2.480)
- 417.Zhu, Z.R., Parviainen, M., Männistö, S., Pietinen, P., Eskelinen, M., Syrjänen, K. and Uusitupa, M. Vitamin E concentration in breast adipose tissue of breast cancer patients. *Cancer Cause. Contr.* 7, 591-595, 1996. (I.F. 3.130)
- 418.Pietiläinen, T., Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V-M. and Syrjänen, K. Expression of p53 protein has no independent prognostic value in breast cancer. *J. Pathol.* 177, 225-232, 1995. (I.F. 7.381)

419. Kuokkanen, H., Rätty, S., Korkala, O., Niskanen, R. and Syrjänen, K.J. Osteosynthesis and allogeneic bone grafting in complex osteoporotic fractures. *Orthopedics* 24, 249-252, 2001 (I.F. 1.420)
420. Aaltonen, M., Lipponen, P., Kosma, V-M., Aaltomaa, S. and Syrjänen K. Prognostic value of cathepsin-D expression in female breast cancer. *Anticancer Res.* 15, 1033-1038, 1995. (I.F. 2.480)
421. Hietanen, S., Ekblad, U., Pelliniemi, T-T., Syrjänen, K., Helenius, H. and Syrjänen, S. Type I diabetic pregnancy and subclinical HPV infections. *Clin. Infect. Dis.* 24, 153-156, 1997. (I.F. 8.886)
422. Zhu, Z.R., Parviainen, M., Männistö, S., Pietinen, P., Eskelinen, M., Syrjänen, K. and Uusitupa, M. Vitamin A concentration in breast adipose tissue of breast cancer patients. *Anticancer Res.* 15, 1593-1596, 1995. (I.F. 2.480).
423. von Krogh, G., Wikström, A., Syrjänen, S. and Syrjänen, K. Anal and penile condylomas in HIV-negative and HIV-positive men; Clinical histological and virological characteristics correlated to therapeutic outcome. *Acta Dermatovenereol.* 75, 470-474, 1995. (I.F. 3.025)
424. Puranen, M., Yliskoski, M., Syrjänen, K. and Syrjänen, S. Vertical transmission of Human papillomavirus (HPV) from infected mothers to their newborn babies and persistence of the virus in childhood. *Am J. Obstet. Gynecol.* 174, 694-699, 1996. (I.F. 4.704)
425. Pietiläinen, T., Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V-M. and Syrjänen, K. Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. *Eur. J. Cancer.* 31a: 329-333, 1995. (I.F. 5.417)
426. Puranen, M., Syrjänen, K. and Syrjänen, S. Transmission of genital Human papillomavirus infections is unlikely through the floor and seats of humid dwellings in countries of high-level hygiene. *Scand. J. Infect. Dis.* 28, 243-246, 1996. (I.F. 1.630)
427. Lipponen, P., Eskelinen, M. and Syrjänen, K. Expression of tumour suppressor gene Rb, apoptosis suppressing protein bcl-2 and c-myc have no independent prognostic value in renal adenocarcinoma. *Brit. J. Cancer.* 71, 863-867, 1995. (I.F. 4.836)
428. Puranen, M., Saarikoski, S., Syrjänen, K. and Syrjänen, S. Polymerase chain reaction (PCR) amplification of Human papillomavirus DNA from archival, Papanicolaou-stained cervical smears. *Acta Cytol.* 40, 391-395, 1996 (I.F. 1.562)
429. Setälä, L., Kosma, V-M., Marin, S., Lipponen, P., Eskelinen, M., Syrjänen, K. and Alhava, E. Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. *Brit. J. Cancer.* 74, 766-772, 1996. (I.F. 4.836)
430. Lu, S., Syrjänen, K., Havu, V.K. and Syrjänen, S. Known HPV types have no association with keratoacanthomas. *Arch. Dermatol. Res.* 288, 129-132, 1996. (I.F. 1.902)
431. Korkala, O. and Syrjänen, K. Intrapelvic cyst formation after hip arthroplasty with a carbon fiber-reinforced polyethylene socket. *Arch. Orthop. Trauma. Surg.* 118, 113-115, 1998 (I.F. 1.597)
432. Kärjä, V., Syrjänen, K. and Syrjänen, S. Immunocompetent cells in benign and malignant salivary gland tumours. *Gen. Diagn. Pathol.* 142, 75-81, 1996. (I.F. 0.730)
433. Syrjänen, K. J. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated HPV. *Eur J. Obstet. Gynecol. Reprod. Biol.* 65, 45-53, 1996. (I.F. 1.662)

434. Setälä, L., Lipponen, P., Kosma, V-M., Marin, S., Eskelinen, M., Syrjänen, K. and Alhava, E. Nuclear morphometry as a predictor of disease outcome in gastric cancer. *J. Pathol.* 181, 46-50, 1997. (I.F. 7.381)
435. Ji, H., Yliskoski, M., Anttila, M., Syrjänen, K. and Saarikoski, S. Management of stage I borderline ovarian tumors. *Int. J. Gynecol. Obstet.* 54, 37-44, 1996. (I.F. 1.674)
436. Chang F, Syrjänen S, Shen Q. and Syrjänen K. p53 overexpression and human papillomavirus (HPV) infection in esophageal squamous cell carcinomas derived from the high-incidence area of China. *Anticancer Res.* 17, 709-715, 1997. (I.F. 2.480)
437. Suonio, E., Lipponen, P., Mäenpää, J., Syrjänen, K., Kangas, L. and Tuomisto, L. Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer. *Cancer Chemother. Pharmacol.* 41, 15-21, 1997. (I.F. 2.824)
438. Vesalainen, S., Lipponen, P., Nordling, S., Talja, M., and Syrjänen, K. Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology. *Anticancer Res.* 15, 569-573, 1995. (I.F. 1.428)
439. Syrjänen, K. Pathogenesis of HPV infections. 9th World Congress of Cervical Pathology & Colposcopy, Sydney, Australia, May 12-16, 1996 (eds.) W. Chanen and K. Atkinson. Monduzzi Editore, Bologna, pp. 205-215, 1996.
440. Lappalainen, K., Pirilä, L., Jääskeläinen, I., Syrjänen, K. and Syrjänen, S. Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene. *Anticancer Res.* 16, 2485-2492, 1996. (I.F. 2.480)
441. Syrjänen, K.J. Natural history of genital Human papillomavirus infections. In: *Papillomavirus Reviews. Current Research on Papillomaviruses.* (ed). C.Lacey. Leeds Medical Information, Leeds University Press, Leeds, pp. 189-206, 1996.
442. Vassallo, J., Derchain, S.F., Pinto, G.A., Martinez, E.Z., Syrjänen, K.J. and Andrade, L.A. High risk HPV and p53 protein expression in cervical intraepithelial neoplasia. *Int. J. Gynecol. Obstet.* 71,45-48, 2000 (I.F. 1.674)
443. Auvinen, P., Lipponen, P., Johansson, R. and Syrjänen, K. Prognostic significance of TGF-beta2 expression in female breast cancer. *Eur. J. Cancer* 31A, 851, 1995. (I.F. 5.417).
444. Pirinen, R., Lipponen, P. and Syrjänen, K. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors. *Anticancer Res.* 15(6B), 2835-2840, 1995. (I.F. 2.480)
445. Rotelli-Martins, C.M., Syrjänen, K.J., Siqueira S.A.C. and Derchain, S.F.M. Flora microbiana vaginal em mulheres com infeccao por Papillomavirus Humano e neoplasia intra-epitelial cervical. *JAMA GO* 5, 4-9, 1997.
446. Shabalova, I.P., Chemeris, G.J., Ermilova, V.D., Rodionova, I.M., Pavlikova, N.A. and Syrjänen, K.J. Phylloides tumour: Cytologic and histologic presentation of 22 cases and immunohistochemical demonstration of p53. *Cytopathol.* 8, 177-187, 1997. (I.F. 1.761)
447. Lu, S., Syrjänen, K., Havu, V.K. and Syrjänen, S. Expression of PCNA is associated with the presence of HPV DNA in skin warts. *Arch Dermatol Res.* 289, 35-39, 1996. (I.F. 1.902)
448. Syrjänen, K.J. Natural history of low grade SIL lesions. In: J. Monsonego (Ed). *Screening of Cervical Cancer: For whom, Why and How? Experts' Consensus Conference.* EUROGIN Scientific Publications, Paris. pp. 10-17, 1995.

- 449.Hietanen, S., Syrjänen, K. and Syrjänen, S. Characterization of keratin and cell cycle protein expression in cell lines from squamous intraepithelial lesions progressing towards a malignant phenotype. *Brit. J. Cancer* 77, 766-775, 1998. (I.F. 4.836)
- 450.Auvinen, P., Lipponen, P., Johansson, R. and Syrjänen, K. Prognostic significance of TGF-1 and TGF-2 expressions in female breast cancer. *Anticancer Res.* 16 (6B), 2627-2631, 1995. (I.F. 2.480).
- 451.Kurvinen, K., Syrjänen, K. and Syrjänen, S. p53 and bcl-2 proteins as prognostic markers in Human papillomavirus-associated cervical lesions. *J. Clin. Oncol.* 14, 2120-2130, 1996 (I.F. 20.982)
- 452.Kärjä, V., Syrjänen, K., Kurvinen, K. and Syrjänen, S. Expression and mutations of p53 in salivary gland tumours. *J. Oral Pathol. Med.* 26, 217-223, 1997. (I.F. 1.859)
- 453.Pirinen, R., Lipponen, P., Aaltomaa, S. and Syrjänen, K. Prognostic value of epidermal growth factor expression in breast cancer. *J. Cancer Res. Clin. Oncol.* 123, 63-68, 1997. (I.F. 3.141)
- 454.Auvinen, P., Lipponen, P., Kataja, V., Johansson, R. and Syrjänen, K. Prognostic significance of TGF- α expression in breast cancer. *Acta Oncol.* 35, 995-998, 1996. (I.F. 3.730)
- 455.Setälä, L., Nordling, S., Kosma, V-M., Lipponen, P., Eskelinen, M., Hollmen, S., Syrjänen, K. and Alhava, E. Comparison of DNA-ploidy and S-phase fraction with prognostic factors in gastric cancer. *Anal. Quant. Cytol. Histol.* 6, 524-532, 1997 (I.F. 0.630).
- 456.Syrjänen, J. STD and anogenital neoplasia. Epidemiology and natural history. In: 9th World Congress of Cervical Pathology & Colposcopy, Sydney, Australia, May 12-16, 1996. (eds.). W. Chanen, K. Atkinson, Monduzzi Editore, Bologna, pp. 151-161, 1996.
- 457.Heinonen, S., Ryyänänen, M., Kirkinen, P., Penttilä, I., Syrjänen, K., Seppälä, M. and Saarikoski, S. Prenatal screening for congenital nephrosis in East Finland: Results and impact on the birth prevalence of the disease. *Prenatal. Diagn.* 16, 207-213, 1996. (I.F. 2.514).
- 458.Pietiläinen, T., Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V-M. and Syrjänen, K. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. *J Cancer Res. Clin. Oncol.* 122, 687-692, 1996. (I.F. 3.141)s
- 459.Hietala, K., Kosma, V-M., Syrjänen, K., Syrjänen, S. and Kellokoski, J. Correlation of MIB-1 antigen expression with transcription factors Skn-1, Oct-1, AP-2 and HPV type in cervical intraepithelial neoplasia. *J. Pathol.* 183, 305-310, 1997. (I.F. 7.381)
- 460.Kärjä, V., Syrjänen, K. and Syrjänen, S. No Epstein-Barr and Cytomegalovirus found in salivary gland tumours. *ORL.* 59, 97-99, 1997. (I.F. 0.640)
- 461.Syrjänen, K., Chang, F. and Syrjänen, S. Infectious agents as etiological factors in esophageal carcinogenesis. In: Tahara, E., Sugimachi, K., Oohara, T. (eds). *Recent Advances in Gastroenterological Carcinogenesis I.* Monduzzi Editore, Bologna, pp. 29-43, 1996.
- 462.Lu, S., Tiekso, J., Hietanen, S., Syrjänen, K., Havu, V-K. and Syrjänen, S. Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement. *Acta Dermatovenereol* 79, 268-273, 1999. (I.F. 3.025).
- 463.Franco, E., Syrjänen, K., de Wolff, C., Patnick, J., Ferenczy, A., McGoogan, E., Bosch, X., Singer, A., Munoz, N., Meheus, A. and Monsonego, J. New developments in cervical cancer screening and prevention. *Cancer Epidemiol. Biomarker. Prev.* 5, 853-856, 1996. (I.F. 4.125)

464. Anttila, M., Ji, H., Juhola, M.T., Saarikoski, S., and Syrjänen, K. The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. *Int. J. Gynec. Pathol.* 18, 42-51, 1999. (I.F. 1.665)
465. Setälä, L., Kosma, V-M., Lipponen, P., Naukkarinen, A., Nordling, S., Hollmen, S., Eskelinen, M., Syrjänen, K. and Alhava, E. Clinical relevance of p53 index and expression of proliferating cell nuclear antigen and Ki-67 in gastric cancer. *J. Cancer Res. Clin. Oncol.* 124, 497-502, 1998 (I.F. 3.141).
466. Syrjänen, K. Epidemiologia de las infecciones genitales por VPH y del cancer cervical. In: *Cancer Cervicouterino y Lesiones Premalignas. Genetica Molecular e Immunologia del VPH.* (Ed. C.S.Pineda), Mexico City. pp. 121-122, 1998.
467. Syrjänen, K. Historia natural de las lesiones intraepiteliales escamosas. In: *Cancer Cervicouterino y Lesiones Premalignas. Genetica Molecular e Immunologia del VPH.* (Ed. C.S.Pineda), Mexico City. pp. 13-14, 1998.
468. Roteli-Martins, C.M., Panetta, K., Alves, V.A.F., Siqueira, S.A.C., Syrjänen K.J. and Derchain S.F.M. Cigarette smoking and high-risk HPV DNA as predisposing factors for high-grade cervical intraepithelial neoplasia (CIN) in young Brazilian women. *Acta Obstet. Gynec. Scand.* 77, 678-682, 1998. (I.F. 1.985).
469. Aaltomaa, S., Lipponen, P., Ala-Opas, M., Eskelinen, M. and Syrjänen, K. Prognostic value of Ki-67 expression in renal cell carcinomas. *Eur. Urol.* 31, 350-355, 1997. (I.F. 14.976).
470. Syrjänen, K.J. Biological behaviour of cervical intraepithelial neoplasia. In: Franco, E., Monsonego, J. (eds.). *New Developments in Cervical Cancer Screening and Prevention.* Blackwell Science, Oxford, pp. 93-108, 1997.
471. Setälä, L., Kosma, V-M., Eskelinen, M., Syrjänen, K. and Alhava, E. Prognostic factors in gastric carcinoma.-Reply. *Brit. J. Cancer* 76, 279-279, 1997. (I.F. 4.836).
472. Rautiainen, J., Rytkönen, M., Syrjänen, K., Pentikäinen, J., Zeiler, T., Virtanen, T. and Mäntyjärvi, R. Tissue localization of bovine dander allergen Bos d2. *J. Allergy Clin. Immunol.* 101, 349-353, 1998. (I.F. 12.485).
473. Solomon, D., Davey D.D., Nozawa, S. and Syrjänen, K.J. Future directions in cervical cytology. Editorial. *Acta Cytol.* 42, 1-4, 1998. (I.F. 1.562).
474. Alafuzoff, I., Hartikainen, P., Hänninen, T., Partanen, K., Kuikka, J., Syrjänen, K., Naukkarinen, A. and Soininen, H. Rapidly progressive multifocal leucoencephalopathy with cognitive decline of non-Alzheimer type and with substantial cell-mediated inflammatory response in a 75-year-old female patient. *Case Report. Clin. Neuropathol.* 18, 113-123, 1999. (I.F. 1.311).
475. Hietanen, S., Auvinen, E., Syrjänen, K. and Syrjänen, S. Anti-proliferative effect of retinoids and interferon- γ on vaginal cell lines derived from squamous intraepithelial lesions. *Int. J. Cancer.* 78, 338-345, 1998 (I.F. 5.531).
476. Aaltomaa, S., Lipponen, P., Vesalainen, S., Ala-Opas, M., Eskelinen, M. and Syrjänen, K. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. *Eur. Urol.* 32, 410-415, 1997. (I.F. 14.976).
477. Richart, R.M., Masood, S., Syrjänen, K.J., Vassilakos, P., Kaufman, R., Meisels, A., Olszewski, W.T., Sakamoto, A., Stoler, M.H., Vooijs, G.P., and Wilbur, D.C. Human papillomavirus. IAC task force summary. *Acta Cytol* 42, 50-58, 1998. (I.F. 1.562).

- 478.Krieger, P.A., McGoogan, E., Vooijs, G.P., Amma, N.S., Cochand-Priollet, B., Colgan, T.J., Davey, D.D., Geyer, J.W., Goodell, R.M., Grohs, D.H., Gupta, S.K., Jones, B.A., Koss, L.G., Mango, L.J., McCallum S.M., Nielsen, M., Robinowitz, M., Sauer, T., Schumann, J.L., **Syrjänen, K.J.**, Suprun, H.Z., Topalides, T., Wertlake, P.T. and Whittaker, J. Quality assurance/control issues. IAC task force summary. *Acta Cytol.* 42, 133-140, 1998. (I.F. 1.562).
- 479.Anttila, M., Syrjänen, S., Ji, H., Saarikoski, S. and Syrjänen, K. Failure to demonstrate Human papillomavirus (HPV) DNA in epithelial ovarian cancer by general primer PCR. *Gynecol. Oncol.* 72, 337-341, 1999. (I.F. 3.774).
- 480.Naud, P., Camozzato, A., Hammes, L., Prolla, J., Catalan, F., Larangeira, M., Matos, J., Milovanovic, P., Schwartzmann, G., Vettorazzi, J., Quadros, C., Gomes, T., Lemos, A., D'Ávila, A., Manfrói, A., Marc, C., Berti, C., Born, C., Rigol, C., Vettori, D., Santos, D., Dias, E., Cislighi, G., Di Domenico, K., M., Santos, R., Marroni, R., Magno, V, and **Syrjänen, K.** Cervical cancer screening in Porto Alegre, Brazil: Alternative methods for detecting cancer precursors in a developing country. *J. Lower Gen. Tract Dis.* 5, 24-28, 2001. (I.F. 1.963).
- 481.Anttila, M., Kosma, V-M., Ji, H., Weiling, X., Puolakka, J., Juhola, M., Saarikoski, S. and Syrjänen, K. Clinical significance of α -catenin, collagen IV and Ki-67 expression in epithelial ovarian cancer. *J. Clin. Oncol.* 16, 2591-2600, 1998. (I.F. 20.982).
- 482.Cintorino, M., Tripodi, S.A., Santopietro, R., Bartolommei, S., Chang, G., Syrjänen, S., Shen, Q., Tosi, P. and Syrjänen, K. Cytokeratin expression in oesophageal squamous cell carcinoma: A study of 354 cases from the high-incidence area of Linxian, China. *Anticancer Res.* 21, 4195-4201, 2001. (I.F. 2.480).
- 483.Derchain, S.F.M., Roteli-Martins, C.M., Syrjänen, K.J., de Abreu, H.J, Martinez, E.Z. and Alves, V.A. Association of oncogenic Human papillomavirus DNA with high-grade cervical intraepithelial neoplasia: The role of cigarette smoking. *Sex. Transm. Infect.* 75, 406-408, 1999. (I.F. 3.015).
- 484.Syrjänen, K.J. and Syrjänen, S.M. HPV typing as an adjunct to cervical cancer screening. Invited review. *Cytopathol.* 10, 8-15, 1999. (I.F. 1.761).
- 485.Syrjänen, K.J. Anogenital HPV and the problem of persistence. *Eur. J. Dermatol.* 8, Suppl.7, 5-7, 1998. (I.F. 1.953).
- 486.de Villiers, E.-M., Lavergne, D., Chang, F., Syrjänen, K., Tosi, P., Cintorino, M., Santopietro, R. and Syrjänen, S. An interlaboratory study to determine the presence of human papillomavirus DNA in esophageal carcinoma from China. *Int. J. Cancer.* 81, 225-228, 1999. (I.F. 5.531).
- 487.Cartwright, R.A., Brincker, H., Teppo, L., Razenberg, L., Carli, P.M., Naukkarinen, A., Jack, A.S., Pukkala, E., Morgan, G., Kruffy, H.J., Olsen, J.H., Puittinen, J., Coebergh, J.W., Syrjänen, K., Vornanen, M., McNally, R.J.Q., Baig, S.S., Tumino, R. and San Jose, S. The descriptive and molecular epidemiology of non-Hodgkin's lymphoma in Europe (EUROLYMPH 1). In: Baig, S.S. (ed). *Cancer Research Supported Under Biomed I.* IOS Press, London. pp. 347-350, 1998.
- 488.Anttila, M., Kellokoski, J., Moisio, K.I., Mitchell, P.J., Saarikoski, S., Syrjänen, K. and Kosma, V-M. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. *Brit. J. Cancer.* 82, 1974-1983, 2000. (I.F. 4.836).
- 489.Anttila, M.A., Tammi, R.H., Tammi, M.I., Syrjänen, K.J., Saarikoski, S.V. and Kosma, V-M. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. *Cancer Res.* 60, 150-155, 2000. (I.F. 9.329).

490.Syrjänen, S.M. and Syrjänen, K.J. New concepts on the role of human papillomavirus in cell cycle regulation. *Ann. Med.* 31, 175-187,1999. (I.F. 2.566).

491.Aaltomaa, S., Lipponen, P., Ala-Opas, M., Eskelinen, M., Syrjänen, K. and Kosma, VM. Expression of cyclins A and D, and p21 (waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. *Brit. J. Cancer.* 80, 2001-2007, 1999. (I.F. 4.836).

492.Costa, S., Sideri, M., Syrjänen, K., Terzano, P., De Nuzzo, M., De Simone, P., Cristiani, P., Finarelli, C., Bovicelli, A., Zamparelli, A. and Bovicelli, L. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer. *Acta Cytol.* 44, 310-318, 2000. (I.F. 1.562).

493.Syrjänen, K.J. Terminology used in cytopathology. *CME J. Gynecol. Oncol.* 5, 12-17, 2000.

494.Anttila, M., Kosma, V-M., Hongxiu, J., Puolakka, J., Juhola, M., Saarikoski, S. and Syrjänen, K. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. *Br. J. Cancer* 79, 1870-1878, 1999. (I.F. 4.836).

495.Costa, S., de Nuzzo, M., Terzano, P., Syrjänen, K., Abbiati, R., Grossi, E., Quagliarella, G., Bovicelli, A., Zamparelli, A. and Bovicelli, L. Speculoscopy for triage of patients with abnormal Pap smear: Data from the GISPE study. *J. Lower Genital Tract Dis.* 4, 212-216, 2000. (I.F. 1.963).

496.Syrjänen, K. La cervice normale. Chapter 1. In: Costa S, Syrjänen, K. (eds). *Gestione delle Pazienti con PAP Test Anormale.* Athena Audiovisuals, Modena, pp. 10-28, 2005.

497.Syrjänen, K. and Costa, S. Strategie globali per il controllo della neoplasia cervicale: diagnosi dei precursori e degli staid precoci. Chapter 2. In: Costa S, Syrjänen, K. (eds). *Gestione delle Pazienti con PAP Test Anormale.* Athena Audiovisuals, Modena, pp. 29-92, 2005.

498.Costa S. and Syrjänen, K. Le lesioni squamose preinvasive: I precursori del carcinoma cervicale. Chapter 8. In: Costa S, Syrjänen, K. (eds). *Gestione delle Pazienti con PAP Test Anormale.* Athena Audiovisuals, Modena, pp. 225-254, 2005.

499.Chang, F., Syrjänen, S., Shen, Q., Cintorino, M., Santopietro, R., Tosi, P. and Syrjänen, K. Detection of HPV DNA in oesophageal squamous cell carcinoma from the high-incidence area of Linxian, China. *Scand. J. Gastroenterol.* 35, 123-130, 2000. (I.F. 2.199).

500.Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, pp. 1-615, 2000 (ISBN 0-471-97168-5).

501.Branca, M., Rossi, E., Alderisio, M., Migliore, G., Morosini, P.L., Vecchione, A., Sopracordevole, F. Mudu, P., Leoncini, L. and Syrjänen, K. Performance of cytology and colposcopy in diagnosis of cervical intraepithelial neoplasia (CIN) in HIV-positive and HIV-negative women. *Cytopathol.* 12, 84-93, 2001 (I.F. 1.761).

502.Syrjänen, K.J., Chang, F. and Syrjänen, S.M. HPV infections in etiology of benign and malignant sinonasal, bronchial and oesophageal squamous cell lesions. In: Monsonego J. (ed). *4th International Multidisciplinary Congress EUROGIN 2000, Paris 5-9, April, 2000.* Monduzzi Editore, Bologna, pp. 169-179, 2000.

503.Tripodi, S., Chang, F., Syrjänen, S., Shen, Q., Cintorino, M., Alia, L., Santopietro, R., Tosi, P. and Syrjänen, K. Quantitative image analysis of oesophageal squamous cell carcinoma from the high-incidence area of China, with special reference to tumour

progression and Papillomavirus (HPV) involvement. *Anticancer Res.* 20, 3855-3862, 2000 (I.F. 2.480).

504. Miller, A.B., Nazeer, S., Fonn, S., Brandup-Lukanow, A., Rehman, R., Cronje, H., Sankaranarayanan, R., Koroltchouk, V., Syrjänen, K., Singer, A. and Onsrud, M. Report on Consensus conference on Cervical Cancer Screening and Management. *Int. J. Cancer.* 86, 440-447, 2000. (I.F. 5.531).

505. Costa, S., Terzano, P., Santini, D., Ceccarelli, C., Martoni, A., Angelelli, B., Panetta, A., Bovicelli, A., Cristiani, P., Lipponen, P., Erzen, M., Syrjänen, S. and Syrjänen, K. Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome. *Am. J. Clin. Pathol.* 116, 729-737, 2001. (I.F. 2.514).

506. Syrjänen, K.J. Management of abnormal PAP smears (MAPS): Implications of terminology used in cytopathology. *J. Lower Genital Tract Dis.* (Invited Editorial). 4, 217-223, 2000. (I.F. 1.963).

507. Syrjänen, K.J. Human papillomaviruses in pathogenesis of lower genital tract neoplasia. Chapter 2. In: Singer, A. and Monaghan, J. (eds). *Lower genital tract precancer. Colposcopy, pathology and treatment.*, 2nd ed. Blackwell Science, pp. 12-27, 1999.

508. Costa, S., Terzano, P., Santini, D., Panetta, A., Martoni, A., Bovicelli, A., De Nuzzo, M., Lipponen, P., Erzen, M., Syrjänen, S. and Syrjänen, K. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. *Gynecol. Oncol.* 80, 67-73, 2001 (I.F. 3.774).

509. Roteli-Martins, C.M., Alves, V.A., Santos, R.T., Martinez, E.Z., Syrjänen, K.J. and Derchain, S.F. Value of morphological criteria in diagnosis of cervical HPV lesions confirmed by in situ hybridization and hybrid capture assay. *Pathol. Res. Pract.* 197, 677-682, 2001. (I.F. 1.397).

510. Roteli-Martins, C.M., Derchain, S.F.M., Siqueira, S.A.C., Alves, V.A.F. and Syrjänen, K.J. Morphological diagnosis of HPV lesions and cervical intraepithelial neoplasia is highly reproducible. *Clin. Exp. Obstet. Gynecol.* 28, 78-80, 2001. (I.F. 0.357).

511. Kurvinen, K., Yliskoski, M., Saarikoski, S., Syrjänen, K. and Syrjänen, S. Variants of the long control region of human papillomavirus 16. *Eur. J. Cancer* 36, 1402-1410, 2000 (I.F. 5.417).

512. Syrjänen, K. Control de calidad citológico para evitar frotis de papanicolaou falsos negativos. In: *Cancer Cervicouterino y Lesiones Premalignas. Genética Molecular e Inmunología del VPH.* (Ed. C.S.Pineda), Mexico City. pp. 42-42, 1998.

513. Syrjänen, K.J. The colposcopy, cytology and histology of genital HPV infections. In: Bösze P, Luesley DM. (eds). *EAGC Course Book on Colposcopy.* Primed-X Press, Budapest. 2003, pp. 71-88.

514. Syrjänen, K., Erzen, M. and Syrjänen, S. Cervical cancer control by organised screening. Issues to be considered in designing a national programme. *Kolposkopia* 2, 95-116, 2001.

515. Syrjänen, K.J. and Erzen, M. The prognostic significance of Human papillomavirus (HPV) infections and cancer screening. *CME J. Gynec. Oncol.* 6, 325-346, 2001.

516. Syrjänen, K. Overview of papillomavirus research. Chapter 1. In: Syrjänen, K. and Syrjänen, S. *Papillomavirus Infections in Human Pathology.* J. Wiley & Sons, New York, 2000: pp. 1-10.

- 517.Syrjänen S. and Syrjänen K. Molecular biology of papillomaviruses. Chapter 2. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 11-52.
- 518.Syrjänen, K. Pathogenesis of HPV infections. Chapter 3. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 53-88.
- 519.Syrjänen, S. and Syrjänen, K. Diagnostic techniques in HPV detection. Chapter 4. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 89-116.
- 520.Syrjänen, K. Epidemiology of genital HPV infections, CIN and cervical cancer. Chapter 5. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 117-142.
- 521.Syrjänen, K. Natural history of cervical HPV infections and CIN. Chapter 6. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 142-166.
- 522.Syrjänen, K. Early detection of CIN and HPV: Prevention of cervical cancer. Chapter 7. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 167-188.
- 523.Syrjänen, K. HPV and cervical adenocarcinoma. Chapter 8. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 189-206.
- 524.Syrjänen, K. HPV infections of the vulva. Chapter 9. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 207-232.
- 525.Syrjänen, K. HPV infections of the vagina. Chapter 10. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 233-248.
- 526.Syrjänen, K. HPV infections in the male. Chapter 11. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 249-276.
- 527.Syrjänen, K. HPV infections in the urinary tract. Chapter 12. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 277-294.
- 528.Syrjänen, K. HPV infections of the anus. Chapter 13. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 295-314.
- 529.Syrjänen, K. HPV infections of the skin. Chapter 14. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 315-340.
- 530.Syrjänen, S. and Syrjänen, K. HPV infections in children. Chapter 15. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 341-354.

531.Syrjänen, K. HPV infections in the respiratory tract. Chapter 16. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 355-378.

532.Syrjänen, S. and Syrjänen, K. HPV infections of the oral mucosa. Chapter 17. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 379-412.

533.Syrjänen, K. HPV infections of the oesophagus. Chapter 18. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 413-428.

534.Syrjänen, K. HPV and squamous cell tumours of the ocular surface epithelium. Chapter 19. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 429-444.

535.Syrjänen, K. HPV infections in other sites and lesions. Chapter 20. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 445-458.

536.Syrjänen, K. Immunology of HPV infections and prospects for vaccination. Chapter 21. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 459-490.

537.Eržen, M., Rakar, S., Cavic, M., Mozina, A., Omahen, A., Kopac, D. and Syrjänen K. Factors predicting disease outcome in early stage adenocarcinoma of the uterine cervix. Eur J. Gynec. Obstet. Reprod. Biol. 101:185-191, 2002. (I.F. 1.662)

538.Eržen, M., Rakar, S., Klančar, B. and Syrjänen, K. Endometriosis-associated ovarian carcinoma (EAOC): An entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol. Oncol. 83, 100-108, 2001. (I.F. 3.774)

539.Syrjänen, S., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Tosi, P., Cintorino, M., Santopietro, R. and Syrjänen, K.J. Human Papillomavirus testing and conventional PAP smear cytology as optional screening tools of women at different risk for cervical cancer in countries of former Soviet Union. J. Lower Genital Tract Dis. 6, 97-110, 2002. (I.F. 1.963)

540.Syrjänen, K.J., Eržen, M. and Costa, S. Histological and quantitative pathological prognostic factors in cervical cancer. CME J. Gynec. Oncol. 6, 279-301, 2001.

541.Merne, M.E., Syrjänen, K.J. and Syrjänen S.M. Systemic and local effects of long-term exposure to alkaline drinking water in rats. Int. J. Exp. Pathol. 82, 213-219, 2001 (I.F. 2.168)

542.Syrjänen, K.J. The glossary. In: Bösze P, Luesley DM. (eds). EAGC Course Book on Colposcopy. Primed-X Press, Budapest, 2003, pp. 197-215.

543.Costa, S., Sideri, M., Syrjänen, K., Terzano, P., De Nuzzo, M., De Simone, P., Cristiani, P., Finarelli, C., Bovicelli, A., Zamparelli, A. and Bovicelli, L. HPV testing for cervical neoplasia. A reply. Acta Cytol. 45, 660-661, 2001. (I.F. 1.562)

544.Sagarra, R.A.M., Andrade, L.A.L.A., Martinez, E.Z., Pinto, G.A., Syrjänen, K.J. and Derchain, S.F.M. P53 and bcl-2 as prognostic predictors in epithelial ovarian cancer. Int. J. Gynecol. Cancer. 12, 720-727, 2002. (I.F. 2.116)

545. Brenna, S.M.F., Zeferino, L.C., Pinto, G.A. Souza, R.A., Andrade, L.A.L. Vassalo, J, Martinez, E.Z. and Syrjänen, K.J. p53 expression as a predictor of recurrence in cervical squamous cell carcinoma. *Int. J. Gynecol. Cancer*. 12, 299-303, 2002. (I.F. 2.116)

546. Brenna, S.M.F., Zeferino, L.C., Pinto, G.A. Souza, R.A., Andrade, L.A.L. Vassalo, J, Martinez, E.Z. and Syrjänen, K.J. C-myc protein expression is not an independent prognostic predictor in cervical squamous cell carcinoma. *Braz. J. Med. Biol. Res*. 35, 425-430, 2002. (I.F. 1.146)

547. Roteli-Martins, C.M., Longatto Filho, A., Galvane, J.O., Martinez, E.Z., di Loreto, C., Utagawa, M.L., Arlindo, F.C., Pereira, S.M.M., Martins, L.M., Pittoli, J.E., Figueiredo, S.F., Aguiar, L.S., Maeda, M.Y.S. and Syrjänen, K.J. Cervical cancer screening in São Paulo: Preliminary results for 3000 women. *DST. J. Bras. Doenças Sex. Transm*. 15, 12-16, 2003.

548. Kusamura, S., Derchain, S., Alvarenga, M., Gomes, C.P., Syrjänen, K.J. and Angelo-Andrade, L.A.L. Expression of p53, c-erbB-2, Ki-67 and CD34 in patients with granulosa cell tumour of the ovary. *Int. J. Gynecol. Cancer*. 13, 450-457, 2003. (I.F. 2.116)

549. Brenna, S.M.F., Bonatto Jr, A., Guerreiro da Silva, I.D.C., Campos, A.S.Q. and Syrjänen, K.J. Excellent cosmetic and functional result achieved by vulvar reconstruction using V-Y myocutaneous flap after vulvectomy and lymphadenectomy in a young woman with stage II vulvar cancer. *Int. Surg*. 87, 6-11, 2002. (I.F. 0.248)

550. Branca, M., Garbuglia, A-R., Benedetto, A., Leoncini, L., Migliore, G., Cappiello, T., Agarossi, A., Costa, S., Santini, D. and Syrjänen, K. Factors predicting the persistence of genital Human papillomavirus (HPV) infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up. *Int J STD & AIDS*. 14, 417-425, 2003. (I.F. 1.300)

551. Syrjänen, K.J. HPV et tumeurs épidermoïdes bénignes et malignes de l'œsophage. Chapter 37. In: Aubin, F., Pretet, J.L. and Mouglin, C. (Eds). *Papillomavirus Humains. Biologie et pathologie tumorale*. Editions TEC & DOC, Paris 2003; pp. 523-548.

552. Costa, S., Simone, P.D., Venturoli, S., Cricca, M., Zerbini, M.L., Musiani, M., Terzano, P., Santini, D., Cristiani, P., Syrjanen, S. and Syrjanen K. Factors predicting Human papillomavirus (HPV) clearance in cervical intraepithelial neoplasia (CIN) lesions treated by conization. *Gynecol. Oncol*. 90, 358-365, 2003. (IF 3.774).

553. Syrjänen, S., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Johansson, B., Tosi, P., Cintorino, M., Santopietro, R. and Syrjänen, K.J. Sexual habits and Human papillomavirus (HPV) infections among women in three new independent states of the former Soviet Union. *Sex Transm Dis*. 30, 680-684, 2003 (IF 2.842).

554. Syrjänen, K. HPV infections and oesophageal cancer. Invited Review. *J. Clin. Pathol*. 55, 721-728, 2002. (I.F. 2.915)

555. Syrjänen, K. and Erzen, M. Sertoli-Leydig cell tumours of the ovary. Implications of histological subtypes. *CME J. Gynec. Oncol*. 7, 145-163, 2002.

556. Syrjänen, K. HPV infections and lung cancer. Invited Review. *J. Clin. Pathol*. 55, 885-891, 2002. (I.F. 2.915)

557. Syrjänen, K.J. HPV infections in benign and malignant sinonasal lesions. *J Clin. Pathol*. Invited Review. 56, 174-181, 2003. (I.F. 2.915)

558.Syrjänen, K. Detection organizada del cancer cervical: un programa que funciona. In: Cancer Cervicouterino cancer cervicouterino y mamario en el proximo milenio. C.S.Pineda (Ed.), Mexico City. pp. 14-15, 2000.

559.Syrjänen, S. and Syrjänen, K. Recherche dans le domaine des HPV- Questions non résolues, controversies et perspectives. Chapter 49. In: Aubin, F., Pretet, J.L. and Mouglin, C. (Eds). Papillomavirus Humains. Biologie et pathologie tumorale. Editions TEC & DOC, Paris 2003; pp. 715-749.

560.Syrjänen, K. and Eržen, M. Polyembryoma of the ovary. Invited review. CME J. Gynec. Oncol. 7, 238-245, 2002.

561.Santos A.L., Derchain, S.F., Martins, M.R., Sarian, L.O., Martinez, E.Z. and Syrjänen, K.J. Human papillomavirus (HPV) viral load in predicting high-grade CIN in women with PAP smears showing only atypical squamous cells (ASC) or low grade squamous intraepithelial lesion (LSIL). Sao Paulo Med J. 121, 238-242, 2003. (I.F. 0.703)

562.Shirata, N.K., Longatto Filho, A., Roteli-Martins, C., Esporatore, L.M.W., Pittoli, J.E. and Syrjänen, K. The applicability of liquid-based cytology in assessment of DNA content in cervical lesions using static cytometry. Anal. Quant. Cytol. Histol. 25: 210-214, 2003. (IF 0.630)

563.Brenna, S.M.F. and Syrjänen, K.J. Regulation of cell cycle is of key importance in Human papillomavirus (HPV)-associated cervical carcinogenesis. Sao Paulo Med. J. 121,128-132, 2003. (I.F. 0.703)

564.Syrjänen, K. Embryonal carcinoma of the ovary. Editors introduction. CME J. Gynec. Oncol. 7, 213-214, 2002.

565.Syrjänen, K. Embryonal carcinoma of the ovary. Editors conclusions. CME J. Gynec. Oncol. 7, 246-248, 2002.

566.Syrjänen, K. Morfología de las lesiones cervicales asociadas al VPH. In: Pineda C.S. (ed). XII Reunión Internacional de Cáncer Cérvico-Uterino y Lesiones Precursoras, Clínica de Diagnóstico Y Prevención del Cancer de la Mujer, Mexico City, 2002: pp. 18-24, 2002.

567.Syrjänen, K. Manejo del Papanicolaou anormal. Implicaciones de las diferentes terminologies. In: Pineda C.S. (ed). XII Reunión Internacional de Cáncer Cérvico-Uterino y Lesiones Precursoras, Clínica de Diagnóstico Y Prevención del Cancer de la Mujer, Mexico City, 2002: pp. 39-48, 2002.

568.Syrjänen, K. Control general del cancer cervical. Tamizaje convencional con Papanicolaou e implicaciones de la prueba del VPH. In: Pineda C.S. (ed). XII Reunión Internacional de Cáncer Cérvico-Uterino y Lesiones Precursoras, Clínica de Diagnóstico Y Prevención del Cancer de la Mujer, Mexico City, 2002: pp. 74-82, 2002.

569.Syrjänen, K. Adenocarcinoma incipiente del cervix, aspectos clínicos y asociación con el VPH. In: Pineda C.S. (ed). XII Reunión Internacional de Cáncer Cérvico-Uterino y Lesiones Precursoras, Clínica de Diagnóstico Y Prevención del Cancer de la Mujer, Mexico City, 2002: pp. 97-108, 2002.

570.Longatto Filho, A., Utagawa, M.L., Miranda Pereira, S.M., Pittoli, J.E., Aguiari, L.S., Maeda, M.Y.S., di Loreto, C., Roteli-Martins, C., Lima, T.P., Galvane, J.O., and Syrjänen, K.J. Low- and high-risk HPV types detected with Hybrid Capture II in liquid-based cytology (DNA CITOLIQ®) system: Experience from the LAMS (Latin American Screening) study. J. Bras. Doencas Sex Transm. 16, 17-20, 2004.

571.Syrjänen, K.J. Role of HPV detection techniques as auxiliary screening tools. In: Audy-Jurkovic A (Ed.). Gynecologic Cytology in Croatia 50 Years After. Croatian Medical Association, Zagreb, 2003; pp. 81-91.

572.Eržen, M., Branca, M., Syrjänen, K. and Coleman, D.V. The PAP test procedure, quality assurance and continuous quality improvement in laboratories participating in cervical cancer screening. Presentation of the items produced by Leonardo da Vinci, Cytotrain 2000 project of European Union. In: Audy-Jurkovic A (Ed.). Gynecologic Cytology in Croatia 50 Years After. Croatian Medical Association, Zagreb, 2003; pp. 93-103.

573.Syrjänen, K., Naud, P., Derchain, S.M., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Serpa-Hammes, L., Gontijo, R., Lima, T.P., Maeda, M.Y.S., Lorincz, A., Dores, G.B., Costa, S. and Syrjänen, S. Comparing PAP smear cytology, aided visual inspection (VIA), screening colposcopy, cervicography and HPV testing by HCII (normal and self-sampling) as optional screening tools in Latin America. Experience from the LAMS study. In: Monsonego J. (Ed). 5th International Multidisciplinary Congress EUROGIN 2003. Monduzi Editore, Milano 2003, pp.65-73.

574.Syrjänen, K.J., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Tosi, P., Cintorino, M., Santopietro, R. and Syrjänen, S. Testing optional screening tools for cervical cancer in the new independent states (NIS) of the former Soviet Union. In: Monsonego J. (Ed). 5th International Multidisciplinary Congress EUROGIN 2003. Monduzi Editore, Milano 2003, pp.55-63.

575.Syrjänen, K.J. Natural history of HPV infections: Recent developments. In: Monsonego J. (Ed). 5th International Multidisciplinary Congress EUROGIN 2003. Monduzi Editore, Milano 2003, pp.1-9.

576.Syrjänen, K. and Eržen, M. Pathogenesis and histopathology of the steroid (lipid) cell tumours of the ovary. CME J. Gynec. Oncol. 8, 156-166, 2003.

577.Brenna, S.M.F., Silva, I.D.C.G., Zeferino, L.C., Pereira, J.S., Martinez, E.Z. and Syrjänen, K.J. Prevalence of codon 72 p53 polymorphism in Brazilian women with invasive cervical carcinoma. Genet. Molec. Biol. 27, 496-499, 2004. (IF 1.202)

578.Syrjänen, S., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Tosi, P., Cintorino, M., Santopietro, R. and Syrjänen, K.J. Clearance of High-Risk Human Papillomavirus (HPV) DNA and PAP smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States of the Former Soviet Union (the NIS cohort study). Eur J. Gynec. Obstet. Reprod. Biol. 119, 219-227, 2005. (I.F. 1.662).

579.Nonogaki, S., Wakamatsu, A., Longatto Filho, A, Pereira, S.M., Utagawa, M.L., Ferreira Alves, V.A., Di Loreto, C., Sakamaoto Maeda, Y., Lima, T.P., Roteli-Martins, C., and Syrjänen, K.J. Hybrid Capture II and polymerase chain reaction for identifying HPV infections in samples collected in the new collection medium: a comparison. Acta Cytol. 48, 514-520, 2004. (I.F. 1.562).

580.Brenna, S.M.F., Silva, I.D.C.G., Zeferino, L.C., Pereira, J.S., Martinez, E.Z. and Syrjänen, K.J. Prognostic value of p53 codon 72 polymorphism in invasive cervical cancer in Brazil. Gynecol. Oncol. 93, 374-380, 2004. (IF 3.774)

581.Oliveira, E.R.Z.M., Derchain, S.F.M., Rabelo-Santos, S.H., Westin, M.C.A., Zeferino, L.C., Campos, E.A., Amaral, R.G. and Syrjänen, K.J. Detection of high-risk Human papillomavirus (HPV) DNA by Hybrid Capture II in women referred due to atypical glandular cells in the primary screening. *Diagn. Cytopathol.* 31, 19-22, 2004. (IF 0.980).

582.Syrjänen, S., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Tosi, P., Cintorino, M., Santopietro, R. and Syrjänen, K.J. Acquisition of Incident High-Risk Human Papillomavirus (HPV) Infections and PAP Smear Abnormalities in a Cohort of Women Subjected to HPV Screening in the New Independent States (NIS) of the Former Soviet Union. *J. Clin. Microbiol.* 42, 505-511, 2004. (I.F. 3.993).

583.Ciotti, M., Giuliani, L., Ambrogi, V., Ronci, C., Benedetto, A., Mineo, T.C., Syrjänen, K. and Favalli, C. Detection and expression of Human papillomavirus oncogenes in non-small cell lung cancer. *Oncology Report.* 16, 183-189, 2006 (I.F. 2.301).

584.Gontijo, R.C. Derchain, S.F.M., Montemor, E., Sarian, L.O., Serra, M.M. Zeferino, L.C. and Syrjänen, K.J. Pap smear, Hybrid Capture II and visual inspection with acetic acid in the screening for uterine cervical lesions. *Cad. Saúde Pública,* 21, 141-149, 2005.

585.Syrjänen, K.J. Chapter editor's introduction. *CME J. Gynec. Oncol.* 8, 154-155, 2003.

586.Syrjänen, S., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Tosi, P., Cintorino, M., Santopietro, R. and Syrjänen, K.J. Age-specific incidence and clearance rates of high-risk Human Papillomavirus (HPV) infections in women subjected to HPV screening in the new independent states. *Int J STD & AIDS.* 16, 217-223, 2005. (I.F. 1.300).

587.Syrjänen, K.J. Chapter editor's conclusions. *CME J. Gynec. Oncol.* 8, 187-188, 2003.

588.Syrjänen, K.J. Evolución natural de las infecciones por papillomavirus humano. In: Tatti, S: (Ed). *Colposcopia y Patologías del Tracto Genital Inferior.* Editorial Médica Panamericana, Buenos Aires, 2008; pp. 64-71.

589.Syrjänen, K.J. Preface (Prefácio). In: de Carvalho, J.J.M. (author). *Falando Sobre o HPV (Papillomavirus humano).* Instituto Garnet, Sao Paulo. pp. 7-14, 2003. (**ISBN 85-89772-01-2**).

590.Ciotti, M., Sesti, F., Paba, P., Benedetto, A., Patrizi, L., Criscuolo, A., Piccione, E., Branca, M., Syrjänen, K. and Favalli, C. Human papillomavirus (HPV) testing in the management of women with abnormal PAP smear. Experience From Colposcopy Referral Clinic. *Eur. J. Gynecol. Oncol.* 25, 577-584, 2004. (I.F. 0.611).

591.Rabelo-Santos, S.H., Levi, E., Derchain, S.F.M., Sarian, L.O., Zeferino, L.C., Messias, S., de Moraes, L.O., Campos, E.A., and Syrjänen, K.J. DNA recovery from Hybrid Capture II samples stored in specimen transport medium with denaturing reagent, for detection of human papillomavirus by PCR. *J. Virol. Meth.* 126, 197-201, 2005. (IF 1.781).

592.Costa, S., Terzano, P., Syrjänen, S. and Syrjänen, K. Indicadores pronosticos de la respuesta a la quimioterapia neoadyuvante en pacientes con neoplasia cervical. *Coleccion Trabajos Distinguidos Serie Oncologia* 14(3), 1-11, 2003.

593.Naud, P., Matos, J., Hammes, L., Stuckzynski, J., Brouwers, K., Magno, V., Dias, E., Crusius, P., d'Avila, A., Campos, C., Costa, M., Höblik, M., Marc, C., Marroni, R. and

Syrjänen, K. Factors predicting intermediate endpoints of cervical cancer and exposure to Human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in South of Brazil. *Cancer Epidemiol. Eur J. Gynec. Obstet. Reprod. Biol.* 124, 110-118, 2006. (I.F. 1.662).

594. Branca, M., Costa, S., Mariani, L., Piccione, E., Sesti, F., Agarossi, A., di Carlo, A., Galati, M., Ciotti, M., Paba, P., Benedetto, A., Giorgi, C., Criscuolo, A., Valieri, M., Favalli, C., Santini, D., Alderisio, M., De Nuzzo, M., di Bonito, L. and Syrjänen, K. Assessment of risk factors and Human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study. *Eur. J. Gynaecol. Oncol.* 25, 689-698, 2004. (I.F. 0.611).

595. Kulmala, S-M., Syrjänen, S., Shabalova, I., Petrovichev, N., Kozachenko, V., Podistov, J., Ivanchenko, O., Zakharenko, S., Nerovjna, R., Kljukina, L., Branovskaja, M., Grunberga, V., Juschenko, A., Tosi, P., Santopietro, R., Syrjänen, K. and the NIS Cohort Study Group. Human papillomavirus testing with hybrid capture 2 assay and PCR as screening tools. *J. Clin. Microbiol.* 42, 2470-2475, 2004. (IF 3.993)

596. Costa, S., Preeti, M., Rivalsi, F., Mariani, L., Terzano, P. and Syrjänen, K. (eds). Patologia della Vagina. Test-Atlante. Vol 2. Athena Audiovisuals Srl, Modena, pp. 455-873, 2011. (ISBN 978-88-86980-71-5).

597. Syrjänen, K.J. Colposcopia como prueba del tamizaje. Experiencia en Latinoamerica. In: Pineda, C.S. (ed). XIII Reunion International de Cancer Cervico-Uterino y Lesiones Precursoras. Clinica de Diagnóstico Y Prevención del Cancer de la Mujer, Mexico City, 2003: pp. 51-59.

598. Syrjänen, K.J. El tamizaje del cancer cervico-uterina bien organizado. El papanicolaou es el camino del exito. In: Pineda, C.S. (ed). XIII Reunion International de Cancer Cervico-Uterino y Lesiones Precursoras. Clinica de Diagnóstico Y Prevención del Cancer de la Mujer, Mexico City, 2003: pp. 103-110. s

599. Syrjänen, K.J. Historia natural de las lesiones precursoras del Ca.Cu. In: Pineda, C.S. (ed). XIII Reunion International de Cancer Cervico-Uterino y Lesiones Precursoras. Clinica de Diagnóstico Y Prevención del Cancer de la Mujer, Mexico City, 2003: pp. 146-159.

600. Syrjänen, K.J. Summary statements on prognostic factors in carcinoma of the uterine cervix. CME J. Gynec. Oncol. 8, 233-236, 2003.

601. Syrjänen, K.J. Historia natural des adenodisplasias, carcinoma in situ y del adenocarcinoma. Documentacion histologica. In: Pineda, C.S. (ed). XIII Reunion International de Cancer Cervico-Uterino y Lesiones Precursoras. Clinica de Diagnóstico Y Prevención del Cancer de la Mujer, Mexico City, 2003: pp. 169-182.

602. Syrjänen, K.J. Tecnicas auxiliares en el tamizaje del Ca.Cu. (inspeccion visual post acido acetico, cervicografia y pruebas del VPH). Experiencia multicentrica en Latinoamericano. In: Pineda, C.S. (ed). XIII Reunion International de Cancer Cervico-Uterino y Lesiones Precursoras. Clinica de Diagnóstico Y Prevención del Cancer de la Mujer, Mexico City, 2003: pp. 186-194.

603. Sarian, L., Derchain, S.F.M., Andrade, L.A.A., Tambascia, J., Morais, S.S. and Syrjänen, K.J. HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia (CIN). *Gynecol Oncol.* 94, 181-186, 2004. (IF 3.774).

604. Branca, M., Morosini, P., Severi, P., Eržen, M., Di Benedetto, C. and Syrjänen, K. A new statistical software for intralaboratory and interlaboratory quality control in clinical cytology.

Validation of the software in a simulation study on clinical samples. *Acta Cytol.* 49, 398-404, 2005. (I.F. 1.562).

605.Syrjänen, K.J. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. *Eur. J. Gynaecol. Oncol.* 26, 5-19, 2005. (IF 0.614).

606.Syrjänen, K.J. Is improved detection of adenocarcinoma in situ (AIS) by screening a key to reducing the incidence of cervical adenocarcinoma? Editorial. *Acta Cytol.* 48, 591-594, 2004. (I.F. 1.562).

607.Pereira S.M.M., Utagawa, M.L., Pittoli, J.P., Aguiar, L.S., Sakamoto Maeda, M.Y., Longatto Filho, A., di Loreto, C., Roteli-Martins, C., Galvana, J.O., Wolf, C.M., Figueiredo, S.F. and Syrjänen, K. Avaliacao da celularidade citoologica em preparados de base liquida. *Rev. Inst. Adolfo Lutz.* 62, 35-39, 2003.

608.Ruutu, M., Johansson, B., Grenman, R., Syrjänen, K. and Syrjänen S. Effect of confluence state and passaging on global cancer gene expression pattern in oral carcinoma cell lines. *Anticancer Res.* 24, 2627-2631, 2004. (IF 2.480)

609.Branca, M., Ciotti, M., Santini, D., Di Bonito, L., Benedetto, A., Giorgi, C., Paba, P., Favalli, C., Costa, S., Agarossi, A., Alderisio, M. and Syrjänen K. p16^{INK4a} expression is related to grade of CIN and high-risk Human papillomavirus but does not predict virus clearance after conization or outcome. *Int J. Gynecol. Pathol.* 23, 354-365, 2004. (IF 1.665)

610.Kulmala, S-M., Syrjänen, S.M., Gyllensten, UB., Shabalova, I.P., Petrovichev. N., Tosi, P., Syrjänen, KJ. and Johansson, BC. Early integration of high-copy HPV16 detectable in women with normal and low-grade cervical cytology and histology. *J Clin. Pathol.* 59, 513-517, 2006. (I.F. 2.915).

611.Syrjänen, K. and Eržen, M. Ovarian gonadoblastoma and related tumours: Classification, histopathology and cellular sources of hormone production. *CME J Gynecol Oncol.* 9, 13-25, 2004.

612.Martinez, E.Z., Louzada-Neto, F., Derchain, S.F.M., Achar, J.A., Gontijo, R.C., Sarian, L.O.Z. and Syrjänen, K.J. Bayesian estimation of performance measures of cervical cancer screening tests in the presence of covariates and absence of a gold standard. *Cancer Informatics.* 4, 3-46, 2008. (I.F. 1.360)

613.Derchain, S.F.M., Rabelo-Santos, S.H., de Oliveira Zambeli, E.R., Sarian, L.O.Z., do Amaral Westin, M.C., Andrade, L.A.L.A., Zeferino, L.C. and Syrjänen, K.J. Human papillomavirus (HPV) DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. *Gynecol Oncol* 95, 618-623, 2004. (I.F. 3.774).

614.Santos, A.L., Derchain, S.F., Sarian, L.O., Martins, M.R., Morais, S.S. and Syrjänen, K.J. Performance of Pap smear and human papillomavirus testing in the follow-up of women with cervical intraepithelial neoplasia grade 1 managed conservatively. *Acta Obstet. Gynecol. Scand.* 85,444-450, 2006. (I.F. 1.618).

615.Branca, M., Ciotti, M., Santini, D., Di Bonito, L., Benedetto, A., Giorgi, C., Paba, P., Favalli, C., Costa, S., Agarossi, A., Alderisio, M. and Syrjänen, K. Activation of ERK/MAP kinase pathway in cervical intraepithelial neoplasia (CIN) is related to grade of the lesion but not to high-risk Human Papillomavirus (HPV), virus clearance, or prognosis in cervical cancer. *Am. J. Clin. Pathol.* 122, 902-911, 2004. (I.F. 2.514).

616.Longatto-Filho, A., Maeda, M.Y.S., Eržen, M., Branca, M., Roteli-Martins, C., Naud, P., Derchain, S.M., Serpa-Hammes, L., Matos, J., Gontijo, R., Sarian, L., Lima, T.P., Tatti, S., Syrjänen, S. and Syrjänen, K. Conventional PAP smear and liquid-based cytology as

screening tools in low-resource settings of Latin America. Experience of the Latin American Screening Study. *Acta Cytol.* 49, 500-506, 2005 (IF 1.562)

617. Buhmeida, A., Ristamäki, R., Ålgars, A., Collan, Y., Syrjänen, K. and Pyrhönen S. Nuclear area is a prognostic determinant in advanced colorectal cancer. *Anticancer Res.* 25, 3083-3088, 2005 (I.F. 2.480)

618. Elzagheid, A., Ålgars, A., Bendardaf, R., Lamlum, H., Ristamäki, R., Collan, Y., Syrjänen, K. and Pyrhönen, S. in primary colorectal carcinomas and their metastasis reflect disease outcome. *World. J. Gastroenterol.* 12, 4304-4309, 2006 (I.F. 2.787).

619. Shirata, N.K., Espoladore, L.M.W., Longatto Filho, A., Pittoli, J.E., di Loreto, C., Pereira, S.M.M., Maeda, M.Y.S., Uttagawa, M.L., da Silva Aguiar, L., Roteli-Martins, C., Edson G. Martinez, E.G. and Syrjänen, K. High-risk HPV detection by Hybrid Capture and ploidy determination by a computer-assisted system in cervical biopsies. *Anal. Quant. Cytol. Histol.* 26, 295-300, 2004. (IF 0.630).

620. Longatto Filho, A., Uttagawa, M.L., Shirata, N.K., Pereira, S.M.M., Namyama, G.M., Kanamura, C.T., Santos, G.D., de Oliveira, M.A., Wakamatsu, A., Nonogaki, S., Roteli-Martins, C., Loreto, C.D., Ferraz, M.D., Sakamoto Maeda, M.Y. Alves, V.A. and Syrjänen, K. Immunocytochemical expression of p16^{INK4A} and Ki-67 in cytologically negative and equivocal PAP smears positive for oncogenic Human papillomavirus. *Int. J. Gynec. Pathol.* 24, 118-124, 2005. (IF 1.665)

621. Nonogaki, S., Wakamatsu, A., Longatto Filho, A., Roteli-Martins, C., di Loreto, C., Maeda, M.Y.S., Uttagawa, M.L., Pereira, S.M.M., Polli, S., Alves, V.A., and Syrjänen, K. Molecular strategies for identifying Human papillomavirus infection in routinely processed samples: Focus on paraffin sections. *J. Lower Genital Tract. Dis.* 9, 219-224, 2005 (I.F.1.963)s

622. Syrjänen, K.J. Chapter editor's introduction. *CME J. Gynec. Oncol.* 9, 93-95, 2004.

623. Syrjänen, K. HPV and oesophageal cancer. Chapter 15. In: Campo, S. (ed). *Papillomavirus Research: From Natural History to Vaccines and Beyond*. Caister Academic Press, Norwich, UK, 2006; pp. 229-253.

624. De Carvalho, J.J.M., Syrjänen, K.J., Jacobino, M., Rosa, N.T., Carvalho, L.Z.M. Prevalence of genital Human papillomavirus (HPV) infections established with different diagnostic techniques among males attending an urological clinic. *Scand. J. Urol. Nephrol.* 40, 138-143, 2006. (IF 1.234)

625. De Carvalho, J.J.M., De Carvalho, J.Z.M., Rosa, N.T., Carvalho, L.Z.M., Syrjänen, K.J. Identification of males at increased risk for genital Human papillomavirus (HPV) infection among patients referred for urological consultation. *Scand. J. Infect. Dis.* 39, 1029-1037, 2007. (IF 1.366).

626. Branca, M., Giorgi, C., Santini, D., Di Bonito, L., Ciotti, M., Costa, S., Benedetto, A., Casolati, E.A., Favalli, C., Paba, P., Di Bonito, P., Mariani, L., Syrjänen, S., Bonifacio, D., Accardi, L., Zanconati, F. and Syrjänen, K. as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. *Am. J. Clin. Pathol.* 124, 113-121, 2005. (IF 2.514).

627. Kulmala, S.M., Shabalova, I.P., Petrovitchev, N., Syrjänen, K.J., Gyllensten, U.B. and Syrjänen, S.M. Prevalence of the most common high-risk HPV genotypes among women in the three new independent states of the former Soviet Union. *J. Med. Virol.* 79, 771-781, 2007. (I.F. 1.998).

628. Syrjänen, K., Naud, P., Derchain, S.M., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Serpa-Hammes, L., Matos, J., Gontijo, R., Sarian, L., Lima, T.P.,

Maeda, M.Y.S., Lörincz, A., Dores, G.B., Costa, S. and Syrjänen, S. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS Study. *Anticancer Res.* 25, 3469-3480, 2005 (I.F. 2.480).

629.Syrjänen, S., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Tosi, P., Cintonino, M., Santopietro, R. and Syrjänen, K.J. Factors predicting persistence of High-Risk Human Papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the Former Soviet Union. *Eur. J. Gynaecol. Oncol.* 26, 491-498, 2005. (IF 0.611).

630.Sarian, L, Derchain, S.M., Naud, P., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Serpa-Hammes, L., Matos, J., Gontijo, R., Lima, T.P., Maeda, M.Y.S., Lörincz, A., Dores, G.B., Costa, S., Syrjänen, S. and Syrjänen, K. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI) cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study. *J. Med. Screen.* 12, 142-149, 2005. (IF 2.722).

631.Montemor, E.B.L., Roteli-Martins, C.M., Longatto Filho, A., Zeferino, L.C., Amaral, R.G., Fonsechi-Carvasan, G.A., Shirata, N.K., Utagawa, M.L., Longatto-Filho A. and Syrjänen, K.J. Whole, Turret and step methods of rapid re-screening: Is there any difference in performance? *Diagn. Cytopathol.* 35, 57-60, 2007. (IF 0.980).

632.Branca, M., Giorgi, C., Santini, D., Di Bonito, L., Ciotti, M., Benedetto, A., Paba, P., Costa, S., Bonifacio, D., Di Bonito, P., Accardi, L., Favalli, C., and Syrjänen, K. Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high-risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. *J. Clin. Pathol.* 59, 40-47, 2006. (IF 2.915).

633.Monsonogo, J., Bohbot, J.M., Pollini, G., Krawec, C., Vincent, C., Merignargues, I., Haroun, F., Dachez, R. and Syrjänen, K. Performance of the ROCHE AMPLICOR[®] Human Papillomavirus (HPV) test in detection of cervical intraepithelial neoplasia (CIN) in management of women with abnormal PAP smear. *Gynecol. Oncol.* 99, 160-168, 2005 (IF 3.774).

634.Branca, M., Giorgi, C., Ciotti, M., Santini, D., Di Bonito, L., Costa, S., Benedetto, A., Bonifacio, D., Di Bonito, P., Paba, P., Accardi, L., Mariani, L., Syrjänen, S., Favalli, C., and Syrjänen K. Relationship of of 67-kD laminin receptor to grade of cervical intraepithelial neoplasia and high-risk HPV types and prognosis in cervical cancer. *Acta Cytologica.* 50, 6-15, 2006 (IF 1.562)

635.Branca, M., Giorgi, C., Ciotti, M., Santini, D., Di Bonito, L., Costa, S., Benedetto, A., Bonifacio, D., Di Bonito, P., Paba, P., Accardi, L., Mariani, Ruutu, M., L., Syrjänen, S., Favalli, C., and Syrjänen K. Upregulation of nuclear factor- κ B (NF- κ B) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer. *Diagnostic Cytopathol.* 34, 555-563, 2006 (IF 0.980)

636.Bendardaf, R., Ålgars, A., Elzagheid, A., Korkeila, E., Ristamäki, R., Lamlum, H., Collan, Y., Syrjänen, K. and Pyrhönen, S. Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. *Oncol. Report.* 15, 741-746, 2006 (IF 2.301).

637.Buhmeida, A., Ålgars, A., Ristamäki, R., Collan, Y., Syrjänen, K. and Pyrhönen, S. Nuclear size as prognostic determinant in stage II and stage III colorectal adenocarcinoma. *Anticancer Res.* 26, 455-462, 2006 (IF 2.480).

638. Bendardaf, R., Lamlum, H., Ristamäki, R., Korkeila, E., Syrjänen, K. and Pyrhönen, S. Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer. *Tumour Biol.* 28, 212-220, 2007 (I.F. 3.611).
639. Buhmeida, A., Collan, Y., Syrjänen, K. and Pyrhönen, S. DNA image cytometry in prognostication of colorectal cancer. Practical considerations of the technique and interpretation of the histograms. *Image Anal. Stereol.* 25, 1-12, 2006. (I.F. 0.971)
640. de Souza, N.C.N., Brenna, S.M. F., Campos, F., Syrjänen, K.J., Baracat, E.C., Silva, I.D.C.G. IL-6 polymorphisms and the risk of cervical cancer. *Int. J. Gynecol. Cancer.* 16, 1278-1282, 2006 (I.F. 2.116).
641. Syrjänen, K.J. Morphological diagnosis. In: Monsonego J. (ed). *Emerging Issues of HPV Infections: From Science to Practice.* Basel, Karger 2006; pp. 157-164.
642. Ruutu, M., Wahlroos, N., Syrjänen, K., Johansson, B. and Syrjänen S. Effects of 17 β -estradiol and progesterone on transcription of human papillomavirus 16 E6-E7 oncogenes in CaSki and SiHa cell lines. *Int. J. Gynecol. Cancer.* 16, 1261-1268, 2006. (IF. 2.116).
643. Longatto-Filho, A., Eržen, M., Branca, M., Roteli-Martins, C., Naud, P., Derchain, S., Hammes, L., Sarian, L.O., Matos, J., Gontijo, R., Lima, T., Maeda, M.Y.S., Tatti, S., Syrjänen, S., Dores, G., Lörincz, A., and Syrjänen, K. Human papillomavirus (HPV) testing as an optional screening tool in low-resource settings of Latin America. Experience from the LAMS Study. *Int. J. Gynecol. Cancer.* 16, 955-962, 2006 (I.F. 2.116).
644. Rintala, A.M., Grénman, S.E., Syrjänen, K.J. and Syrjänen, S.M. High risk human papillomavirus DNA in oral and genital mucosa of infants during their first three years of lives; Experience from the Finnish HPV Family Study. *Clin. Infect. Dis.* 41, 1728-1733, 2005 (IF. 8.886).
645. Branca, M., Giorgi, C., Ciotti, M., Santini, D., Di Bonito, L., Costa, S., Benedetto, A., Bonifacio, D., Di Bonito, P., Paba, P., Accardi, L., Mariani, L., Ruutu, M., Favalli, C., and Syrjänen K. Down-regulation of nucleoside diphosphate (NDP) kinase nm23-H1 expression is unrelated to high-risk Human papillomavirus (HPV) but associated with progression of CIN and unfavourable prognosis of cervical cancer. *J. Clin. Pathol.* 59, 1044-1051, 2006. (I.F. 2.915).
646. Branca, M., Giorgi, C., Ciotti, M., Santini, D., Di Bonito, L., Costa, S., Benedetto, A., Bonifacio, D., Di Bonito, P., Paba, P., Accardi, L., Mariani, L., Ruutu, M., Syrjänen, S., Favalli, C., and Syrjänen K. Over-expression of topoisomerase II α is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk Human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. *Int. J. Gynecol. Pathol.* 25, 383-392, 2006. (IF 1.665)
647. Gontijo, R.C., Derchain, S.F.M., Roteli-Martins, C., Bragança, J.C., Sarian, L.O.Z., Morais, S.S., Maeda, M.Y.S., Longatto-Filho, A. and Syrjänen, K.J. Human Papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for two years in the LAMS Study. *Eur. J. Gynec. Obstet. Reprod. Biol.* 133, 239-246, 2007. (I.F. 1.662)
648. Branca, M., Giorgi, C., Ciotti, M., Santini, D., Di Bonito, L., Costa, S., Benedetto, A., Bonifacio, D., Di Bonito, P., Paba, P., Accardi, L., Mariani, L., Ruutu, M., Syrjänen, S., Favalli, C., and Syrjänen K. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus (HPV), virus persistence or disease outcome in cervical cancer. *Diagnostic Cytopathol.* 34, 739-748, 2006. (I.F. 0.980).

649.Buhmeida, A, Elzagheid, A., Ålgars, A., Collan, Y., Syrjänen, K and Pyrhönen, S. Expression of the cell-cell adhesion molecule β -catenin in colorectal carcinomas and their metastases. *APMIS* 116, 1-9, 2008. (I.F. 1.933)

650.Costa S, Syrjänen, K. (eds). Gestione delle Paziienti con PAP Test Anormale. Volume I. Athena Audiovisuals, Modena, pp. 1-350, 2005 (ISBN 88-86980-52-3).

651.Syrjänen, K.J. The colposcopy, cytology and histology of genital HPV infections. *CME J Gynecol Oncol* 10, 46-61, 2005.

652.Giuliani, L., Coletti, A., Syrjänen, K., Favalli, C. and Ciotti, M. Comparison of DNA sequencing and array® in Human papillomavirus (HPV) genotyping. *Anticancer Res.* 26, 3939-3941, 2006 (IF 2.480).

653.Santopietro, R., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Tosi, P., Cintonino, M., Syrjänen, K.J. and Syrjänen, S.M. Cell cycle regulators p105, p107, Rb2/p130, E2F4, p21^{CIP1/WAF1}, Cyclin-A in predicting CIN, High-Risk Human Papillomavirus infections and their outcome in women screened in three New Independent States of the Former Soviet Union. *Cancer Epidemiol. Biomarker Prevent.* 15, 1250-1256, 2006. (IF.4.125).

654.Branca, M., Giorgi, C., Ciotti, M., Santini, D., Di Bonito, L., Costa, S., Benedetto, A., Bonifacio, D., Di Bonito, P., Paba, P., Accardi, L., Syrjänen, S., Favalli, C., and Syrjänen K. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. *Anticancer Res.* 26, 1543-1556, 2006 (I.F. 2.480)

655.Branca, M., Giorgi, C., Ciotti, M., Santini, D., Di Bonito, L., Costa, S., Benedetto, A., Bonifacio, D., Di Bonito, P., Paba, P., Accardi, L., Syrjänen, S., Favalli, C., and Syrjänen K. Upregulation of proliferating cell nuclear antigen (PCNA) is closely associate with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. *Eur. J. Gynec. & Obstet. Reprod. Biol.* 130, 223-231, 2007. (I.F. 1.662).

656.Branca, M., Giorgi, C., Ciotti, M., Santini, D., Di Bonito, L., Costa, S., Benedetto, A., Bonifacio, D., Di Bonito, P., Paba, P., Accardi, L., Syrjänen, S., Favalli, C., and Syrjänen K. Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer. *Eur. J. Gynaecol. Oncol.* 27, 215-223, 2006. (I.F. 0.611)

657.Syrjänen, K. HPV and squamous cell carcinogenesis. *Ginecorama XVI* (1), 21-23, 1993.

658.Paba, P., Bonifacio, D., Di Bonito, L., Ombres, D., Favalli, C., Syrjänen, K. and Ciotti, M. Co-expression of HSV2 and *Chlamydia trachomatis* in human papillomavirus (HPV) positive cervical cancer and CIN lesions is associated with aberrations in key intracellular pathways. *Intervirol.* 51, 230-234, 2008. (I.F. 1.773).

659.Hammes, L.S., Tekmal, R.R., Naud, P., Edelweiss, M.I., Kirma, N., Valente P.T., Syrjänen, K.J. and Cunha-Filho, S. Up-regulation of VEGF, C-FMS and COX-2 expression correlates with cervical cancer precursor (CIN) lesion severity and invasive disease. *Gynecol. Oncol.* 110, 445-451, 2008. (I.F. 3.774).

660.von Knebel-Döberitz, M. and Syrjänen, K. Molecular markers. How to apply in practice. *Gynecol. Oncol.* 103, 18-20, 2006. (IF 3.774).

661.Vihinen, P.P., Hilli, J., Vuoristo, M-S., Kähäri, V-M., Syrjänen, K.J. and Pyrhönen, S.O. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. *Acta Oncol.* 46, 678-684, 2007 (I.F. 3.730)

662.Bendardaf, R., Elzagheid, A., Ålgars, A., Korkeila, E., Ristamäki, R., Collan, Y., Syrjänen, K. and Pyrhönen, S. Thymidylate synthase expression in the primary colorectal tumours correlate with its expression in metastases. *Scand. J. Gastroenterol.* 42, 471-476, 2007 (I.F. 2.199).

663.Syrjänen, K.J. Molecular markers of gynaecological malignancies. Chapter Editor's Introduction. *CME J Gynecol Oncol* 11, 21-22, 2006.

664.Bubendorf, L., Grote, H.J. and Syrjänen, K.J. Molecular Techniques. Chapter 36. In: Bibbo, M. and Wilbur D (Eds). *Comprehensive Cytopathology*, Third Edition. Elsevier, 2008. pp. 1071-1090.

665.Ciotti, M., Coletti, A., Giuliani, L., Cappiello, T, Syrjänen, K. and Favalli, C. The p53 codon 72 arg/arg homozygous women in Central Italy are at increased risk for HPV infections. *Anticancer Res.* 26, 3745-3748, 2006. (I.F. 2.480)

666.Monsonogo J., Pollini, G., Evrard, M.J., Sednaoui, P., Monfort, L., Quinzat, D., Dachez, R. and Syrjänen, K. p16^{INK4a} immunocytochemistry in liquid based cytology (LBC) samples gives added value in management of women with equivocal PAP smear. *Acta Cytol.* 51, 755-766, 2007. (IF 1.562).

667.Syrjänen, K.J., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Santopietro, R., Cintonino, M., Tosi, P., and Syrjänen, S.M. Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections. *Anticancer Res.* 26, 4729-4740, 2006 (IF. 2.480).

668.Alderisio, M., Branca, M., Eržen, M., Longatto-Filho, A., Derchain, S., Tatti, S., Vighi, S., Roteli-Martins, C., Leoncini, L., Maeda, M.Y.S., Gontijo, R., Sarian, L. and Syrjänen, K. Inter-laboratory quality control in gynecological cytopathology using the novel CONQUISTADOR software. Inter-observer reproducibility in the LAMS* study. *Acta Cytol.* 51, 872-881, 2007. (I.F. 1.562)

669.Guedes A.C., Brenna, S.M., Coelho S.A., Martinez, E.Z., Syrjänen, K.J. and Zeferino, L.C. p16^{ink4a} expression does not predict the outcome of cervical intraepithelial neoplasia grade 2 (CIN2). *Int. J. Gynecol. Cancer.* 17, 1099-1103, 2007 (I.F. 2.116)

670.Di Bonito, P., Grasso, F., Mochi, S., Accardi, L., Dona, M.G., Branca, M., Costa, S., Mariani, L., Agarossi, A., Ciotti, M., Syrjänen, K. and Giorgi, C. Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. *Infect. Agent. Cancer.* 1 (6),1-9, 2006. (I.F. 2.071)

671.Elzagheid, A., Bendardaf, R., Syrjänen, K., Collan, Y. and Pyrhönen, S. E-cadherin expression significantly correlated with the response to chemotherapy (irinotecan plus 5-fluorouracil) in locally advanced and metastatic colorectal carcinoma. *Jamahiriya Med. J.* 6, 120-123, 2006. (I.F. 0.000).

672.Monsonogo J., Pollini, G., Evrard, M.J., Sednaoui, P., Monfort, L., Quinzat, D., Dachez, R. and Syrjänen, K. Linear array genotyping and hybrid capture II assay in detecting of high-risk Human papillomavirus (HPV) types in women with abnormal PAP smear. *Int. J. STD &*

AIDS. 19, 385-392, 2008. (IF 1.300).

673.Hammes, L.S., Naud, P., Passos, E., Rivoire, W., Matos, J., Brouwers, K. and Syrjänen, K.J. Value of the International Federation of Colposcopy and Cervical Pathology (IFCPC) terminology in predicting cervical pathology. *J. Lower Genital Tract Dis.* 11, 158-165, 2007. (I.F. 1.963)

674.Costa, S., Negri, G., Sideri, M., Santini, D., Venturoli, S., Pelusi, C., Syrjänen, S., Syrjänen, K. and Pelusi, G. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. *Gynecol Oncol.* 106, 170-176, 2007 (IF 3.774).

675.Giuliani, L., Jaxmar, T., Casadio, C., Gariglio, M., Manna, A., D'Antonio, D., Syrjänen, K., Favalli, C. and Ciotti, M. Detection of oncogenic viruses (SV40, BKV, JCV, HCMV, HPV) and p53 codon 72 polymorphism in lung carcinoma. *Lung Cancer* 57, 273-281, 2007. (I.F. 3.958).

676.Buhmeida, A., Ålgars, A., Ristamäki, R., Collan, Y., Syrjänen, K. and Pyrhönen, S. DNA cytometry is a useful adjunct tool in the prediction of disease outcome in patients with stage II and stage III colorectal cancer. *Oncology* 70, 427-437, 2007. (I.F. 2.152).

677.Kulmala, S.M., Shabalova, I., Petrovitchev, N., Syrjänen, K., Gyllenstein, U., Johansson, B. and Syrjänen, S. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. *Cancer Epidemiol. Biomarker. Prev.* 16, 17-22, 2007. (IF.4.125).

678.Hammes, L.S., Tekmal, R.R., Naud, P., Edelweiss, M.I., Kirma, N., Valente P.T., Syrjänen, K.J. and Cunha-Filho, S. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression. *Clinicopathological correlation.* *Gynecol. Oncol.* 105, 157-165, 2007. (I.F. 3.774).

679.Salminen, E., Clemens, K.E., Syrjänen, K. and Salmenoja, H. Needs of developing the skills of palliative care at the oncology ward. An audit of symptoms among 203 consecutive cancer patients in Finland. *Support Care Cancer.* 16, 3-8, 2008. (I.F. 2.535).

680.Giorgi C., Di Bonito, P., Grasso, F., Mochi, S., Accardi, L., Donà, M.G., Branca, M., Costa, S., Mariani, L., Agarossi, A., Ciotti, M. and Syrjänen, K. Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPV) measured by a novel ELISA based denatured recombinant HPV16 late (L) and early (E) antigens. *Infect. Agent. Cancer.* 3, 9-19, 2008. (I.F. 2.071)

681.Branca, M., Ciotti, M., Giorgi, C., Santini, D., Di Bonito, L., Costa, S., Benedetto, A., Bonifacio, D., Di Bonito, P., Paba, P., Accardi, L., Syrjänen, S., Favalli, C., and Syrjänen K. Predicting high-risk human papillomavirus (HPV) infection, progression of cervical intraepithelial neoplasia (CIN) and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modelling. *Int. J. Gynecol. Pathol.* 27, 265-273, 2008. (I.F. 1.665).

682.Vihinen, P.P., Kallioinen, M., Vuoristo, M-S., Ivaska, J., Syrjänen, K.J., Hahka-Kempinen, M., Kellokumpu-Lehtinen, P-L. and Pyrhönen, S.O. Serum angiogenin levels predict treatment response and survival in patients with stage IV melanoma. *Clin. Exp. Metast.* 24, 567-574, 2007. (I.F. 3.491).

683.Latvala, A., Syrjänen, K., Salmenoja, H. and Salminen, E. Anaemia and other predictors of fatigue among patients on palliative therapy for advanced cancer. *Anticancer Res.* 29, 2569-2575, 2009. (I.F. 2.480)

684.Elzagheid, A., Korkeila, E., Bendardaf, R., Buhmeida, A., Heikkilä, S., Vaheri, A., Syrjänen, K., Pyrhönen, S. and Carpen, O. Expression of ezrin predicts disease-specific

survival and survival with metastases in advanced colorectal cancer. *Human Pathol.* 39, 1737-1743, 2008. (I.F. 2.769)

685.Syrjänen, K.J., Kulmala, S-M., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Santopietro, R., Cintonino, M., Tosi, P., and Syrjänen, S.M. Epidemiological, clinical and viral determinants of the increased prevalence of High-Risk Human Papillomavirus (HPV) infections in elderly women. *Eur. J. Gynecol. Oncol.* 29, 114-122, 2008. (I.F. 0.611)

686.Bendardaf, R., Buhmeida, A., Ristamäki, R., Syrjänen, K. and Pyrhönen, S. MMP-1 (Collagenase-1) expression in the primary colorectal cancer and their metastases. *Scand. J. Gastroenterol.* 42, 1473-1478, 2007. (IF. 2.199).

687.Monsonogo J., Pollini, G., Evrard, M.J., Sednaoui, P., Monfort, L., Zerat, L. and Syrjänen, K. Detection of Human papillomavirus (HPV) genotypes among high-risk women: Comparison of hybrid capture and linear array tests. *Sex. Transm. Dis.* 35, 521-527, 2008. (IF 2.842).

688.Vihinen, P., Koskivuo, I., Syrjänen, K., Tervahartiala, T., Sorsa, T. and Pyrhönen, S. Serum MMP-8 is associated with ulceration and vascular invasion of malignant melanoma. *Melanoma Res.* 18, 268-273, 2008. (I.F. 2.282).

689.Syrjänen, K.J. Mechanisms and predictors of high-risk human papillomavirus (HPV) clearance in the uterine cervix. *Eur. J. Gynecol. Oncol.* 28, 337-351, 2007. (I.F. 0.611)

690.Elzagheid, A., Buhmeida, A., Korkeila, E., Collan, Y., Syrjänen, K. and Pyrhönen, S. Nuclear β -catenin expression as prognostic factor in advanced colorectal carcinoma. *World J. Gastroenterol.* 14, 3866-3871, 2008 (I.F. 2.787).

691.Roteli-Martins, C.M., Longatto Filho, A., Hammes, L.S., Derchain, S.F.M., Naud, P., Mattos, J., Etlinger, D., Sarian, L., Gontijo, R., Maeda, M.Y.S. and Syrjänen, K.J. Associação entre idade ao início da atividade sexual e subsequente infecção por papilomavírus humano: resultados de um programa de rastreamento brasileiro. *Rev. Bras. Ginec. Obstet.* 29, 580-587, 2007. (I.F. 0.370)

692.Longatto-Filho, A., Roteli-Martins, C., Hammes, L., Etlinger; D., Pereira, S.M.M., Eržen, M., Branca, M., Naud, P., Derchain, S.F.M., Sarian, L.O., Matos, J., Gontijo, R., Lima, T., Maeda, M.Y.S., Tatti, S., Syrjänen, S. and Syrjänen, K. Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS Study. *Eur. J. Gynecol. Oncol.* 29,327-332, 2008. (I.F. 0.611)

693.Syrjänen, K., Shabalova, I., Petrovichev, N., Kozachenko, V., Zakharova T., Pajanidi, A., Podistov, J., Chemeris, G., Sozaeva, L., Lipova, E., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L., Erokhina, O., Branovskaja, M., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Santopietro, R., Cintonino, M., Tosi, P., and Syrjänen, S.M. Age at menarche is not an independent risk factor for high-risk Human Papillomavirus (HPV) infections and cervical intraepithelial neoplasia (CIN). *Int. J. STD & AIDS.* 19, 16-25, 2008 (IF. 1.300).

694.Giuliani, L., Favalli, C., Syrjänen, K. and Ciotti, M., Human papillomavirus (HPV) infections in lung cancer. Detection of E6 and E7 transcripts and review of the literature. *Anticancer Res.* 27, 2697-2704, 2007. (IF 2.480).

695.Syrjänen, K.J., Shabalova, I.P., Petrovichev, N., Kozachenko, V.P., Zakharova T., Pajanidi, A., Podistov, J.I., Chemeris, G., Sozaeva, L.G., Lipova, E.V., Tsidaeva, I., Ivanchenko, O. Pshepurko, G., Zakharenko, S., Nerovjna, R., Kljukina, L.B., Erokhina, O.A., Branovskaja, M.F., Nikitina, M., Grunberga, V., Grunberg, A., Juschenko, A., Santopietro,

R., Cintonino, M., Tosi, P., and Syrjänen, S.M. Smoking is an independent risk factor for oncogenic human Papillomavirus (HPV) infections but not high-grade CIN. *Eur. J. Epidemiol.* 22, 723-735, 2007. (I.F. 7.105).

696.Costa, S., Marra, E., Martinelli, G.N., Santini, D., Casadio, P., Formelli, G., Pelusi, C., Ghi, T., Syrjänen, K. and Pelusi, G. Outcome of conservatively treated microinvasive squamous cell carcinoma of the uterine cervix during a 10-year follow-up. *Int J Gynecol Cancer* 19, 33-38, 2009. (I.F. 2.116).

697.Derchain, S.F., Sarian, L-O., Naud, P., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Matos, J., Gontijo, R., Bragança, J.F., Lima, T.P., Maeda, M.Y.S., Lörincz, A., Dores, G.B., Costa, S., Syrjänen, S. and Syrjänen, K. Safety of screening with Human papillomavirus (HPV) testing for cervical cancer at three-year intervals in a high-risk population: Experience from the LAMS study. *J. Med. Screen.* 15, 97-104, 2008. (I.F. 2.722).

698.Syrjänen, K.J. Prefácio. In: Coelho F.R.G., Soares F.A., Focchi, J., Fregnani, J.H.T.G., de Andrade, J. M., Zeferino, L.C., Villa, L.L., Frederico, M.H., Novais, P.E.R. and Costa R.L.R. (eds). *Câncer do Colo do Útero*. Tecmed Editora, Sao Paulo, Brazil. 2008, pp. vii-viii.

699.Longatto-Filho A. and Syrjänen, K.J. Citologia cervical. In: Coelho F.R.G., Soares F.A., Focchi, J., Fregnani, J.H.T.G., de Andrade, J. M., Zeferino, L.C., Villa, L.L., Frederico, M.H., Novais, P.E.R. and Costa R.L.R. (eds). *Câncer do Colo do Útero*. Tecmed Editora, Sao Paulo, Brazil. 2008, pp. 128-140.

700.Sarian, L.O.Z., Syrjänen, K.J. Metodos de inspecao visual para rastreamento do câncer do colo úterino. In: Coelho F.R.G., Soares F.A., Focchi, J., Fregnani, J.H.T.G., de Andrade, J. M., Zeferino, L.C., Villa, L.L., Frederico, M.H., Novais, P.E.R. and Costa R.L.R. (eds). Câncer do Colo do Útero. Tecmed Editora, Sao Paulo, Brazil. 2008, pp. 141-145.

701.Syrjänen, K., Naud, P., Derchain, S.F., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Matos, J., Gontijo, R., Sarian, L., Bragança, J., Arlindo, F.C., Maeda, M.Y.S., Lörincz, A., Dores, G.B., Costa, S. and Syrjänen, S. Drug Addiction is not an independent risk factor for oncogenic human papillomavirus (HPV) infections or high-grade CIN. Case-control study nested within the LAMS Study* cohort. *Int. J. STD & AIDS.* 19, 251-258, 2008. (I.F. 1.300)

702.Bendardaf, R., Lamlum, H., Ristamäki, R., Korkeila, E., Syrjänen, K. and Pyrhönen, S. Thymidylate synthase and microsatellite instability in colorectal cancer. Implications for disease free survival, treatment response and survival with metastases. *Acta Oncol.* 47, 1046-1053, 2008. (I.F. 3.730).

703.Syrjänen, K., Naud, P., Derchain, S.F., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Matos, J., Gontijo, R., Sarian, L-O., Bragança, J.F., Arlindo, F.C., Maeda, M.Y.S., Lörincz, A., Dores, G.B., Costa, S. and Syrjänen, S. Value of conventional, Liquid Based Cytology, visual inspection (VIA) and Human papillomavirus (HPV) testing as optional screening tools among Latin American women <35 and >35 years of age. Experience from the LAMS Study. *Acta Cytol.* 52, 641-653, 2008. (I.F. 1.562)

704.Elzagheid, A., Buhmeida, A., Korkeila, E., Collan, Y., Syrjänen, K. and Pyrhönen, S. Up-regulation of α -catenin is associated with increased risk of lymph node involvement in colorectal cancer. *World. J. Gastroenterol.* 14, 4903-4908, 2008. (I.F. 2.787)

705.Giuliani, L., Ronci, C., Bonifacio, D., Di Bonito, L., Favalli, C., Perno, C.F., Syrjänen, K., and Ciotti, M. Detection of oncogenic DNA viruses in colorectal cancer. *Anticancer Res.* 28, 1405-1410, 2008 (I.F. 2.480)

706.Pitta, D.R., Sarian, L.O., Campos, E.A., Rabelo-Santos, S.H., Syrjänen, K and Derchain, S.F. Phylogenetic classification of human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia in women from a densely populated Brazilian urban region. Sao Paulo Med. J. 127,122-127, 2009 (I.F. 0.703).

707.Costa, S., Rivasi, F., Barbolini, G., Negri, G., Terzano, P. and Syrjänen, K. Chapter 16. Infezioni virali: Human papillomavirus (HPV). In: Costa, S., Preeti, M., Rivalsi, F., Mariani, L., Terzano, P. and Syrjänen, K. (eds). Patologia della Vagina. Test-Atlante. Vol 2. Athena Audiovisuals Slr, Modena, pp. 489-561, 2011 (ISBN 978-88-86980-71-5)

708.Bendardaf, R., Ristamäki, R., Syrjänen, K. and Pyrhönen, S. Bcl-2 expression significantly correlates with thymidylate synthase expression in colorectal cancer. World J. Gastroenterol. 14, 6218-6223, 2008 (I.F. 2.787).

709.Sarkola, M.E., Grenman, S.E., Rintala, M.A.M., Syrjänen, K.J. and Syrjänen, S.M. Effect of second pregnancy on maternal carriage and outcome of high-risk human papillomavirus (HPV). Experience from the prospective Finnish HPV Family Study. Gynec. Obstet. Invest. 67, 208-216, 2009. (I.F. 1.696).

710.Syrjänen, K.J. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. Eur. J. Gynecol. Oncol. 29, 205-221, 2008. (I.F. 0.611).

711.Rama, C.H., Roteli-Martins, C.M., Derchain, S.F., Longatto-Filho, A., Gontijo, R.C., Sarian, L.O., Syrjänen, K. and Aldrighi, J.M. Prevalence of genital HPV infection among women screened for cervical cancer. Rev. Saude Publica 42, 123-130, 2008. (I.F. 1.219)

712.Longatto-Filho, A., Hammes, L.S., Sarian, L.O., Roteli-Martins, C., Derchain, S.F.M., Eržen, M., Branca, M., Tatti, S., Naud, P., de Matos, J.C., Gontijo, R., Maeda, M.Y.S., Lima, T., Costa, S., Syrjänen, S. and Syrjänen, K. Hormonal contraceptives and the length of their use are not independent risk factors for high-risk human papillomavirus (HPV) infections or high-grade CIN. Gynec. Obstet. Invest. 71, 93-103, 2011. (I.F. 1.696).

713.Buhmeida, A., Bendardaf, R., Hilska, M., Collan, Y., Laato, M., Syrjänen, S., Syrjänen, K. and Pyrhönen, S. Prognostic significance of Matrix Metalloproteinase-9 (MMP-9) in Stage II colorectal carcinoma. J. Gastrointest Cancer. 40, 91-97, 2009 (I.F. 0.920).

714.Simen-Kapeu, A., Kataja, V., Yliskoski, M., Dillner, J., Koskela; P., Syrjänen, K., Saarikoski, S., Paavonen, J. and Lehtinen, M. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. Scand. J. Infect. Dis. 40, 745-751, 2008 (I.F. 1.366).

715.Simen-Kapeu, A., La Ruche, G., Kataja, V., Yliskoski, M., Bergeron, C., Horo, A., Syrjänen, K., Saarikoski, S., Lehtinen, M., Dabis, F. and Sasco A.J. Tobacco smoking and chewing as risk factors of multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Côte d'Ivoire and Finland) with different tobacco exposure. Cancer Causes Contr. 20, 163-170, 2009 (I.F. 2.735).

716.Syrjänen, K., Shabalova, I., Naud, P., Kozachenko, V., Derchain, S., Zakharchenko, S., Roteli-Martins, C., Nerovjna, R., Longatto-Filho, A., Kljukina, L., Tatti, S., Branovskaja, M., Serpa Hammes, L., Branca, M., Grunjberga, V., Eržen, M., Juschenko, A., Costa, S., Sarian, L., Podistov, J. and Syrjänen, S. and the NIS and LAMS Study Research Groups. Persistent High-Risk Human Papillomavirus (HPV) infections and other endpoint markers of progressive cervical disease among women prospectively followed-up in the NIS and LAMS cohorts. Int. J. Gynecol. Cancer. 19, 934-942, 2009 (I.F. 2.116)

717.Sarkola, M., Grénman, S., Rintala, M., Syrjänen, K. and Syrjänen, S. Human papillomavirus (HPV) in the placenta and umbilical cord blood. *Acta Obstet. Gynec. Scand.* 87, 1181-1188, 2008. (I.F. 1.618).

718.Syrjänen, K.J., Shabalova, I.P., Ivanchenko, O., Kljukina, L.B., Grunberga, V. and Syrjänen, S.M. Reproducibility of classification and correction for verification bias as determinants of performance of Papanicolaou smear cytology in the screening setting: Experience from the New Independent States of the former Soviet Union cohort study. *Acta Cytologica.* 53, 2009; 548-557, 2009 (IF. 1.562).

719.Costa, S., Rivasi, F., Barbolini, G. and Syrjänen, K. Chapter 22. Neoplasia intraepiteliale della vagina (VaIN): epidemiologia, eziopatogenesi e diagnosi. In: Costa, S., Preeti, M., Rivalsi, F., Mariani, L., Terzano, P. and Syrjänen, K. (eds). Patologia della Vagina. Test-Atlante. Vol 2. Athena Audiovisuals Srl, Modena, pp. 643-716, 2011 (ISBN 978-88-86980-71-5) 643-716, 2011 (ISBN 88-86980-52-4).

720.Syrjänen, S. and Syrjänen, K. The history of Papillomavirus research. *Cent. Eur. J. Pub. Health* 16, S7-S13, 2008. (I.F. 0.798).

721.Rama, C.H., Roteli-Martins, C.M., Derchain, S.F., Longatto-Filho, A., Gontijo, R.C., Sarian, L.O., Syrjänen, K., Ching, T. and Aldrighi, J. Previous screening for cervical cancer among women with cytological and histological abnormalities. *Rev. Saude Publica* 42, 411-419, 2008. (I.F. 1.219).

722.Bendardaf, R., Lamlum, H., Ristamäki, R., Syrjänen, K. and Pyrhönen, S. Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. *Oncol. Rep.* 20, 999-1004, 2008 (I.F. 2.301).

723.Avoranta, S.T., Korkeila, E.A., Ristamäki, R.H. Syrjänen, K.J., Carpén, O.M., Pyrhönen, S.O. and Sundström J.T.T. ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer. *Hum. Pathol.* 44, 966-974, 2013. (I.F. 2.769).

724.Sarian, L, Serpa-Hammes, L., Longatto-Filho, A., Derchain, S.M., Roteli-Martins, C., Naud, P., Eržen, M., Branca, M., Tatti, S., Matos, J., Gontijo, R., Maeda, M.Y.S., Lima, T.P., Costa, S., Syrjänen, S. and Syrjänen, K. Increased risk of oncogenic Human papillomavirus (HR-HPV) infections and incident high-grade cervical intraepithelial neoplasia (CIN) among smokers: Experience from the Latin American Screening (LAMS) Study. *Sex. Transm. Dis.* 36, 241-248, 2009 (I.F. 2.842).

725.Guarisi, R., Sarian, L.O., Hammes, L.S., Longatto-Filho, A., Derchain, S.F.M., Roteli-Martins, C., Naud, P., Eržen, M., Branca, M., Tatti, S., Costa, S., Syrjänen, S., Braganca, J.F. and Syrjänen, K. Smoking worsens the prognosis of mild abnormalities in cervical cytology. *Acta Obstet. Gynec. Scand.* 88, 514-520, 2009 (I.F. 1.985)

726.Syrjänen, K.J. Human papillomavirus (HPV) involvement in esophageal carcinogenesis. In: Medeiros A, Veloso C. (eds). *Nose and Viral Cancer, Etiology, Pathogenesis and Treatment.* Nova Science Publishers, Inc., New York, USA. 2010; pp. 1-54. (ISBN-978-1-60741-735-4)

727.Korkeila, E.A., Talvinen, K., Jaakkola, P.M., Minn, H., Syrjänen, K., Sundström, J. and Pyrhönen, S. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. *Br. J Cancer.* 100, 874-880, 2009 (I.F. 4.836)

728.Guedes, A.C., Zeferino, L.C., Syrjänen, K.J. and Brenna, S.M.F. Short-term outcome of intraepithelial neoplasia grade 2: Considerations for management strategies and reproducibility of diagnosis. *Anticancer Res.* 30, 2319-2323, 2010 (I.F. 2.480).

729.Syrjänen, S., Waterboer, T., Sarkola, M., Michael, K., Rintala, M., Syrjänen, K., Grenman, S. and Pawlita, M. Dynamics of Human papillomavirus (HPV) serology in women followed-up for 36 months after pregnancy. *J Gen. Virol.* 90, 1515-1526, 2009. (I.F. 3.529)

730.Costa, S., Preti, M., Mariani, L., Sideri, M., Negri, G. and Syrjänen K. Chapter 24. Neoplasia invasiva della vagina. In: Costa, S., Preti, M., Rivalisi, F., Mariani, L., Terzano, P. and Syrjänen, K. (eds). *Patologia della Vagina. Test-Atlante. Vol 2. Athena Audiovisuals Slr, Modena, pp. 743-790, 2011 (ISBN 978-88-86980-71-5)*

731.Buhmeida, A., Hilska, M., Elzagheid, A., Laato, M., Collan, Y., Syrjänen, K. and Pyrhönen, S. DNA image cytometry predicts disease outcome in stage II colorectal carcinoma. *Anticancer Res.* 29, 99-106, 2009 (I.F. 2.480).

732.Buhmeida, A., Bendardaf, R., Hilska, M., Laine, M., Collan, Y., Laato, M., Syrjänen, K. and Pyrhönen, S. PLA2 (Group IIA Phospholipase A2) as a Prognostic Determinant in Stage II Colorectal Carcinoma. *Ann. Oncol.* 20, 1230-1235, 2009. (I.F. 9.269).

733.Xavier, S.D., Bussolati Filho, I., de Carvalho, J.M., Castro, T.M., Framil, V.M. and Syrjänen, K.J. Prevalence of Human papillomavirus (HPV) DNA in oral mucosa of men with anogenital HPV infection. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* 108, 732-737, 2009 (I.F. 1.499).

734.Syrjänen, K.J. Histology, classification and natural history of cervical intraepithelial neoplasia (CIN). *CME J. Gynecol. Oncol.* 14, 4-21, 2009.

735.Syrjänen, K., Shabalova, I., Naud, P., Sarian, L., Derchain, S., Kozachenko, V., Zakharchenko, S., Roteli-Martins, C., Nerovjna, R., Longatto-Filho, A., Kljukina, L., Tatti, S., Branovskaja, M., Serpa Hammes, L., Branca, M., Grunjberga, V., Eržen, M., Juschenko, A., Costa, S., Podistov, J. and Syrjänen, S. and the NIS and LAMS Study Research Groups. Cofactors of High-Risk Human Papillomavirus (HPV) infections display unique profiles in incident CIN1, CIN2 and CIN3. Analysis of the combined prospective cohort of the NIS* and LAMS studies. *Int. J. STD & AIDS.* 22, 263-272, 2011. (I.F. 1.300).

736.Bendardaf, R., Buhmeida, A., Hilska, M., Laato, M., Syrjänen, S., Syrjänen, K., Collan, Y. and Pyrhönen, S. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-free survival. *Anticancer Res.* 28, 3865-3870, 2008. (I.F. 2.480).

737.Ibrahim, N., Elzagheid, A., El-Hashmi, H. Syrjänen, K. and Alhakim, S. The potential value of EGFR and P53 immunostaining in urinary bladder tumors. *Libyan J. Med.* 4, doi:10.4176/090625, 2009. (I.F. 1.429)

738.Syrjänen, K.J. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland. *Scand. J. Infect. Dis. Suppl.* 107, 3-32, 2009 (I.F. 1.366).

739.Bendardaf, R., Buhmeida, A., Hilska, M., Laato, M., Syrjänen, S., Syrjänen, K., Collan, Y. and Pyrhönen, S. MMP9 (Gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. *Cancer Invest.* 28, 38-43, 2010 (I.F. 2.218).

740.Syrjänen, K., Shabalova, I., Naud, P., Sarian, L., Derchain, S., Kozachenko, V., Zakharchenko, S., Roteli-Martins, C., Nerovjna, R., Longatto-Filho, A., Kljukina, L., Tatti, S., Branovskaja, M., Serpa Hammes, L., Branca, M., Grunjberga, V., Eržen, M., Juschenko, A., Costa, S., Podistov, J. and Syrjänen, S. and the NIS and LAMS Study Research Groups. Risk estimates for persistent High-Risk Human Papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease critically depend on reference category. Analysis of the combined prospective cohort of the NIS* and LAMS** studies. *Int. J. STD & AIDS.* 22, 315-323, 2011. (I.F. 1.300).

741.Syrjänen, S., Naud, P., Derchain, S., Sarian, L., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Matos, J., Gontijo, R., Bragança, J., Arlindo, F.C., Maeda, M.Y.S., Costa, S. and Syrjänen, K. Upregulation of Activator Inhibitor-2 (PAI-2, Serpin-B2) is associated with High-Risk human papillomavirus (HPV) and grade of cervical lesion at baseline but does not predict outcomes of HR-HPV infections or incident CIN. *Am. J. Clin. Pathol.* 132, 883-892, 2009. (I.F. 2.514)

742.Zucchi, F., da Silva, I.D.C.G., Ribalta, J.C.L., de Souza, N.C.N., de Góis Speck, N.M., Girão, M.J.B.C., Brenna, S.M.F. and Syrjänen, K.J. Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. *Eur. J. Gynaec. Oncol.* 30, 142-144, 2009 (I.F. 0.611).

743.Martinez, E.Z., Louzada-Neto, F., Achar, J.A., Syrjänen, K.J., Derchain, S.F.M., Gontijo, R.C. and Sarian, L.O.Z. Bayesian estimation of performance measures of screening tests in the presence of covariates and absence of a gold standard. *Braz. J. Probab. Stat.* 23, 68-81, 2009. (I.F. 0.469)

744.Syrjänen, S., Naud, P., Derchain, S., Sarian, L., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Matos, J., Gontijo, R., Bragança, J., Arlindo, F.C., Maeda, M.Y.S., Costa, S. and Syrjänen, K. P300 expression is related to high-risk human papillomavirus infections and severity of cervical intraepithelial neoplasia but not to viral or disease outcomes in a longitudinal setting. *Int. J. Gynecol. Pathol.* 29, 135-145, 2010 (I.F. 1.665)

745.Syrjänen, K. (ed). Selected Papers on Gynaecologic Oncology. In honour of 70th birthday of Professor Peter Bosze. PressCon, Budapest, pp. 1-95, 2009 (ISBN 978-963-86403-5-2).

746.Syrjänen, K. Introduction. In: Syrjänen, K. (ed). Selected Papers on Gynaecologic Oncology. In honour of 70th birthday of Professor Peter Bosze. PressCon, Budapest, pp. 7-8, 2009.s

747.Branca, M. and Syrjänen, K. Novel markers as predictors of CIN and prognosis of cervical cancer. In: Syrjänen, K. (ed). Selected Papers on Gynaecologic Oncology. In honour of 70th birthday of Professor Peter Bosze. PressCon, Budapest, pp. 51-78, 2009.s

748.Syrjänen, K.J. Human papillomavirus (HPV) involvement in esophageal carcinogenesis. Nova Science Publishing, New York, USA. pp. 1-96, 2010 (ISBN 978-1-60876-211-8).

749.Korkeila, E.A., Talvinen, K., Jaakkola, P.M., Minn, H., Syrjänen, K., Sundström, J. and Pyrhönen, S. Expression of carbonic anhydrase isozyme suggests poor response to therapy in rectal cancer. *Br. J Cancer.* 101, 373-373, 2009 (I.F. 4.836).

750.Lindström, A., Tot, T., Stendahl, U., Syrjänen, S., Syrjänen, K. and Hellberg, D. Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma on cervical cancer. *Anticancer Res.* 29, 2577-2578, 2009. (I.F. 2.480).

751.Syrjänen, S., Naud, P., Derchain, S., Sarian, L., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Matos, J., Gontijo, R., Bragança, J., Arlindo, F.C., Maeda, M.Y.S., Costa, S. and Syrjänen, K. Immunosuppressive Cytokine IL-10 (Interleukin-10) is Up-Regulated in High-Grade CIN but not Associated with High-Risk Human Papillomavirus (HPV) at Baseline, Outcomes of HR-HPV Infections or Incident CIN in the LAMS* Cohort. *Virchows Arch. Pathol.* 455, 505-515, 2009. (I.F. 2.651)

752.Syrjänen, S., Naud, P., Derchain, S., Sarian, L., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Matos, J., Gontijo, R., Bragança, J., Arlindo, F.C., Maeda, M.Y.S., Costa, S. and Syrjänen, K. Upregulation of Lipocalin 2 is associated with high-risk human papillomavirus and grade of cervical lesion at baseline but does not predict outcomes of infections or incident Cervical Intraepithelial Neoplasia. *Am. J. Clin. Pathol.* 134, 50-59, 2010. (I.F. 2.514)

753.Syrjänen, S., Naud, P., Derchain, S., Sarian, L., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Matos, J., Gontijo, R., Bragança, J., Arlindo, F.C., Maeda, M.Y.S., Costa, S. and Syrjänen, K. Upregulation of 14-3-3 σ (Stratifin) is Associated with High-Grade CIN and High-Risk Human Papillomavirus (HPV) at Baseline but Does Not Predict Outcomes of HR-HPV Infections or Incident CIN in the LAMS* Study. *Am. J. Clin. Pathol.* 133, 232-240, 2010 (I.F. 2.514)

754.Syrjänen, K.J. Annual disease burden due to human papillomavirus (HPV) 16 and 18 infections in Finland. *Scand. J. Infect. Dis. Suppl.* 108, 2-32, 2009. (I.F. 1.366).

755.Koskimaa, H-M., Kurvinen, K., Costa, S., Syrjänen, K. and Syrjänen, S. Molecular markers implicating early malignant events in cervical carcinogenesis. *Cancer Epid. Biomarker Prev.* 19, 2008-2012, 2010. (I.F. 4.125).

756.Syrjänen, K.J. Prophylactic HPV vaccines: the Finnish Perspective. *Exp. Rev. Vaccin.* Invited review. 9, 45-57, 2010. (I.F. 4.217)

757.Al-Maghrabi, J., Buhmeida, A., Emam, E., Syrjänen, K., Sibiany, A., Al-Qahtani, M. and Al Ahwal, M. Cyclooxygenase-2 Expression as predictor of outcome in colorectal carcinoma. *World J. Gastroenterol.* 18, 1793-1799, 2012. (I.F. 2.787)

758.Palmroth J., Namujju, P., Simen-Kapeu, A., Kataja, V., Surcel, H-M., Tuppurainen, M., Yliskoski, M., Syrjänen, K. and Lehtinen, M. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. *Scand. J. Infect. Dis.* 42, 379-384, 2010. (I.F. 1.366)

759.Buhmeida, A., Al-Maghrabi, J., Merdad, A., Al-Thubaity, F., Chaudhury, A., Gari, M., Abuzenadah, A., Collan, Y., Syrjänen, K. and Al-Qahtani, M. Nuclear morphometry in prognostication of breast cancer in Saudi Arabian patients: comparison with European and African breast cancer. *Anticancer Res.* 30, 2185-2191, 2010. (I.F. 2.480)

760.Syrjänen, K., Di Bonito, L., Gonçalves, L., Murjal, L., Santamaria, M., Mahovlic, V., Karakitsos, P., Önal, B. and Schmitt, F. Cervical cancer screening in the Mediterranean countries. Summary of the Satellite Symposium in the 35th European Congress of Cytology. *Cytopathol.* 21, 359-367, 2010 (I.F. 1.561).

761.Louvanto, K., Rintala, M.A., Syrjänen, K.J., Grénman, S.E. and Syrjänen, S.M. Genotype-specific persistence of genital human papillomavirus (HPV) infections in women followed for 6 years in the Finnish Family HPV Study. *J. Infect. Dis.* 202, 436-444, 2010. (I.F. 6.344).

762.Louvanto, K., Rintala, M.A., Syrjänen, K.J., Grénman, S.E. and Syrjänen, S.M. Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study. *BMC Infect. Dis.* 11, 179, 2011. (I.F. 2.561).

763.Louvanto, K., Syrjänen, K.J., Grénman, S.E., Rintala, M.A. and Syrjänen, S.M. Genotype-specific clearance of genital human papillomavirus (HPV) infections among mothers in the Finnish Family HPV Study. *J. Clin. Microbiol.* 48, 2665-2671, 2010. (I.F. 3.993).

764.Louvanto, K., Syrjänen, K.J., Rintala, M.A., Grénman, S.E. and Syrjänen, S.M. Human papillomavirus (HPV) and predictors of cervical intraepithelial neoplasia among young

mothers in a prospective follow-up study. *Acta Obstet. Gynec. Scand.* 90, 167-173, 2011. (I.F. 1.985).

765.Syrjänen, K.J. Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV16/18) prophylactic HPV vaccines. *Eur. J. Gynecol. Oncol.* 32, 17-33, 2011 (I.F. 0.611)

766.Korkeila, E., Jaakkola, P.M., Syrjänen, K., Sundström, J. and Pyrhönen, S. Preoperative radiotherapy downregulates the nuclear expression of hypoxia-inducible factor-1 α in rectal cancer. *Scand. J. Gastroenterol.* 45, 340-348, 2010 (I.F. 2.199).

767.Korkeila, E., Syrjänen, K., Bendardaf, R., Laulajainen, M., Carpen, O., Pyrhönen, S. and Sundström, J. Preoperative radiotherapy modulates ezrin expression and its value as a predictive marker in patients with rectal cancer. *Hum. Pathol.* 42, 384-392, 2010 (I.F. 2.769).

768.Louvanto, K., Rautava, J., Willberg, J., Wideman, L., Syrjänen, K., Grénman, S. and Syrjänen, S. Genotype-specific incidence and clearance of human papillomavirus in oral mucosa of women: a six-year follow-up study. *PloS One.* 8(1) e53413 doi 10.1371/journal.pone.0053413, 2013 (I.F. 3.234)

769.Louvanto, K., Rautava, J., Willberg, J., Wideman, L., Syrjänen, K.J., Grénman, S.E., and Syrjänen, S.M. Prevalence, genotype distribution and persistence of human papillomavirus in oral mucosa of women: a six-year follow-up study. *PloS One.* 7(8), e42171, doi: 10.1371/journal.pone.0042171, 2012. (I.F. 3.234).

770.Sarian, L., Naud, P., Shabalova, I., Derchain, S., Longatto-Filho, A., Tatti, S., Syrjänen, S., Syrjänen, K. and the NIS and LAMS Study Research Groups. Optional screening strategies for cervical cancer using stand-alone tests and their combinations among low- and medium-income populations in Latin America and Eastern Europe. *J. Med. Screen.* 17, 195-203, 2010. (I.F. 2.722).

771.Koskimaa, H-M., Waterboer, T., Pawlita, M., Grenman, S., Syrjänen, K. and Syrjänen, S. Human Papillomavirus genotypes present in the oral mucosa of newborns and their concordance with maternal cervical human papillomavirus genotypes. *J. Pediatr.* 160, 837-843, 2012. (I.F. 3.890).

772.Bösze, P. and Syrjänen, K. Tissue based classifications of HPV infections of the uterine cervix and vagina (mucosal HPV infections). *Eur. J. Gynaecol. Oncol.* 31, 605-611, 2010. (I.F. 0.611)

773.Monsonogo, J., Hudgens, MG, Zerat, L., Zerat, J-C., Syrjänen, K., Halfon, P., Ruiz, F. and Smith, J.S. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE Int. *J. Cancer* 129, 691-701, 2011. (I.F. 5.531)

774.Avoranta, T., Sundström, J., Korkeila, E., Syrjänen, K., Pyrhönen, S. and Laine, J. The expression and distribution of group IIA phospholipase A2 in human colorectal tumours. *Virchow Arch.* 457, 659-667, 2010. (I.F. 2.651).

775.Syrjänen, K. Citopatología de las lesiones cervicales por VPH y In: cancer cervicouterino y mamario en el proximo milenio. C.S.Pineda (Ed.), Mexico City. pp. 17-22, 1999.

776.Syrjänen, K. Terminología de las lesiones cervicales. In: Pineda C.S. (ed). XII Reunión Internacional de Cáncer Cérvico-Uterino y Lesiones Precursoras, Clínica de Diagnóstico Y Prevención del Cáncer de la Mujer, Mexico City. pp. 16-25, 2002.

777.Vihinen, P., Ramadan, S., Vuoristo, M-S., Hernberg, M., Tyynelä-Korhonen, K., Skyttä,

T., Koskivuo, I., Kellokumpu-Lehtinen, P-L., Syrjänen, K. and Pyrhönen, S. Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. *Melanoma Res.* 21, 431-437, 2011 (I.F. 4.163).

778.Buhmeida, A., Al-Maghrabi, J., Merdad, A., Al-Thubaity, F., Chaudhury, A., Gari, M., Abuzenadah, A., Collan, Y., Syrjänen, K. and Al-Qahtani, M. Prognostic value of mitotic counts in breast cancer of Saudi Arabian patients. *Anticancer Res.* 31, 97-103, 2011. (I.F. 2.480)

779.Buhmeida, A., Merdad, A., El-Maghrabi, J., Al-Thobaiti, F., Hidmi, M., Boghas, A., Syrjänen, K., Abuzenadah, A., Chaudhary, A., Gari, M., Al-Qahtani, M. and Dallol, A. RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. *Anticancer Res.* 31, 2975-2982, 2011. (I.F. 2.480)

780.Al-Maghrabi, J., Buhmeida, A., Syrjänen, K., Al-Qahtani, M. and Al-Ahwal, M. Expression of cell-cycle regulators p21 and p27 as predictors of disease outcome in colorectal carcinoma. *J. Gastrointest. Cancer.* 43, 279-287, 2012. (I.F. 0.920)

781.El-Zagheid, A., Buhmeida, A., Laato, M., El-Faitori, O., Syrjänen, K., Collan, Y. and Pyrhönen, S. Loss of E-Cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma. *APMIS.* 120, 539-548, 2012 (IF 1.933)

782.El Gehani, K., El Kekhia, L., Ibrahim, N., Syrjänen, K., Al-Fituri, O. and Elzagheid, A. Angiogenesis in urinary bladder carcinoma as defined by microvessel density (MVD) after immunohistochemical staining for Factor VIII and CD31. *Libyan J Med.* 2011 Mar 31;6. doi: 10.3402/ljm.v6i0.6016. (I.F. 1.333)

783.Korkeila, E., Jaakkola, P.M., Syrjänen, K., Sundström, J. and Pyrhönen, S. Pronounced tumour regression after radiotherapy is associated with negative/weak Glucose Transporter-1 expression in rectal cancer. *Anticancer Res.* 31, 311-315, 2011. (I.F. 2.480)

784.Kero, K., Rautava, J., Syrjänen, K., Grenman, S. and Syrjänen, S. Human papillomavirus (HPV) genotypes in male genitalia and their concordance among pregnant spouses participating in the Finnish Family HPV study. *J. Sex. Med.* 8, 2522-2531, 2011. (I.F. 3.570)

785.Rintala, M., Louvanto, K., Rantanen, V., Grénman, S., Syrjänen, K. and Syrjänen, S. High-risk human papillomavirus associated with incident cervical intraepithelial neoplasia developing in young mothers in the Finnish Family HPV study cohort. *Scand. J. Infect. Dis.* 44, 115-125, 2012. (I.F. 1.366)

786.Elzagheid, A., Emaetig, F., Buhmeida, A., Laato, M., El-faitori, O., Syrjänen, K., Collan, Y. and Pyrhönen, S. Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma. *Tumor Biol.* 34, 621-628, 2013. (I.F. 3.611)

787.Paaso, A.E., Louvanto, K., Syrjänen, K.J., Waterboer, T., Grénman, S.E., Pawlita, M. and Syrjänen, S.M. Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. *J. Gen. Virol.* 92, 2034-2046, 2011. (I.F. 3.192)

788.Syrjänen, K. Dynamics of human papillomavirus (HPV) infections among males eventually being uncovered. Invited editorial. *Asian J. Androl.* 13, 361-362, 2011 (I.F. 2.530)

789.Avoranta, T., Korkeila, E., Minn, H., Syrjänen, K., Pyrhönen, S. and Sundström, J. Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo)radiotherapy. *Acta Oncol.* 50, 1158-1166, 2011. (I.F. 3.730)

790.Longatto-Filho, A., Naud, P., Derchain, S., Roteli-Martins, C., Tatti, T., Serpa Hammes, L., Sarian, L.O., Eržen, M., Branca, M., de Matos, J.C., Gontijo, R., Maeda, M.Y.S., Lima, T., Costa, S., Syrjänen, S. and Syrjänen, K. Performance characteristics of Pap test, VIA,

VILI, HR-HPV testing, cervicography and colposcopy in diagnosis of significant cervical pathology. *Virchows Arch.* 460, 577-585, 2012. (I.F. 2.651)

791.Syrjänen, K., Silvonieni, M., Salminen, E., Vasankari, T. and Syrjänen, S. Detection of human papillomavirus (HPV) genotypes in bronchial cancer using sensitive Multimetrix assay. *Anticancer Res.* 32, 625-631, 2012 (I.F. 2.480)

792.Monsonogo, J., Hudgens, MG, Zerat, L., Zerat, J-C., Syrjänen, K. and Smith, J.S. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening setting. (THE FASE* STUDY). *Gynecol. Oncol.* 125, 175-180, 2012 (I.F. 3.774)

793.Monsonogo, J., Zerat, L., Syrjänen, K., Zerat, J-C., Smith, J.S. and Halfon, P. Prevalence of type-specific human papillomavirus infection among women in France. Implications for screening, vaccination and a future generation of multivalent HPV vaccines. *Vaccine* 30, 5215-5221, 2012. (I.F. 3.624)

794.Costa, S., Venturoli, S., Negri, G., Sideri, M., Preti, M., Pesaresi, M., Falasca, A., Barbieri, D., Zerbini, M., Santini, D., Sandri, M.T., Ghiringhello, B., Venturini N.C., Syrjänen, S. and Syrjänen, K. Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: An analysis of 166 cases. *Gynecol. Oncol.* 124, 490-495, 2012 (I.F. 3.774)

795.Korkeila, E., Sundström, J., Pyrhönen, S. and Syrjänen, K. The main effects and interactions of carbonic anhydrase IX, hypoxia-inducible factor 1a, ezrin and glucose transporter-1 in multivariate analysis for disease outcome in rectal cancer. *Anticancer Res.* 32, 3299-3303, 2012. (I.F. 2.480)

796.Korkeila, E., Sundström, J., Pyrhönen, S. and Syrjänen, K. Carbonic anhydrase IX, hypoxia-inducible factor 1a, ezrin and glucose transporter-1 as predictors of disease outcome in rectal cancer. Multivariate Cox survival models following data reduction by principal component analysis of the clinicopathological predictors. *Anticancer Res.* 31, 4529-4535, 2011. (I.F. 2.480)

797.Syrjänen K., Shabalova, I., Sarian, L., Naud, P., Longatto-Filho, A., Derchain, S., Kozachenko, V., Zakharchenko, S., Roteli-Martins, C., Nerovjna, R., Kljukina, L., Tatti, S., Branovskaja, M., Branca, M., Grunjberga, V., Eržen, M., Juschenko, A., Serpa Hammes, L., Podistov, J., Costa, S. and Syrjänen, S. and the NIS* and the LAMS** Study Research Groups. Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models. *Eur. J. Gynecol. Oncol.* 33, 5-14, 2012. (I.F. 0.611)

798.Salminen, E., Silvonieni, M., Syrjänen, K., Kaasa, S., Kloke, M. and Klepstad, P. Opioids in pain management of mesothelioma and lung cancer patients. Case-control study nested within the EPOS* cohort. *Acta Oncol.* 52, 30-37, 2013. (I.F. 3.730)

799.Rautava, J., Turunen, J., Syrjänen, K., Grenman, R. and Syrjänen, S. HPV genotypes and their prognostic significance in head and neck squamous cell carcinomas. *J. Clin. Virol.* 53, 116-120, 2012. (I.F. 3.016)

800.Syrjänen K., Shabalova, I., Sarian, L., Naud, P., Longatto-Filho, A., Derchain, S., Kozachenko, V., Zakharchenko, S., Roteli-Martins, C., Nerovjna, R., Kljukina, L., Tatti, S., Branovskaja, M., Branca, M., Grunjberga, V., Eržen, M., Juschenko, A., Serpa Hammes, L., Podistov, J., Costa, S. and Syrjänen, S. and the NIS* and the LAMS Study Research Groups. Longitudinal outcomes of high-risk human papillomavirus (HPV) infections as competing-risks events following cervical HPV test at baseline visit in the *NIS-LAMS** cohort. *Eur. J. Gynecol. Oncol.* 33, 341-352, 2012. (I.F. 0.611).**

- 801.El Gehani, K., Al-Kikhia, L., Emaetig, F., Syrjänen, K., Al-Fituri, O. and Elzagheid, A. Over-Expression of HER-2 is associated with the Stage in carcinomas of the urinary bladder. *Libyan J. Med.* 7, DOI: 10.3402/ljm.v7i0.14694, 2012 (I.F. 1.429)
- 802.Vihinen, P., Vainio-Kaila, M., Koskivuo, I., Syrjänen, K. and Pyrhönen, S. Previous pregnancy is a favorable prognostic factor in women with localised cutaneous melanoma. *Acta Oncol.* 51, 662-668, 2012. (I.F. 3.730)
- 803.Syrjänen, S., Longatto-Filho, A., Sarian, L., Naud, P., Derchain, S., Roteli-Martins, C., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Matos, J., Gontijo, R., Bragança, J., Arlindo, F.C., Maeda, M.Y.S., Costa, S. and Syrjänen, K. Competing-Risks Regression Models in Analysis of Biomarkers as Predictors of High-Risk Human Papillomavirus (HPV) Infection Outcomes and Incident CIN in the LAMS* Cohort. *Int. J. Gynec. Pathol.* 32, 406-415, 2013. (I.F. 1.665)
- 804.Longatto Filho, A., Villa, L.L. and Syrjänen, K. Papillomavirus from the bench to the clinics. *J Oncol.* 2012;2012:437438. doi: 10.1155/2012/437438. (I.F. 5.600)
- 805.Syrjänen, K.J. Geographic origin is a significant determinant of human papillomavirus (HPV) prevalence in esophageal squamous cell carcinoma: systematic review and meta-analysis. *Scand. J. Infect. Dis.* 45, 1-18, 2013. (I.F. 1.366)
- 806.Syrjänen, K.J. Detection of human papillomavirus (HPV) in lung cancer: systematic review and meta-analysis. *Anticancer Res.* 32, 3235-3250, 2012. (I.F. 2.480)
- 807.Syrjänen, K. and Syrjänen, S. Detection of human papillomavirus (HPV) in sinonasal papillomas: systematic review and meta-analysis. *Laryngoscope* 123, 181-192, 2013. (I.F. 2.032)
- 808.Abdalla F.B.E., Markus, R., Buhmeida, A., Boder, J., Syrjänen, K. and Collan, Y. Estrogen receptor, progesterone receptor, and nuclear size features in female breast cancer in Libya: Correlation with clinical features and survival. *Anticancer Res.* 32, 3485-3493, 2012 (I.F. 2.480)
- 809.Syrjänen, K. and Syrjänen, S. Detection of human papillomavirus (HPV) in esophageal papillomas: systematic review and meta-analysis. *APMIS.* 121, 363-374, 2013. (I.F. 1.933)
- 810.Syrjänen, K. and Syrjänen, S. Detection of human papillomavirus (HPV) in sinonasal carcinoma: systematic review and meta-analysis. *Hum. Pathol.* 44, 983-991, 2013 (I.F. 2.769)
- 811.Kero, K., Rautava, J., Syrjänen, K., Grenman, S. and Syrjänen, S. Oral mucosa as a reservoir of HPV - Point prevalence, genotype distribution and incident infections among males in 7-year prospective study. *Eur. Urol.* 62, 1063-1070, 2012. (I.F. 14.976)
- 812.Syrjänen, K. and Syrjänen, S. Solitary bronchial squamous cell papilloma – Another human papillomavirus (HPV)-associated benign tumor: systematic review and meta-analysis. *Contemp. Oncol.* 17, 429-436, 2013 (I.F. 0.215)
- 813.Kero, K., Rautava, J., Syrjänen, K., Grenman, S. and Syrjänen, S. Reply from Authors re: Barbagli G, Salvatore S, Lazzeri M. Oral Mucosa and Urethroplasty: It's Time to Change. *Eur Urol.* In press. Oral Mucosa as a Reservoir of Human Papillomavirus: Implications for the Use of Oral Mucosal Transplants in Urethroplasty. <https://doi.org/10.1016/j.eururo.2012.08.005> (I.F. 14.976)
- 814.Avoranta S.T., Korkeila, E.A., Syrjänen, K.J., Pyrhönen, S.E. and Sundström, J.T. Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence.

World J Gastroenterol. 18, 4549-4556, 2012. (I.F. 2.787)

815.Ragin C, Obikoya-Malomo M, Kim S, Chen Z, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso NE, Carpagnano GE, Ciotti M, Dosaka-Akita H, Fukayama M, Goto A, Spandidos DA, Gorgoulis V, Heideman DA, van Boerdonk RA, Hiroshima K, Iwakawa R, Kastrinakis NG, Kinoshita I, Akiba S, Landi MT, Liu HE, Wang JL, Mehra R, Khuri FR, Lim WT, Owonikoko TK, Ramalingam S, Sarchianaki E, Syrjänen K, Tsao MS, Sykes J, Hee SW, Yokota J, Zaravinos A, Taioli E. Etiologic role of HPV in a subset of lung cancers: an International Pooled Analysis. *Carcinogen*. 35, 267-1275, 2014. (I.F. 5.334)

816.Syrjänen, K. Ihmisen papilloomavirusta (HPV) löytyy keuhkosyövästä. Systemaattinen katsaus ja meta-analyysi. *BestPractice Onkologia* 2, 6-11, 2012.

817.Syrjänen, K. Yksinkertainen testi paljastaa onko mahalaukku terve. *BestPractice Onkologia* 4, 26-33, 2013.

818.Avoranta, T., Korkeila, E., Ristamäki, R., Syrjänen, K., Carpen, O., Pyrhönen, S., Sundström, J.T. ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer. *Hum. Pathol.* 44, 966-974, 2013. (I.F. 2.769).

819.Syrjänen, K.J. Light source. *CytoPaths* 23(5), 5-6, 2006

820.Kero, K., Rautava, J., Syrjänen, K., Grenman, S. and Syrjänen S. Reply to Kathleen D'Hauwers, Gunter De Win and Wiebren Tjalma's Letter to the Editor re: Katja Kero, Jaana Rautava, Kari Syrjänen, Seija Grenman, Stina Syrjänen. Oral Mucosa as a Reservoir of Human Papillomavirus: Point Prevalence, Genotype Distribution, and Incident Infections Among Males in a 7-year Prospective Study. *Eur Urol* 2012;62:1063-70. *Eur Urol*. 2013 Apr 11. <http://dx.doi.org/10.1016/j.eururo.2012.06.045>, <http://dx.doi.org/10.1016/j.eururo.2013.04.003>. (IF 17.298)

821.de Castro Mattos, J.S., Mauad, E.C., Syrjänen, K.J., Longatto-Filho, A., Haikel J., R.L., de Costa Vieira R.A., Buosi Silva, T. and de Barros, N. The impact of breast cancer screening among young women in the Barretos region, Brazil. *Anticancer Res.* 33, 2651-2655, 2013. (I.F. 2.480)

822.Silveira, C.E.G, Silva, T.B., da Costa Vieira, R.A., Haikel Jr., R.L., Syrjänen, K., Fregnani J.H.G.T., Carvalho, A.L. and Mauad, E. Digital photography in screening of skin cancer by mobile units in remote areas of Brazil. *BMC Dermatol.* 24,19-25, 2014. (I.F. 3.080)

823.Monsonogo, J., Zerat, L., Syrjänen, K., Zerat, J-C., Smith, J.S. and Halfon, P. Prévalence des génotypes d'HPV chez les femmes en France: Implications pour dépistage et la vaccination. *Gynecol. Obstet. Fertil.* 41, 305-313, 2013. (I.F. 0.510)

824.El-Zagheid, A., Emaetig, F., Akikhia, L., Buhmeida, A., Syrjänen, K., El-faitori O., Latta, M., Collan, Y. and Pyrhönen, S. High cyclooxygenase-2 expression is associated with advanced stage in colorectal cancer. *Anticancer Res.* 33, 3137-3143, 2013 (I.F. 2.480)

825.Kero, K., Rautava, J., Syrjänen, K., Willberg, J., Grenman, S. and Syrjänen, S. Smoking increases oral HPV persistence among men: - Seven-Year-Follow-Up-Study. *Eur. J. Clin. Microbiol. Infect. Dis.* 33, 123-133, 2014. (I.F. 2.857)

826.Benberin, V., Bektayeva, R., Karabayeva, R., Lebedev, A., Akemeyeva, K., Paloheimo, L. and Syrjänen, K. Prevalence of *H.pylori* infection and atrophic gastritis among asymptomatic and dyspeptic adults in Kazakhstan. A Hospital-Based screening with a panel of serum biomarkers. *Anticancer Res.* 33, 4595-4602, 2013. (I.F. 2.480)

827.Syrjänen, K. Suomalainen FIT-testi: entistä tehokkaampaa suolistosyövän seulontaa. *BestPractice Onkologia* 6, 10-14, 2013.

828.Koskela, H., Syrjänen, K. and Korkeila, E. Disease outcome of patients with pancreatic cancer in a cohort treated outside clinical trials. *Anticancer Res.* 33, 5491-5494, 2013. (I.F. 2.480)

829.Syrjänen, K. Keynotes from the new editor-in-chief. *Acta Cytol.* 57, 543-544, 2013. (I.F. 1.562)

830.Vohlonen, I., Syrjänen, K. and Karhu, J. Serum biomarker-based screening of the risk groups of stomach cancer. Preliminary results of a feasibility study in Finland. *Güncel Gastroenteroloji* 17,170-175, 2013. (I.F. 0.650)

831.Vohlonen, I., Syrjänen, K. and Karhu, J. Serum biomarker-based screening of the risk groups of stomach cancer. Preliminary results of a feasibility study in Finland. *Turkish J. Acad. Gastroenterol.* 12, 47-51, 2013. (I.F. 0.400)

832.Kero, K., Rautava, J., Syrjänen, K., Grenman, S. and Syrjänen, S. Stable marital relationship protects the men from oral and genital HPV infections *Eur. J. Clin. Microbiol. Infect. Dis.* 33:1211-1221, 2014. (I.F. 2.857)

833.De Sousa Sabino, S.M., den Heeten, G.J., Silva, T.B., Watanabe, A.H.U., Lopes Carvalho, A., Syrjänen, K.J., and Mauad, E.C. Implementation of a clinical quality control program in mammography screening service of Brazil. *Anticancer Res.* 34, 5057-5065, 2014. (I.F. 2.480)

834.Koskimaa, H-M., Paaso, A.E., Welters, M.J.P., Grénman, S.E., Syrjänen, K.J., , Sjoerd H. van der Burg, S.H. and Syrjänen, S.M. Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort. *J. Translat. Med.* 12, 44-49, 2014. (I.F. 3.930)

835.Louvanto, K., Rautava, J., Syrjänen, K.J., Grenman, S. and Syrjänen, S. The clearance of oral high-risk HPV infection is impaired by long-term persistence of cervical HPV infection. *Clin. Microbiol. Infect.* 20, 1167-1172, 2014. (I.F. 5.197)

836.Syrjänen, S., Waterboer, T., Kero, K., Rautava, J., Syrjänen, K., Grenman S. and Pawlita M. Oral human papillomavirus infection in men might contribute to HPV serology. *Eur. J. Clin. Microbiol. Infect. Dis.* 34, 237-245, 2015. (I.F. 2.857)

837.Vihinen, P., Tervahartiala, T., Sorsa, T., Hansson, J., Bastholt, L., Aamdal, S., Stierner, U., Pyrhönen, S., Syrjänen, K., Lundin, J. and Hernberg, M. Benefit of adjuvant interferon alfa-2b (IFN- α) therapy in melanoma patients with high serum MMP-8 levels. *Cancer Immunol. Immunother.* 64, 173-180, 2015. (I.F. 4.846)

838.Syrjänen, K.J., Sipponen, P., Härkönen, M., Peetsalu, A. and Korpela, S. Accuracy of GastroPanel testing in detection of atrophic gastritis. *Eur. J. Gastroenterol. Hepatol.* 27, 102-104, 2015. (I.F. 2.132)

839.Syrjänen, K. Historia natural del cancer de cuello uterino. Papel de los cofactores. Chapter 1. In: Tatti, S., Fleider, L., Tinnirello, M.D.L.A. and Caruso, R. (eds). *Enfoque integral de las Patologías relacionadas con el Virus del Papilloma Humano. En la Era de la Vacunación y del Tamizaje Viroológico.* Editorial Médica Panamericana, Buenos Aires. pp. 5-12, 2017 (ISBN 978-950-06-9536-7)

840.Syrjänen, K. Marcadores moleculares en las infecciones por HPV. Chapter 8. In: Tatti, S., Fleider, L., Tinnirello, M.D.L.A. and Caruso, R. (eds). *Enfoque integral de las Patologías relacionadas con el Virus del Papilloma Humano. En la Era de la Vacunación y del Tamizaje Viroológico.* Editorial Médica Panamericana, Buenos Aires. pp. 43-50, 2017 (ISBN 978-950-

06-9536-7)

841.Silva, T.B., Oliveira, C.Z., Faria, E.F., Mauad, E.C., Syrjänen, K.J. and Carvalho, A.L. Development and validation of a nomogram to estimate the risk of prostate cancer in a Brazilian population. *Anticancer Res.* 35, 2881-2886, 2015. (I.F. 2.480).

842.Vasilyev, S., Smirnova, E., Popov, D., Semenov, A., Eklund, C., Hendolin, P., Paloheimo, L. and Syrjänen, K. A new-generation fecal immunochemical test (FIT) is superior to guaiac-based test in detecting colorectal neoplasia among colonoscopy referral patients. *Anticancer Res.* 35, 2873-2880, 2015. (I.F. 2.480).

843.Kaur, A., El Zagheid, A., Birkman, E-M., Avoranta, T., Korkeila, E., Syrjänen, K., Westermarck, J. and Sundström, J. Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer. *Cancer Med.* 4, 1798-1808, 2015. (I.F. 3.420)

844.Paaso, A., Koskimaa, H-M., Welters, M., Grénman, S., Syrjänen, K., van der Burg, S.H. and Syrjänen, S. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years. *J. Translat. Med.* 13, 163-174, 2015. (I.F. 3.930).

845.Syrjänen, K., Vielh, P., Schmitt, F., and Nold, T. Editorial. *Acta Cytol.* 59, 1-1, 2015. (I.F. 1.562).

846.Syrjänen, K. Serologinen testi dyspepsia-potilaiden diagnostiikkaan ja mahasyövän riskiryhmien seulontaan. *BestPractice Gastroenterol.* 1, 2-7, 2015.

847.de Lima Vazquez, F., Buosi Silva, T., da Costa Vieira, R.A., da Costa, A.M., Scapulatempo, C., Fregnani, J.H.T.G., Mauad, E.C, Longatto, A. and Syrjänen, K.J. Retrospective analysis of breast cancer prognosis among young and older women in a Brazilian cohort of 738 patients, 1985-2002. *Oncol. Let.* 12, 4911-4924, 2016. (I.F. 1.600).

848.Turunen, A., Rautava, J., Grénman, R., Syrjänen, K. and Syrjänen, S. Epstein-Barr virus (EBV)-encoded small RNAs (EBERs) associated with poor prognosis of head and neck carcinomas. *Oncotarget* 8, 27328-27338, 2017. (I.F. 5.008)

849.Gama, R.R., Carvalho, A.L., Longatto Filho, A., Scorsato, A.P., Mendoza López, R.V., Rautava, J., Syrjänen, S. and Syrjänen, K. Detection of Human papillomavirus (HPV) in laryngeal squamous cell carcinoma (LSCC): Systematic review and meta-analysis. *Laryngoscope* 126, 885-893, 2016. (I.F. 2.032)

850.Lorenzi, A.T., Syrjänen, K.J. and Longatto Filho, A. Human papillomavirus (HPV) screening and cervical cancer burden. A brazilian perspective. *Virol. J.* 12, 112-117, 2015. (I.F. 2.090).

851.Salaspuro, M., Härkönen, M., Marvola, M., Peetsalu, A., Sarna, S., Sipponen, P., Suovaniemi, O., Syrjänen, K., Syrjänen, S. and Wikström, M. Asetaldehydi on vaiettu karsinogeeni. *SLL* 70(33), 1978-1979, 2015.

852.Hellström, P.M., Hendolin, P., Kaihovaara, P., Kronberg, L., Meierjohann, A., Millerhov, A., Paloheimo, L., Sundelin, H., Syrjänen, K., Webb, D-L. and Salaspuro, M. Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over study of Helicobacter-associated atrophic gastritis. *Scand. J. Gastroenterol.* 52, 230-237, 2016. (I.F. 2.199)

853.Salaspuro, M., Härkönen, M., Marvola, M., Peetsalu, A., Sarna, S., Sipponen, P., Suovaniemi, O., Syrjänen, K., Syrjänen, S. and Wikström, M. Mittasuhdeharha asetaldehdyin karsinogeenisyydessä. *SLL* 70(45), 3000, 2015.

854.Syrjänen, K., Salminen, J., Aresvuo, U., Hendolin P., Paloheimo, L., Eklund C., Salaspuro, M. and Suovaniemi, O. Elimination of cigarette smoke-derived acetaldehyde in saliva by slow-release L-cysteine lozenge is an effective new method to assist smoking cessation. A randomised, double-blind, placebo-controlled intervention. *Anticancer Res.* 36, 2297-2306, 2016. (I.F. 2.480)

855.Kurilovich, SA., Belkovets, A.V., Reshetnikov, O.V., Openko, T.G., Malyutina, S.K., Ragino, Y.I., Scherbakova, L.V., Leja, M., Paloheimo, L., Syrjänen, K. and Voevoda, M.I. Stomach-specific biomarkers (GastroPanel) can predict the development of gastric cancer in Caucasian population: A longitudinal nested case-control study in Siberia. *Anticancer Res.* 36, 247-254, 2016. (I.F. 2.480).

856.Koskimaa, H-M., Paaso, A., Welters, M.J.P., Grénman, S., Syrjänen, K., van der Burg, S.H. and Syrjänen, S. Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative. *J. Transl. Med.* 13, 370-381, 2015. (I.F. 3.930)

857.Kero, K., Rautava, J., Louvanto, K., Syrjänen, K., Grenman, S. and Syrjänen, S. Genotype-specific concordance of oral and genital Human Papillomavirus infections among marital couples is low. *Eur. J. Clin. Microbiol. Infect. Dis.* 35, 697-704, 2016. (I.F. 2.668).

858.Lorenzi, A., Rautava, J., Kero, K., Syrjänen, K., Longatto-Filho, A., Grenman, S. and Syrjänen, S. Physical state and copy numbers of HPV16 in oral infections that persisted or cleared. *J. Gen. Virol.* 98, 681-689, 2017. (I.F. 3.131)

859.Hirvonen, O.M., Alalahti, J.E., Syrjänen, K.J. and Jyrkkiö, S.M. End-of-life decisions guiding palliative care of cancer patients visiting emergency department in South Western Finland: a retrospective cohort study. *BMC Palliat. Care* 17, 128-135, 2018 (I.F. 2.335)

860.Paiva, C.E., Rezende, F.F., Paiva, B.S., Mauad, E.C., Zucca-Matthes, G., Carneseca, E.C., Syrjänen, K.J. and Schover, L.R. Associations of body mass index and physical activity with sexual dysfunction in breast cancer survivors. *Arch. Sex. Behav.* 45, 2057-2068, 2016. (I.F. 2.589)

861.Mariano, V.S. Pastrez, P.R.A., Costa, A.M., Guimarães, D.P., Cunha, T.R., Neto, S.A.Z., Scapulatempo-Neto, C., Syrjanen, K.J. and Longatto-Filho, A. Impact of brush cytology analysis for the diagnosis of esophageal squamous cell carcinoma: the quality of liquid-based preparation of cytological slides. *Acta Cytol.* 63, 240-246, 2019. (I.F. 1.562)

862.Longatto-Filho, A, Syrjänen, K.J. (Eds). Liquid-based techniques in non-gynecological cytology. *Acta Cytol.* 58(6), 515-604, 2014 (I.F. 1.562)

863.Munari, F.I., Carloni, A.C., Mariano, V.S., Syrjänen, K., Reis, R.M. and Longatto-Filho, A. The relationship among esophageal cancer, chagasic megaesophagus and HPV: myths, tales or reality? *Histol. Histopathol.* 33, 1135-1149, 2018. (I.F. 2.025)

864.Syrjänen, S., Rautava, J. and Syrjänen, K. HPV in head and neck cancer - 30 years of history. *Recent Res. Cancer Res.* 206, 3-25, 2017.

865.Koskimaa, H-M., Paaso, A., Welters, M., Grénman, S., Syrjänen, K., van der Burg, S. and Syrjänen, S. The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization. *Eur. J. Clin. Microbiol. Infect. Dis.* 36, 1491-1503, 2017. (I.F. 2.668)

866.Aine, R., Kahar, E., Aitokari, K., Salminen, J., Eklund, C., Paloheimo, L., Peetsalu, A. and Syrjänen, K. Atrophic gastritis (AG) and its clinical sequels among elderly people in Finland

and Estonia. A comparative study using GastroPanel and B12-vitamin testing of the residents in assisted-housing facilities. *J. Aging Res. Clin. Pract.* 5, 194-202, 2016. (I.F. 1.996)

867.Roman, L.D., Lukyanchuk, R., Sablin, O.A., Araslanova, E.I., Eklund, C., Hendolin, P., Paloheimo, L. and Syrjänen, K. Prevalence of infection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel®) in St. Petersburg. *Anticancer Res.* 36, 4129-4138, 2016. (I.F. 1.826)

868.Syrjänen, K. A Panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. *Anticancer Res.* 36, 5133-5144, 2016. (I.F. 1.895)

869.El-Zagheid, A., Emaetig, F., Alzaway, W., Torjman, F., Syrjänen, K., Latto, M., Collan, Y. and Pyrhönen, S. Neurofibromin expression is associated with aggressive disease and poor outcome in colorectal carcinoma. *Anticancer Res.* 36, 5301-5306, 2016. (I.F. 1.895)

870.Ebule, I.A., Djune, Fokou A. K., Sitedjeya Moko, I.L., Tanni B., Heugueu C., Longdoh A.N., Noah Noah. D., Okomo Assoumou M.C., Paloheimo L., Njoya O. and Syrjanen, K. Prevalence of *H. pylori* infection and atrophic gastritis among dyspeptic subjects in Cameroon using a panel of serum biomarkers (PGI, PGII, G-17, HpIgG). *Sch. J. Appl. Med. Sci.* 5(4A), 1230-1239, 2017.

871.Birkman, E-M., El-Zagheid, A., Jokilehto, T., Avoranta, T., Korkeila, E., Kulmala, J., Syrjänen, K., Westermarck, J. and Sundström, J. Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer. *Cancer Med.* 7, 698-706, 2018. (I.F. 3.362)

872.Syrjänen, K. and Eronen, K. Serological testing in management of dyspeptic patients and in screening of gastric cancer risks. *J. Gastrointest. Disord. Liver Funct.* 2(3),1-5, 2016.

873.Syrjänen, K. Caveats in diagnosis of *Helicobacter pylori* infection can be avoided by a panel of serum biomarkers (GastroPanel®). An Invited Editorial. *J. Carcinog. Mutagen.* 7(6), e123. doi:10.4172/2157-2518.1000e123.

874.Syrjänen, K. False positive and false negative results in diagnosis of *Helicobacter pylori* infections can be avoided by a panel of serum biomarkers (GastroPanel). *M. J. Gast.* 1 (1), 007-014, 2017.

875.Pastrez, P.R.A., Mariano, V.S., da Costa, A.M., Silva, E.M., Neto, C.S., Guimarães, D.P., Fava, G., Neto, S.A.Z., Nunes, E.M., Sichero, L., Villa, L.L., Syrjänen, K.J. and Longatto-Filho, A. The relation of HPV infection and expression of p53 and p16 proteins in esophageal squamous cell carcinoma. *J. Cancer.* 8(6), 1062-1070, 2017. (I.F. 3.609)

876.Louvanto, K., Sarkola, M., Rintala, M., Syrjänen, K., Grenman, S. and Syrjänen, S. Breast milk is a potential vehicle for HPV transmission to oral mucosa of the spouse. *Pediatr. Infect. Dis. J.* 36(7), 627-630, 2017. (I.F. 2.587)

877.Syrjänen K. Role of serological biomarker testing (GastroPanel®) in diagnosis of symptomatic dyspepsia and in screening of the risks of stomach cancer. *EC Gastroenterol Digest Syst* 1(6), 209-222, 2017.

878.Syrjänen, K. 2017: Sixty years of *Acta Cytologica*. Editorial. *Acta Cytologica.* 61,1-2, 2017. (I.F. 3.000)

879.Syrjänen, K. and Paloheimo, L. Foreword. In: Ebule, A.I. (author). *GastroPanel for the Diagnosis of Gastritis*. Nyaa Publishers, Yaoundé, Cameroon. pp. v-vii, 2016 **(ISBN 978-9956-454-52-4)**

880.Syrjänen, K. Serological biomarker panel (GastroPanel®): A test for non-invasive diagnosis of dyspeptic symptoms and for comprehensive detection of *Helicobacter pylori* infection. *Biomark. J.* 3, 1-10, 2017

881.Bendardaf, R., El Sherafy, A., Syrjänen, K., Collan, Y. and Pyrhönen, S. Effect of vascular endothelial growth Factor-1 expression on survival of advanced colorectal cancer patients. *Libyan J. Med.* 12, 1290741 <http://dx.doi.org/10.1080/19932820.2017.1290741>;2017 (I.F. 1.743)

882.Suumann, J., Sillakivi, T., Riispere, Z., Syrjänen, K., Sipponen, P. Kirsimägi, Ü. and Peetsalu, A. Serological biomarker testing helps avoiding unnecessary endoscopies in obese patients before bariatric surgery. *BMC Obes.* 5, 9-17, 2018. (I.F. 1.549)

883.Syrjänen, K., Sipponen, P., Härkönen, M. and Tamm, H. A young man dying of fulminant hepato-renal syndrome. The tagging to alcohol addiction obscured the diagnosis and precluded the treatment of chronic viral hepatitis (HBV, HCV, HDV) as the cause of his liver cirrhosis. *Gastroenterol. Pancreatol. Liver Dis.* 4 (2), 1-7, 2017.

884.Slävescu, K.C., Pirvan, A., Gheban, D., Eklund, C., Paloheimo, L. and Syrjänen, K. A point-of-care test for anti-transglutaminase (tTG2A) IgA, IgG, IgM antibodies (CELIAC Quick Test®) validated in diagnosis of incident celiac disease (CD) in pediatric patients. *EC Gastroenterol. Digest. Syst.* 3(1), 4-13, 2017.

885.Syrjänen, K. Two landmark studies published in 1976/1977 paved the way to recognition of human papillomavirus (HPV) as the major source of global cancer burden. *Acta Cytol.* 61, 316-337, 2017. (I.F. 3.000)

886.Syrjänen, K., Eronen, K., Hendolin, P., Paloheimo, L., Eklund, C., Bäckström, A. and Suovanemi, O. Slow-release L-cysteine (Acetium®) lozenge is an effective new method in smoking cessation. A randomized, double-blind, placebo-controlled intervention. *Anticancer Res.* 37, 3639-3648, 2017. (I.F. 2.480)

887.Syrjänen, K. The six decades of *Acta Cytologica*. Editorial. 61, 259-261, 2017. (I.F. 3.000)

888.Kero, K., Rautava, J., Syrjänen, K., Grenman, S. and Syrjänen S. Association of asymptomatic bacterial vaginosis with persistence of female genital human papillomavirus infection *Eur. J. Clin. Microbiol. Infect. Dis.* 36, 2215-2219, 2017. (I.F. 5.103)

889.Louvanto, K., Roger, M., Faucher, M-C., Syrjänen, K. Grenman, S. and Syrjänen, S. HLA-G and vertical mother-to-child transmission of human papillomavirus infection. *Hum. Immunol.* 79, 471-476, 2018. (I.F. 2.211)

890.Mariano, V.S., Silva, E.M., Pastrez, P.R.A., Pinto, M.C., Castro, A.G., Syrjänen, K.J. and Longatto-Filho, A. High systemic IL-6 level is associated with worse prognosis in patients with non-small cell lung cancer. *PLoS ONE* 12(7): e0181125. <https://doi.org/10.1371/journal.pone.0181125>. (I.F. 3.752).

891.da Costa, A.M., Fregnani, J.H.T.G., Pastrez, P.R.A., Mariano, V.S., Neto, C.S., Guimarães, D.P., de Oliveira, K.M.G., Neto, S.A.Z., Nunes, E.M., Ferreira, S., Sichero, L., Villa, L.L., Syrjänen, K.J. and Longatto-Filho, A. Prevalence of high risk HPV DNA in esophagus is high in Brazil but not related to esophageal squamous cell carcinoma. *Histol. Histopathol.* 33(4), 357-363, 2018. (I.F. 2.025).

892.Syrjänen, K. Serum biomarker panel (GastroPanel®) and slow-release L-cysteine (Acetium® Capsule): Rationale for the primary prevention of gastric cancer. *EC Gastroenterol. Digest. Syst.* 3(6), 172-192, 2017.

893.Poluschkin, L., Rautava, J., Turunen, A., Wang, Y., Hedman, K., Syrjänen, K., Grénman, R. and Syrjänen, S. Polyomaviruses detectable in head and neck carcinomas. *Oncotarget* 9 (32), 22642-22652, 2018. (I.F. 2.678)

894.da Costa, A.M., Fregnani, J.H.T.G., Pastrez, P.R.A., Mariano, V.S., Silva, E.M., Scapulatempo-Neto C., Guimarães, D.P., Villa, L.L., Sichero, L., Syrjänen, K.J. and Longatto-Filho, A. HPV infection and P53 and P16 expression in esophageal cancer: are they prognostic factors?" *Infect. Agent. Cancer*. 2017 Oct 13;12:54. doi: 10.1186/s13027-017-0163-4. (I.F. 3.698)

895.Syrjänen, K. Subjects with compromised stomach health need special attention: Serological biomarker panel (GastroPanel®) for monitoring and slow-release L-cysteine (Acetium® Capsule) for protection of the stomach. *EC Gastroenterol. Digest. Syst.* 4(3), 75-86, 2017.

896.Suumann, J., Sillakivi, T., Riispere, Z., Syrjänen, K., Sipponen, P., Kirsimägi, Ü. and Peetsalu, A. Serum gastric biomarker levels after sleeve gastrectomy and Roux-en-Y gastric bypass operations: A prospective study with 1-year follow-up. *Surg. Gastroenterol. Oncol.* 24(2):86-94, 2019. DOI: 10.21614/sgo-24-2-86 (I.F. 1.110)

897.Syrjänen, K. Diagnosis of the patients with upper abdominal symptoms (dyspepsia) using non-invasive serological tests. *EC Gastroenterol. Digest. Syst.* 5(2), 52-62, 2018.

898.Ebule, I.A., Djune F.A.K., Njeambosay B.A., Doh, G.N., Metaghue, G., Majuikouo, L., Befolo, M.H.D.M., Nkayo, M., Tanni, B., Heugueu, C., Feutsapk, C., Noah, N.D., Paloheimo, L. and Syrjanen, K. Association of Helicobacter pylori infection and diabetes mellitus type 2 subjects in Yaounde Cameroon using a panel of serum biomarkers (PGII, HpIgG): A case control study. *J. Clin. Gastroenterol. Treat.* 3 (4), 053-058, 2017. <https://doi.org/10.23937/2469-584X/1510053>

899.Ebule, I.A., Djune F.A.K., Njeambosay B.A., Doh, G.N., Befolo, M.H.D.M., Nkayo, M., Metaghue, G., Majuikouo, L., Tanni, B., Heugueu, C., Feutsapk, C., Noah, N.D., Paloheimo, L. and Syrjanen, K. Atrophic gastritis and gastric cancer risk amongst diabetes mellitus type 2 subjects and controls in Yaounde Cameroon using a panel of serum biomarkers (PGI, G-17). *J. Clin. Gastroenterol. Treat.* 3 (4), 052, 2017. <https://doi.org/10.23937/2469-584X/1510052>

900.Syrjänen, K.J. (Ed). The six decades of Acta Cytologica. Acta Cytol. 61 (4-5), 253-408, 2017. (I.F. 2.319)

901.Guimarães, D.P., Fregnani, J.H., Reis, R.M., Taveira, L.N., Scapulotempo-Neto, C., Matsushita, M., Silva, S.R., Oliveira, C.Z., Longatto-Filho, A., Eklund, C., Paloheimo, L.I., Mauad, E. and Syrjänen, K. A new-generation fecal immunochemical test compared with guaiac fecal occult blood test for colorectal neoplasia detection in colonoscopy referral patients. *Anticancer. Res.* 39, 261-269, 2019. (I.F. 2.480)

902.Bendardaf, R., Sharif Askari, F.S., Sharif-Askari, N.S., Syrjänen, K. and Pyrhönen S. Patients with hMLH1 or/and hMSH2-deficient metastatic colorectal cancer are associated with reduced level of vascular endothelial growth factor-1 expressions and higher response-rate to irinotecan-based regimen. *Anticancer Res.* 38, 6399-6404, 2018. (IF 2.480)

903.Syrjänen K.J. (ed.) Must Reads in Cytology. Breast pathology, liquid biopsy, HPV. Karger Topic Article Packages, Karger, Basel, 2018; pp. 1-152.

904.Bendardaf, R., Sharif-Askari, F.S., Sharif-Askari, N.S., Syrjänen, K. and Pyrhönen S. Cytoplasmic E-cadherin expression is associated with higher tumour level of VEGFA, lower response rate to Irinotecan-based treatment and poorer prognosis in patients with metastatic colorectal cancer. *Anticancer Res.* 39, 1953-1957, 2019. (I.F. 2.480)

- 905.Syrjänen, S. and Syrjänen, K. HPV in head and neck carcinomas. Different HPV profile in oropharyngeal carcinomas – why? *Acta Cytol.* 63, 124-142, 2019. (I.F. 2.319)
- 906.Syrjänen, K., Eskelinen, M., Peetsalu, A., Sillakivi, T., Sipponen, P., Härkönen, M., Paloheimo, L., Mäki, M., Tiusanen, T., Suovaniemi, O., DiMario, F. and Fan, ZP. GastroPanel® Biomarker Panel: The most comprehensive test for *Helicobacter pylori* infection and its clinical sequelae. A critical review. *Anticancer Res.* 39, 1091-1104, 2019. (IF 2.480)
- 907.Longatto-Filho, A. and Syrjänen, K.J. (Eds). HPV: A Virus-Dinosaur Living among Us? *Acta Cytol.* 63(2), 79-170, 2019. (I.F. 2.319)
- 908.Longatto-Filho, A. and Syrjänen, K. HPV: A Virus-Dinosaur Living among Us? *Acta Cytologica* 63(2), 83-84, 2019. (I.F. 2.319)
- 909.Meklin, J., Eskelinen, M., Syrjänen, K. and Eskelinen, M. Gender-specific performance of a diagnostic score in acute appendicitis. *In Vivo.* 34, 3687-3703, 2020. (I.F. 2.115)
- 910.Silva, E.M., Mariano, V.S., Pastres, P.R.A., Pinto, M.C., Nunes, E.M., Sichero, L., Villa, L.L., Scapulatempo-Neto, C., Syrjänen, K.J. and Longatto-Filho, A. Human papillomavirus is not associated to non-small cell lung cancer: data from a prospective cross-sectional study. *Infect. Agent. Cancer* 14(18), 2019. <https://doi.org/10.1186/s13027-019-0235-8> (I.F. 1.422)
- 911.Syrjänen, K. and Paloheimo, L. A blood test for checking stomach health. *Clin. Lab. Int. (CLI)* 37, 14, 2013.
- 912.Syrjänen, K. Papa, Bethesda vai jokin muu? *Duodecim*, 116, 1248-1252, 2000.
- 913.Mecklin, J., Syrjänen, K. and Eskelinen, M. Colorectal Cancer (CRC) Screening with traditional and new-generation fecal immunochemical tests (FIT): A critical review of fecal occult blood tests (FOBTs). *Anticancer Res.* 40, 575-581, 2020. (I.F. 2.480)
- 914.Ali Alkhayyal, N., Talaat, I.M., Vinodnadat, A., Maghazachi, A.A., Abusnana, S., Syrjänen, K. and Bendaraf, R. Correlation of insulin-like growth factor 1 receptor expression with different molecular subtypes of breast cancer in UAE. *Anticancer Res.* 40, 1555-1561, 2020 (I.F. 2.480)
- 915.Syrjänen, K. and Schmitt, F. Journal impact factor (JIF) returned to *Acta Cytologica* in 2020. Editorial. *Acta Cytol.* 64, 1, 2020 (I.F. 2.319).
- 916.Mecklin, J., Syrjänen, K. and Eskelinen, M. Fecal occult blood tests in colorectal cancer screening: A systematic review and meta-analysis of the traditional and new-generation fecal immunochemical tests. *Anticancer Res.* 40, 3591-3604, 2020 (I.F. 2.480)
- 917.Koivurova, O-P., Ukkola, O., Koivikko, M., Ebeling, T., Yliaska, I., Koskela, R., Blomster, T., Ala-Rämi, A., Kettunen, O., Karttunen, T.J., Mäkinen, M., Ronkainen, J. and Syrjänen, K. Screening of the patients with autoimmune thyroid disease (AITD) and type 1 diabetes mellitus (DM1) for atrophic gastritis (AG) by serological biomarker testing (GastroPanel®). *EC Gastroenterol. Digest. Syst.* 7(9), 181-195, 2020.
- 918.Sobanski, T., Batista Arantes, L.M.L., dos Santos, W., Matsushita, M., de Oliveira, M.A., Costa, M., de Carvalho, A.C., Berardinelli, G.N., Syrjänen, K., Reis, R.M. and Guimarães, D.P. Methylation profile of colon cancer genes in colorectal cancer precursor lesions and tumor tissue: perspectives for screening. *Scand. J. Gastroenterol.* 56(8), 920-928, 2021 (I.F. 2.130)

919.Meklin, J., Eskelinen, M., Syrjänen, K. and Eskelinen, M. Leucocyte count does not improve the diagnostic performance of a diagnostic score (DS) in distinguishing acute appendicitis (AA) from nonspecific abdominal pain (NSAP). *In Vivo*. 34, 3327-3339, 2020. (I.F. 2.155)

920.Mäki, M., Söderström, D., Paloheimo, L., Hendolin, P., Suovaniemi, O and Syrjänen, K. Helicobacter pylori (Hp) IgG ELISA of the new-generation GastroPanel® is highly accurate in diagnosis of Hp-Infection in gastroscopy referral patients. *Anticancer Res.* 40, 6387-6398, 2020. (I.F. 2.480)

921.Ebule, A.I., Ndze, V.N., Thierry, N.K. Etienne, G., Ornella, M.M.M., Aurelien, M.A., Dominique, N.N., Maki, M., and Syrjänen, K. Association of Helicobacter pylori infection and atrophic gastritis with chronic renal insufficiency in Yaounde Cameroon, using GastroPanel® serological biomarker panel (Pepsinogen I; Pepsinogen II; Gastrin-17; Helicobacter pylori IgG). *J. Adv. Microbiol.* 21(2), 62-67, 2021.

922.Meklin, J., Eskelinen, M., Syrjänen, K. and Eskelinen, M. Performance of a diagnostic score in confirming acute cholecystitis among patients with acute abdominal pain. *Anticancer Res.* 40, 6947-6956, 2020. (I.F. 2.480)

923.Santos, W., dos Reis, M.B., Porto, J., de Carvalho, A.C., Matsushita, M., Oliveira, G., Syrjänen, K., Reis, R.M. and Guimarães, D.P. Somatic targeted mutation profiling of colorectal cancer precursor lesions. *BMC Med. Genom.* 15(143), 1-11, 2022. (I.F. 2.931)

924.Tiusanen, T., Paloheimo, L., Suovaniemi, O. and Syrjänen, K. Serological biomarker test (GastroPanel®) in diagnosis of functional gastric disorders, Helicobacter pylori and atrophic gastritis in a random sample of patients referred for testing due to dyspeptic symptoms. *Anticancer Res.* 41, 811-891, 2021. (I.F. 2.480)

925.Eskelinen, M., Meklin, J., Syrjänen, K. and Eskelinen, M. Pediatric acute appendicitis score in children with acute abdominal pain (AAP). *Anticancer Res.* 41, 297-306, 2021. (I.F. 2.480)

926.Syrjänen, S., Rintala, M., Sarkola, M., Rautava, J., Willberg, J., Koskimaa, H., Paaso, A., Syrjänen, K. and Grenman, S. Oral human papillomavirus (HPV) infection in children during the first 6 years of their life. *Emerg. Infect. Dis.* 27(3), 759-766, 2021. (I.F. 6.507)

927.Paaso, A., Welters, M., Kero, K., Rautava, J., Syrjänen, K., van der Burg, S. and Syrjänen, S. Interferon- γ and IL-5 associated cell-mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa. *Clin. Exp. Dent. Res.* 7, 903-912, 2021. (I.F. 0.720)

928.Sharif-Askari, FS., Al-Khayyal, N., Talaat, I., Sharif-Askari, NS., Rawat, S., Jundi, M., Syrjänen, K., Hamoudi, R. and Bendardaf, R. Immunohistochemical assessment of TNFAIP3/A20 expression correlates with early tumorigenesis in breast cancer. *Anticancer Res.* 41,739-745, 2021. (I.F. 2.480)

929.Eskelinen, M., Meklin, J., Syrjänen, K. and Eskelinen, M. A Diagnostic Score (DS) is a powerful tool in diagnosis of acute appendicitis in elderly patients with acute abdominal pain. *Anticancer Res.* 41, 1459-1469, 2021. (I.F. 2.480)

930.Eskelinen, M., Meklin, J., Syrjänen, K. and Eskelinen, M. A Diagnostic Score for acute small bowel obstruction. *Anticancer Res.* 41, 1959-1970, 2021. (I.F. 2.480)

931.Jaakola, A.J., Roger M., Faucher, M-C., Syrjänen, K., Grénman, S., Syrjänen, S. and Louvanto, K. HLA-G polymorphism impacts the outcome of oral HPV infections in women. *BMC Infect. Dis.* 21,419-428, 2021. (I.F. 2.688)

932.Eskelinen, M., Meklin, J., Syrjänen, K. and Eskelinen, M. A. A diagnostic score for reliable confirmation of acute renal colic among patients with acute abdominal pain. *Anticancer Res.* 41, 3045-3054, 2021. (I.F. 2.480)

933.Eskelinen, M., Meklin, J., Selander, T., Syrjänen, K. and Eskelinen, M. History-taking, clinical signs tests and scores for detection of non-organic dyspepsia (NOD) among patients with acute abdominal pain (AAP). *Cancer Diagn. & Progn.* 1(4), 265-274, 2021 . DOI: 10.21873/cdp.10034

934.Eskelinen, M., Meklin, J., Selander, T., Syrjänen, K. and Eskelinen, M. A diagnostic score (DS) in the difficult diagnosis of non-specific abdominal pain (NSAP). *In Vivo* 35, 2729-2738, 2021. (I.F. 2.155)

935.Syrjänen, K., Schmitt, F. and Turner, S. The New (2020) Journal Impact Factor of *Acta Cytologica* is 2.319. Editorial. *Acta Cytologica* 65, 359-360. (I.F. 2.319) DOI: 10.1159/000518784

936.Kallela, M., Nissilä, M., Keski-Säntti, P., Sumelahti, M-L., Kärppä, M., Ilmavirta, M., Färkkilä, M., Paloheimo, L., Mäki, M., Syrjänen, K. and Suovaniemi, O. Elimination of histamine liberator (acetaldehyde) by L-cysteine in prevention of migraine attacks. Randomized controlled trial with a medical device (Acetium® Capsules). *Clin. Case Studie. Rep.* 4, 1-3, 2021. doi: 10.15761/CCSR.1000167

937.Syrjänen, S, and Syrjänen, K. HPV-associated benign squamous cell papillomas in the upper aero-digestive tract and their malignant potential. Special Issue: HPV in the Head and Neck Region. *Viruses.* 2021, 13(8), 1624. doi: 10.3390/v13081624. (I.F. 5.048).

938.Meklin, J., Eskelinen, M., Guimaraes, D.P., Selander, T., Inkinen, J., Tiusanen, T., Syrjänen, K. and Eskelinen, M. The new generation immunochemical test for fecal occult blood (ColonView quick test) shows a high diagnostic accuracy in colorectal cancer detection. *Anticancer Res.* 41, 5071-5079, 2021. (I.F. 2.480).

939.Koivurova, O-P., Koskela, R., Blomster, T., Ala-Rämi, A., Lumme, H., Kettunen, O., Hukkanen, J., Karttunen, T.J., Mäkinen, M., Ronkainen, J. and Syrjänen, K. Serological biomarker panel in diagnosis of atrophic gastritis and *Helicobacter pylori* infection in gastroscopy referral patients. Clinical validation of the new-generation GastroPanel® test. *Anticancer Res.* 41, 5527-5537, 2021. (I.F. 2.480).

940.Suominen, N., Jaakola, A.J., Roger M., Faucher, M-C., Syrjänen, K., Grénman, S. and Syrjänen, S. The association of HLA-G polymorphism with oral and genital HPV infection in men. *Eur. J. Clin. Microbiol. Infect. Dis.* 41, 219-226, 2022. doi: 10.1007/s10096-021-04362-8. (I.F. 2.837).

941.Meklin, J., Eskelinen, M., Guimaraes, D.P., Selander, T., Tiusanen, T., Syrjänen, K. and Eskelinen, M. The automatically analyzed (AA) ColonView (CV) Quick Test for fecal occult blood shows higher diagnostic accuracy in detection of colorectal adenoma than visually analyzed test. *Anticancer Res.* 41, 5517-5525, 2021. (I.F. 2.480).

942.Bakulina, N., Tikhonov, S., Malkov, V., Vorobyev, S., Belyakov, I., Peshkova, N., Belko, E. and Syrjänen, K. Non-invasive screening of autoimmune atrophic gastritis (AAG) in asymptomatic subjects by serological biomarker (GastroPanel®) test. *Anticancer Res.* 42, 1517-1526, 2022. (I.F. 2.480).

943.Syrjänen, S., Waterboer, T., Rintala, M., Pawlita, M., Syrjänen, K., Louvanto, K. and Grenman, S. Maternal HPV-antibodies and seroconversion to HPV in children during the first three years of life. *Sci Rep.* 2022 12(1): 2227. doi: 10.1038/s41598-022-06343-z. (I.F. 4.379)

944.Syrjänen, K. Accuracy of serum biomarker panel (GastroPanel®) in diagnosis of atrophic gastritis of the corpus (AGC). Systematic review and meta-analysis. *Anticancer Res.* 42, 1679-1696, 2022. (I.F. 2.480).

945.Eskelinen, M., Meklin, J., Guimaraes, D.P., Selander, T., Tiusanen, T., Syrjänen, K. and Eskelinen, M. The ColonView (CV) Quick Test for fecal occult blood shows significantly higher diagnostic accuracy in detecting distal than proximal colorectal cancer. *Anticancer Res.* 42,1879-1891, 2022. (I.F. 2.480).

946.Vuorinen, S., Syrjänen, K., Waterboer, T., Grénman, S., Syrjänen, S. and Louvanto, K. Outcomes of HPV type-specific serostatus do not associate with oral or genital HPV-carriage in non-vaccinated women followed for three years. *BMC Women's Health.* 22, 141, 2022. doi: 10.1186/s12905-022-01717-x. (I.F. 2.809).

947.Eskelinen, M., Meklin, J., Guimaraes, D.P., Selander, T., Tiusanen, T., Syrjänen, K. and Eskelinen, M. Site-specific performance of colon view (CV) fecal immunochemical test (FIT) with differences between proximal and distal colorectal adenoma. *Anticancer Res.* 42, 3557-3567, 2022. (I.F. 2.480).

948.Eskelinen, M., Meklin, J., Selander, T., Syrjänen, K. and Eskelinen, M. A simple prediction score for diagnosis of acute pancreatitis. *In Vivo* 36, 2287-2296, 2022. (I.F. 2.406).

949.Laine, H.K., Waterboer, T., Syrjänen, K., Grenman, S., Louvanto, K. and Syrjänen, S. Seroprevalence of polyomaviruses BK and JC in Finnish women and their spouses followed-up for three years. *Sci. Rep.* 13:879, 2023. <https://doi.org/10.1038/s41598-023-27850-7> (I.F. 4.996).

950.Suominen, H., Paaso, A., Koskimaa, H-M., Grénman, S., Syrjänen, K., Syrjänen, S. and Louvanto, K. Peripheral blood T-lymphocyte phenotypes in mother-child pairs stratified by the maternal HPV-status: persistent HPV16 vs. HPV-negative: A case-control study. *Viruses* 14, 2633, 2022. <https://doi.org/10.3390/v14122633> (I.F. 5.818).

951.Syrjänen, K. A Novel strategy for the primary prevention of gastric cancer: Serological biomarker (GastroPanel®) screening for acid-free stomach followed by protection of the risk subjects with slow-release L-cysteine (Acetium®). [Biomed. J. Sci. & Tech. Res. 47\(4\) 2022. BJSTR. MS.ID.007546](#) (I.F. 1.229)

952.Syrjänen, K., Nissilä, M., Kallela, M. and Suovaniemi, O. Controlling the headache attacks in special subgroups of migraine patients. Preliminary experience with slow-release L-cysteine (Acetium® Capsules) that eliminates acetaldehyde, a powerful liberator of histamine. [Biomed. J. Sci. & Tech. Res. 48\(4\)-2023, 2023.](#) (I.F. 1.229)

953.Eskelinen, M., Meklin, J., Guimaraes, D.P., Selander, T., Syrjänen, K. and Eskelinen, M. Diagnostic accuracy of fecal immunochemical test (FIT) in bleed-positive and bleed-negative colorectal cancer (CRC) among a cohort of 5,090 subjects who participated in the colorectal neoplasia (CRN) screening in Brazil. *Anticancer Res.* 43,1569-1580, 2023 (I.F. 2.435).

954.ADDENDUM to: *Syrjänen K, Eronen K, Hendolin P, Paloheimo L, Eklund C, Bäckström A and Suovaniemi O: Slow-release L-cysteine (Acetium®) lozenge is an effective new method in smoking cessation. A randomized, double-blind, placebo-controlled intervention. Anticancer Res 37(7): 3639-3648, 2017. DOI: 10.21873/ anticancer.11734.* *Anticancer Res.* 43, 2379, 2023 (I.F. 2.435).

955.Syrjänen, K and Schmitt, F. (Eds). Abstracts. 21st International Congress of Cytology Held Jointly with the ASC 70th Annual Scientific Meeting. Next Generation Cytology. *Acta Cytologica* 66, Suppl 1, 1-150, 2022 (I.F. 1.800).

956.Laine, H., Waterboer, T., Syrjänen, K., Grenman, S., Louvanto, K. and Syrjänen, S.

Human polyomavirus BKPyV and JCPyV serostatus has no impact on women's human papillomavirus infection outcome. *Frontier Cell. Infect. Microbiol.* 13:1190019. doi: 10.3389/fcimb.2023.1190019 (I.F. 6.073)

957.Eskelinen, M., Meklin, J., Guimaraes, D.P., Selander, T., Syrjänen, K. and Eskelinen, M. Fecal Immunochemical Test (FIT) in triage of bleed-positive (Crab+) and bleed-negative colorectal adenoma (Crab-) patients in colorectal neoplasia screening. *Anticancer Res.* 43,3517-3528, 2023 (I.F. 2.435).

958.Suominen. N.T., Roger.M., Faucher, M-C., Syrjänen, K.J., Grénman, S.E., Syrjänen, S.M. and Louvanto. K. HLA-G Alleles Impact the Perinatal Father-Child HPV Transmission. *Curr. Issues Mol. Biol.* 45, 5798-5810, 2023. (I.F. 2.976)

959.Syrjänen, K., Patrakka, I., Paloniemi, E., Soppi, A., Hendolin, P. and Suovaniemi, O. Awareness and uptake of nicotine-free smoking intervention methods (Acetium® lozenge) increased among health care professionals by targeted E-Training as confirmed by post-training surveys. *Anticancer Res.* 43, 4961-4968, 2023. (I.F. 2.435)

960.Eskelinen, M., Pulkkinen, J., Selander, T., Syrjänen, K. and Eskelinen, M. Accuracy of prediction models in diagnosis of acute diverticulitis. *In Vivo* 37, 2597-2608, 2023 (I.F. 2.406)

961.Laine, H.K., Waterboer, T., Syrjänen, K., Grenman, S., Louvanto, K. and Syrjänen, S. IgG seroreactivities to viral capsid protein VP1 of JC and BK polyomaviruses in children at early age with special reference to parental cofactors. *Children* 10, 1645, 2023. <https://doi.org/10.3390/children10101645> (I.F. 2.400)

962.Suominen, H., Suominen, N., Syrjänen, K., Waterboer, T., Grénman, S., Syrjänen, S. and Louvanto, K. Effect of second pregnancy on HPV serology in mothers followed-up in the Finnish Family HPV Study. *Viruses* 15, 2109, 2023. <https://doi.org/10.3390/v15102109>. (I.F. 4.700)

963.Eskelinen, M., Meklin, J., Guimaraes, D.P., Selander, T., Syrjänen, K. and Eskelinen, M. Triage process at endoscopy with ColonView fecal immunochemical test (FIT) will enhance diagnostic accuracy (DA) of colorectal cancer screening. *Anticancer Res.* 43, 5535-5544, 2023 (I.F. 2.435)

964.Kirjavainen, L., Suominen, H., Syrjänen, K., Waterboer, T., Grenman, S., Syrjänen, S. and Louvanto, K. Impact of different cofactors on naturally acquired HPV antibody levels among unvaccinated pregnant women. *Viral Immunol.* 37(1), 1-8, 2024 Feb 5. doi: 10.1089/vim.2023.0108. (I.F. 2.200)

965.Syrjänen, K. Meeting Report: The Kymi odyssey honorary ceremony and the future G.N. Papanicolaou museum. *Editorial. Acta Cytol.* 68, 1-3, 2024. (I.F. 1.800)

966.Eskelinen, M., Meklin, J., Guimaraes, D.P., Selander, T., Syrjänen, K. and Eskelinen, M. Diagnostic accuracy (DA) of VolonView fecal immunochemical test (FIT) in detecting colorectal adenoma (CRA) can be improved by the diagnostic models (DM) that include triage and risk features of CRA. *Anticancer Res.*44:173-184, 2024 (I.F. 2.435).

967.Syrjänen, K., Eskelinen, M., Meklin, J., Hendolin, P., Eskelinen, M. and Suovaniemi, O. Colorectal cancer screening by fecal immunochemical tests (FIT). Considerations on sampling and markers (Hb and Hb/Hp complex) of fecal occult blood (FOB). *Anticancer Res.* 44:1513-1523, 2024. (I.F. 2.435).

968.Papadia, C., Marelli, L., Wood, E., Novelli, M., Feakins, R., Syrjänen, K and Shidrawi, R. Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation study. *BMJ Open Gastroenterol*

2025;12:e001559. doi:10.1136/bmjgast-2024-001559. (I.F. 3.300).

969.Suominen, H., Syrjänen, K. Waterboer, T., Grénman, S., Syrjänen, S. and Louvanto, K. Serum IgG antibodies to HPV6 L1, E2, E4, E6, and E7 proteins among children prospectively followed-up for three years. *J. Infect. Dis.* May 31;230(6):e1207–e1213, 2024. (I.F. 6.400).

970.Koivurova, O-P., Blomster, T., Eskelinen, M., Sipponen, P., Hendolin, P., Suovaniemi, O., Martikainen, J., Syrjänen, K. and Vohlonen, I. Uniformity between the diagnostic techniques and cost containment achieved by serological biomarker screening of gastroscopy referral patients. *BMJ*. Submitted 2025 (I.F. 6.047)

971.Eskelinen, M., Selander, T., Guimaraes, D.P., Kaarniranta, K., Syrjänen, K. and Eskelinen, M. Artificial intelligence models (AI) could enhance the diagnostic accuracy (DA) of fecal immunochemical test (FIT) in detection of colorectal adenoma in a screening setting. *Anticancer Res.* 45, 267-275, 2025. (I.F. 1.600)

972.Chabbra, M., Singh, G., Joshi, A., Kolatkar, A., Holopainen, H., Hendolin, P., Syrjänen, K. Point-of-Care Diagnosis of Atrophic Gastritis by Serological Biomarker Test (GastroPanel® Quick Test) in Gastroscopy Referral Patients in India. *J Clin Med.* 14, 787-805, 2025 (I.F. 3.000)

973.Koskela, N., Butt, J., Michels, B., Syrjänen, K., Grenman, S., Waterboer, T., Syrjänen, S. and Louvanto, K. Risk factors associated with igG seropersistence to *Chlamydia trachomatis* and *Mycoplasma genitalium*. *Infect Epidemiol.* 2025 Jan 24:1-20. doi: 10.1017/S095026882500007X. (I.F. 2.500)

974.Syrjänen, K. Study designs in cytological research: Impact in evidence-based medicine. Editorial. *Acta Cytol.* 69, 107-113, 2025 (I.F. 1.600)

975.Koskela, N., Butt, J., Michels, B., Syrjänen, K., Grenman, S., Waterboer, T., Syrjänen, S. and Louvanto, K. Maternal-fetal transfer and longitudinal trends of antibodies to *Chlamydia trachomatis* and *Mycoplasma genitalium* in early childhood. *Acta Obstet Gynec Scand.* 104, 1366–1372, 2025. DOI: 10.1111/aogs.15105 (I.F. 3.500)

976.Syrjänen, K., Rinne, S., Koskela, N., Michels, B., Butt, J., Grénman, S., Waterboer, T., Syrjänen, S., and Louvanto, K. *Helicobacter pylori* (Hp) multiplex serology and its dynamics within families during a three year prospective follow-up. *Int J Infect Dis.* 155, 107893, 2025. <https://doi.org/10.1016/j.ijid.2025.107893> (I.F. 4.800).

977.Eskelinen, M., Selander, T., Guimaraes, D.P., Kaarniranta, K., Syrjänen, K. and Eskelinen, M. Four different artificial intelligence models versus logistic regression to enhance the diagnostic accuracy of(AI) could enhance the diagnostic accuracy (DA) of fecal immunochemical test in the detection of colorectal carcinoma in a screening setting. *Anticancer Res.* 45, 2477-2491, 2025. (I.F. 1.600)

978.Rinne, S., Michels, B., Butt, J., Syrjänen, K., Grénman, S., Waterboer, T., Syrjänen, S., and Louvanto, K. Epstein-Barr virus (EBV) serology and its impact on oral human papillomavirus (HPV) infection outcomes in children during early childhood. *Microbiol. Spectr.* In press (2025)(I.F. 3.204)

979.Syrjänen, K. Overall accuracy of the GastroPanel® test in diagnosis of its target disorders of the stomach. A pooled analysis of three clinical validation studies using random-effects bivariate model and hierarchical multilevel logistic regression models. *Anticancer Res.* In press. 2025 (I.F. 1.600)

980.Rinne, S., Michels, B., Butt, J., Syrjänen, K., Grénman, S., Waterboer, T., Syrjänen, S., and Louvanto, K. Epstein-Barr virus serology associated with persistent oral human papillomavirus infections in men. *J Oral Path. Med.* In press 2025 (I.F. 2.300)